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OBJECTIVES:	  To	  establish	  the	  extent	  to	  which	  health	  inequality	  operates	  in	  a	  cohort	  of	  patients	  
admitted	  with	  heart	  failure	  to	  a	  single	  centre	  serving	  an	  elderly	  population.	  
	  
DESIGN:	  Historical	  cohort	  study	  of	  patients	  admitted	  with	  a	  first	  coded	  presentation	  of	  heart	  failure.	  
	  
SETTING:	  Single	  district	  general	  hospital	  on	  the	  South-­‐East	  coast	  of	  England.	  
	  	  
PARTICIPANTS:	  883	  patients	  admitted	  with	  a	  coded	  diagnosis	  of	  heart	  failure	  in	  the	  first	  or	  second	  
diagnostic	  position.	  
	  
MAIN	  OUTCOME	  MEASURES:	  Mortality,	  readmission	  rates,	  and	  proportion	  of	  patients	  receiving	  
recommended	  care.	  
	  
RESULTS:	  This	  was	  an	  elderly	  cohort,	  with	  a	  median	  age	  of	  82.4	  years.	  Just	  over	  half	  were	  women	  
(51.3%),	  who	  tended	  to	  be	  older	  than	  men	  (84	  vs.	  80	  years).	  Crude	  mortality	  rates	  at	  30	  days	  and	  1	  
year	  were	  17%	  and	  38%	  respectively.	  All	  cause	  readmission	  at	  30	  days	  occurred	  in	  21.3%	  of	  cases	  and	  
the	  rate	  of	  heart	  failure	  readmission	  within	  1	  year	  was	  35%.	  	  
The	  most	  deprived	  patients	  were	  younger	  at	  the	  time	  of	  admission	  than	  those	  from	  less	  deprived	  
areas	  (77.9	  vs.	  82.3	  years	  [p=0.036]).	  No	  association	  was	  found	  between	  deprivation	  and	  mortality	  
but	  rates	  of	  readmission	  at	  30	  days	  were	  higher	  in	  more	  deprived	  quintiles	  (p=0.01).	  	  
Rates	  of	  prescription	  of	  beneficial	  medications	  were	  not	  different	  between	  quintiles	  of	  deprivation,	  
but	  significantly	  lower	  rates	  of	  B-­‐blocker	  and	  aldosterone	  antagonist	  prescription	  were	  observed	  in	  
the	  elderly.	  Comorbidity	  and	  left	  ventricular	  ejection	  fraction	  were	  also	  associated	  with	  differential	  
rates	  of	  prescribing.	  Provision	  of	  echocardiography	  and	  documentation	  of	  ejection	  fraction	  was	  
strongly	  associated	  with	  age	  as	  was	  provision	  of	  specialist	  follow-­‐up.	  
	  
CONCLUSIONS:	  Hospitalization	  for	  heart	  failure	  appears	  to	  occur	  at	  an	  earlier	  age	  in	  individuals	  from	  
more	  deprived	  areas,	  but	  subsequent	  specialist	  management	  is	  heavily	  dependent	  on	  age,	  not	  level	  of	  







	  TABLE	  OF	  CONTENTS	  
	  
	  
Declaration	   	   	   	   	   	   	   	   	   	   1	  
	  
Acknowledgements	   	   	   	   	   	   	   	   	   2	  
	  
List	  of	  commonly	  used	  acronyms	  and	  abbreviations	  	   	   	   	   3	  
	  
List	  of	  figures	  and	  tables	   	   	   	   	   	   	   	   5	  
	  
1. Introduction	   	   	   	   	   	   	   	   	   8	  
	  
2. The	  concept	  of	  health	  inequality	   	   	   	   	   	   	   9	  
	  
3. The	  syndrome	  of	  chronic	  heart	  failure	   	   	   	   	   	   12	  
	  
3.I	  	   Pathophysiology	  
3.I.i	   How	  does	  heart	  failure	  start?	  
3.I.ii	   The	  consequences	  of	  left	  ventricular	  
dysfunction	  
3.I.iii	   Heart	  failure	  with	  normal	  ejection	  fraction	  
3.II	  	   Diagnosis	  
3.III	  	   Epidemiology	  
3.IV	   Defining	  heart	  failure	  
3.V	   Determinants	  of	  outcome	  in	  heart	  failure	  
3.VI	   Modern	  Management	  of	  heart	  failure	  
3.VI.i	   Diuretics	  
3.VI.ii	   Disease	  modifying	  drug	  therapies	  
3.VI.iii	   Adjunctive	  drug	  therapies	  
3.VI.iv	   Integrated,	  multidisciplinary	  disease	  
management	  programmes	  
3.VI.v	   Implantable	  device	  therapy	  
	  4. Inequality	  in	  heart	  failure	  	   	   	   	   	   	   	   30	  
	  
4.I	   Reasons	  to	  suspect	  the	  operation	  of	  health	  inequality	  in	  
heart	  failure	  
4.II	   A	  contemporary	  overview	  of	  heart	  failure	  management	  in	  
the	  UK	  –	  The	  National	  Heart	  Failure	  Audit	  
4.II.i	   Summary	  of	  the	  findings	  of	  the	  National	  Heart	  
Failure	  Audit	  2011/12	  
4.III	   Annotated	  references	  on	  heart	  failure	  and	  inequality	  
4.III.i	   General	  themes	  and	  reference	  selection	  
4.III.ii	   A	  starting	  point	  for	  considering	  the	  
relationship	  between	  socioeconomic	  status	  
and	  heart	  failure	  
4.III.iii	   Incident	  heart	  failure	  and	  socioeconomic	  
status	  
4.III.iv	   Prevalence	  of	  heart	  failure	  and	  socioeconomic	  
status	  
4.III.v	   Mortality	  in	  heart	  failure	  and	  socioeconomic	  
status	  
4.III.vi	   Readmission	  and	  socioeconomic	  status	  in	  
heart	  failure	  
4.III.vii	  Treatment	  in	  heart	  failure	  and	  socioeconomic	  
status	  
4.IV	   Summary	  of	  current	  knowledge	  
	  
	  






	  6. Methods	   	   	   	   	   	   	   	   	   	   80	  
	  
6.I	   Overview	  of	  the	  study	  design	  
6.II	   Setting	  
6.II.i	   Local	  health	  services	  and	  infrastructure	  
6.II.ii	   Defining	  the	  study	  period	  
6.III	   Assembling	  the	  cohort	  
6.IV	   Data	  extraction	  
6.V	   Variables	  
6.V.i	   Outcome	  measures	  
6.V.ii	   Assigning	  socioeconomic	  status	  
6.V.iii	   Effect	  modifiers	  
6.V.iv	   Confounders	  
6.VI	   Sample	  size	  calculation	  
6.VII	   Analysis	  
6.VII.i	   General	  analyses	  
6.VII.ii	   Death	  rates	  and	  survival	  analyses	  
6.VIII	   Data	  protection	  and	  data	  storage	  
6.IX	   Ethical	  considerations	  
6.X	   Sponsorship	  
	  
7. Results	   	   	   	   	   	   	   	   	   	   108	  
	  
7.I	   Final	  composition	  of	  the	  cohort	  
7.II	   Demographics	  and	  characteristics	  of	  the	  final	  cohort	  
7.III	   Comparison	  of	  those	  surviving	  to	  discharge	  with	  those	  not	  
surviving	  
7.IV	   Characteristics	  of	  the	  cohort	  surviving	  to	  discharge	  
7.V	   Socioeconomic	  status	  in	  the	  cohort	  surviving	  to	  discharge	  
and	  its	  effect	  on	  outcome	  
7.VI	   The	  effect	  of	  age	  on	  outcome	  
7.VII	   Care	  Quality	  
	  7.VII.i	   Overall	  quality	  of	  care	  and	  the	  effect	  of	  gender	  
7.VII.i.a	  Echocardiography	  
7.VII.i.b	  Prescription	  of	  medications	  
7.VII.ii	   The	  effect	  of	  socioeconomic	  status	  on	  care	  
quality	  
7.VII.iii	  The	  effect	  of	  age	  on	  care	  quality	  
7.VII.iv	  Considering	  those	  with	  left	  ventricular	  systolic	  
impairment	  
7.VII.v	   Overall	  determinants	  of	  care	  quality	  
	  
8. Discussion	  	   	   	   	   	   	   	   	   	   133	  
	  
8.I	   Overall	  summary	  of	  findings	  
8.II	   Demography	  of	  the	  cohort	  
8.III	   Comorbidity	  in	  the	  cohort	  
8.IV	   Mortality	  
8.V	   Readmission	  
8.VI	   The	  effect	  of	  deprivation	  
8.VII	   Age	  related	  inequality	  
	  
9. Limitations	   	   	   	   	   	   	   	   	   158	  
	  
10. Clinical	  relevance	   	   	   	   	   	   	   	   	   161	  
	  
11. General	  conclusions	  and	  recommendations	   	   	   	   	   164	  
	  
12. Figures	  and	  Tables	   	   	   	   	   	   	   	   169	  
	  




This	  thesis	  was	  composed	  by	  Dr	  Paul	  Michael	  Haydock	  and	  relates	  to	  a	  study	  
designed	  and	  performed	  by	  him.	  It	  is	  an	  original	  piece	  of	  work	  and	  has	  not	  been	  
accepted	  in	  any	  previous	  application	  for	  a	  degree.	  All	  quotations	  contained	  herein	  






















My	  thanks	  go	  to	  my	  supervisors,	  Professor	  Martin	  Cowie	  and	  Dr	  Hugh	  McIntyre,	  for	  
their	  support,	  guidance,	  and	  patience.	  Each	  has	  taught	  me	  a	  great	  deal	  and	  I	  shall	  be	  
forever	  in	  their	  debt	  for	  the	  opportunities	  that	  they	  have	  provided.	  I	  have	  no	  doubt	  
that	  my	  future	  endeavors	  will	  be	  influenced	  by	  their	  rationality	  and	  enthusiasm	  in	  
equal	  measure.	  
	  
I	  am	  also	  grateful	  to	  Takeda	  (UK)	  for	  their	  financial	  support	  in	  funding	  my	  research	  
and	  to	  all	  my	  colleagues	  at	  the	  Conquest	  Hospital,	  Hastings,	  who	  helped	  to	  make	  my	  
time	  there	  enjoyable	  as	  well	  as	  rewarding.	  
	  
Finally,	  I	  would	  like	  to	  thank	  Alan,	  without	  the	  support	  of	  whom	  none	  of	  this	  would	  









	  	  	  
	  3	  
COMMONLY	  USED	  ACRONYMS	  AND	  ABBREVIATIONS	  
	  
ACEi	   	   Angiotensin	  Converting	  Enzyme	  Inhibitor	  
AF	   	   Atrial	  Fibrillation	  
ALP	   Alkaline	  Phosphatase	  
ALT	   Alanine	  Aminotransferase	  
APC	   	   Admitted	  Patient	  Care	  
ARB	   Angiotensin	  II	  Receptor	  Antagonist	  (Blocker)	  
BNP	   	   B-­‐type	  Natriuretic	  Peptide	  
BHF	   	   British	  Heart	  Foundation	  
CCST	   Certificate	  of	  Completion	  of	  Specialist	  Training	  
	  
CRT-­‐D	   Cardiac	  Resynchronization	  Therapy	  +	  Implantable	  Cardioverter	  
Defibrillator	  
	  
CRT-­‐P	   	   Cardiac	  Resynchronization	  Therapy	  (pacing	  function	  only)	  
ESHT	   	   East	  Sussex	  Hospitals’	  NHS	  Trust	  
Hb	   Haemaglobin	  concentration	  
HES	   Hospital	  Episodes	  Statistics	  
HFNEF	   Heart	  Failure	  with	  Normal	  Ejection	  Fraction	  
ICD	   	   Implantable	  Cardioverter	  Defibrillator	  
ICD-­‐10	  	   International	  Classification	  of	  Diseases	  10th	  edition	  
IHD	   Ischaemic	  Heart	  Disease	  
IMD	  2007	   Index	  of	  Multiple	  Deprivation	  2007	  
IQR	   Inter-­‐quartile	  range	  




LSOA	   Lower	  layer	  Super	  Output	  Area	  	  
LV	   Left	  Ventricle	  
LVEDD	   Left	  Ventricular	  End	  Diastolic	  Diameter	  
LVEF	   Left	  Ventricular	  Ejection	  Fraction	  
MCV	   Mean	  Corpuscular	  Volume	  
NHS	   National	  Health	  Service	  
NICE	   	   National	  Institute	  of	  Health	  and	  Clinical	  Excellence	  
NYHA	   New	  York	  Heart	  Association	  
ONS	   Office	  for	  National	  Statistics	  (UK)	  
PAS	   Patient	  Administration	  System	  
RAAS	   Renin-­‐Angiotensin-­‐Aldosterone	  System	  
SD	   Standard	  Deviation	  
SES	   	   Socioeconomic	  Status	  
U&E	   Urea	  and	  Electrolytes	  
UK	   United	  Kingdom	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1.	   INTRODUCTION	  
	  
This	  thesis	  is	  an	  examination	  of	  the	  operation	  of	  health	  inequality	  in	  a	  contemporary	  
UK	  cohort	  of	  individuals	  with	  the	  syndrome	  of	  heart	  failure.	  Previous	  work,	  both	  
international	  and	  UK	  based,	  has	  demonstrated	  evidence	  for	  the	  existence	  of	  
inequalities	  in	  several	  heart	  failure	  outcomes.	  Several	  themes	  dominate	  the	  
literature	  and	  the	  most	  striking	  are	  for	  inequality	  related	  to	  differences	  in	  age,	  
gender	  and	  various	  measures	  of	  socioeconomic	  status.	  I	  will,	  in	  this	  thesis,	  address	  
these	  three	  factors	  by	  reviewing	  the	  existing	  evidence	  and	  examining	  these	  complex	  
relationships	  in	  a	  well	  described,	  contemporary	  heart	  failure	  cohort.	  I	  will	  begin,	  
however,	  with	  an	  introduction	  to	  health	  inequality	  and	  the	  syndrome	  of	  heart	  failure	  












2.	   THE	  CONCEPT	  OF	  HEALTH	  INEQUALITY	  
	  
Health	  inequality	  is	  difficult	  to	  define[1],	  and	  yet	  it	  has	  been	  the	  focus	  of	  extensive	  
research	  in	  the	  last	  quarter	  of	  the	  20th	  Century	  and	  the	  beginning	  of	  the	  new	  
millennium[2-­‐4].	  	  An	  attempt	  to	  review	  the	  literature	  on	  the	  subject	  in	  its	  entirety	  is	  
beyond	  the	  scope	  of	  this	  thesis,	  but	  an	  understanding	  of	  the	  concepts	  involved	  and	  
the	  evolution	  of	  health	  inequalities	  research	  in	  its	  historical	  context	  is	  essential	  to	  
understand	  both	  the	  questions	  that	  this	  thesis	  will	  ask	  and	  the	  conclusions	  that	  it	  will	  
suggest.	  
	  
Inequality	  exists	  in	  many	  forms	  and	  as	  an	  entity	  it	  is	  familiar	  to	  the	  casual	  observer.	  
The	  Cambridge	  Dictionary	  defines	  it	  thus:	  
	  
“A	  situation	  in	  which	  there	  is	  no	  equality	  or	  fair	  treatment	  in	  the	  sharing	  of	  wealth	  or	  
opportunities	  between	  different	  groups	  in	  society”[5]	  
	  
and	  this	  captures	  the	  essence	  of	  the	  usual	  meaning	  in	  the	  context	  of	  health.	  
Fundamental	  to	  appreciating	  health	  inequality	  is	  to	  understand	  that	  the	  definition	  of	  
inequality	  depends	  upon	  the	  fact	  that	  human	  beings	  can	  be	  categorized	  into	  
different	  groups	  based	  on	  societal	  norms.	  So,	  it	  is	  apparent	  that	  inequality	  exists	  to	  




Differences	  between	  individuals	  exist	  at	  the	  genetic	  level	  to	  give	  rise	  to	  distinct	  
phenotypes	  –	  some	  of	  which	  will	  be	  grouped	  together	  on	  the	  basis	  of	  the	  interaction	  
between	  these	  phenotypes	  and	  the	  environment	  and	  society.	  Therefore,	  when	  
health	  inequality	  is	  investigated	  and	  discussed	  it	  is	  best	  qualified	  by	  a	  description	  of	  
the	  grouping	  variable	  being	  used	  to	  define	  the	  basis	  of	  the	  inequality	  e.g.	  gender,	  
race,	  class	  etc.	  
	  
Because	  the	  determination	  of	  certain	  of	  these	  groups	  is	  ultimately	  dependent	  upon	  
immutable	  genetic	  differences	  between	  individuals,	  it	  is	  to	  be	  expected	  that	  some	  
differences	  in	  health	  and	  health	  outcomes	  are	  unavoidable	  facts	  of	  biology.	  Where	  
this	  is	  true,	  inequality	  –	  “un-­‐equalness”	  –	  should	  not	  concern	  us.	  Whitehead	  argues	  
that	  “a	  situation	  where	  everyone	  in	  the	  population	  has	  the	  same	  level	  of	  health,	  
suffers	  the	  same	  type	  and	  degree	  of	  illness,	  and	  dies	  after	  exactly	  the	  same	  lifespan”	  
is	  neither	  “achievable	  nor	  desirable”[7],	  and	  most	  would	  agree	  with	  this.	  Clearly,	  
nowhere	  is	  this	  inevitable	  variation	  more	  obvious	  then	  when	  considering	  individuals	  
at	  different	  stages	  of	  the	  life-­‐course	  –	  a	  sense	  of	  unfairness	  is	  an	  unlikely	  reaction	  to	  
the	  fact	  that	  a	  30	  year	  old	  is	  less	  likely	  to	  suffer	  a	  stroke	  than	  an	  80	  year	  old.	  
	  
Such	  fatalistic	  thinking,	  however,	  can	  itself	  lead	  to	  inequality.	  If	  it	  is	  accepted	  that	  
some	  health	  outcomes	  are	  more	  common	  in	  certain	  defined	  groups	  then	  a	  situation	  
where	  beneficial	  therapies	  are	  withheld	  might	  be	  generally	  tolerated	  by	  society	  on	  
the	  basis	  that	  higher	  rates	  of	  the	  health	  outcome	  are	  to	  be	  expected[8,	  9].	  In	  the	  era	  
of	  preventative	  medicine,	  being	  fair	  and	  just	  requires	  a	  great	  effort	  on	  the	  part	  of	  
governments,	  health	  services	  and	  individual	  practitioners[10].	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Nevertheless,	  there	  is	  a	  general	  acceptance	  that	  inequality	  can	  exist	  as	  a	  perfectly	  
legitimate	  entity,	  insofar	  as	  unequal	  outcomes	  are	  determined	  by	  factors	  which	  are	  
not	  fundamentally	  unjust.	  Clearly,	  the	  determination	  of	  what	  differences	  are	  
avoidable	  or	  unnecessary	  requires	  a	  judgment	  made	  on	  the	  basis	  of	  the	  values	  on	  
which	  the	  society	  in	  which	  the	  inequality	  operates	  are	  founded.	  For	  these	  reasons	  it	  
is	  necessary	  to	  be	  precise	  when	  considering	  the	  literature	  on	  this	  subject	  as	  
conclusions	  regarding	  observed	  inequalities	  must	  be	  viewed	  through	  the	  lens	  of	  the	  
social	  model	  and	  political	  ideology	  operating	  in	  the	  population	  being	  studied[11].	  
	  
This	  thesis	  aims	  to	  explore	  inequalities	  in	  the	  management	  of	  chronic	  heart	  failure	  in	  
a	  single	  UK	  secondary	  care	  setting,	  and	  to	  what	  extent	  differences	  in	  socioeconomic	  
status	  determine	  outcomes.	  What	  follows	  will	  include	  an	  introduction	  to	  the	  
syndrome	  of	  heart	  failure	  and	  the	  various,	  evidence	  based	  interventions	  known	  to	  
improve	  prognosis	  and	  reduce	  readmission.	  I	  will	  also	  address	  the	  specific	  historical	  
literature	  on	  inequality	  in	  heart	  failure,	  before	  outlining	  the	  methods	  of	  the	  SUSSEX-­‐
HF	  study	  and	  presenting	  its	  results.	  	  Finally,	  I	  will	  present	  my	  conclusions	  and	  
recommendations,	  based	  on	  the	  results	  in	  the	  context	  of	  previously	  published	  data,	  







3.	   THE	  SYNDROME	  OF	  CHRONIC	  HEART	  FAILURE	  
	  
3.I.	   PATHOPHYSIOLOGY	  
	  
3.I.i.	   HOW	  DOES	  HEART	  FAILURE	  START?	  
Current	  concepts	  regarding	  the	  pathogenesis	  of	  heart	  failure	  involve	  the	  idea	  of	  an	  
“index	  event”.	  This	  is	  most	  easily	  conceptualized	  as	  a	  discrete,	  definable	  insult	  
affecting	  the	  structure	  or	  function	  of	  the	  heart.	  A	  familiar	  example	  of	  such	  an	  event	  
in	  clinical	  practice	  is	  acute	  myocardial	  infarction,	  in	  which	  the	  death	  of	  an	  area	  of	  
myocardium	  leads	  to	  an	  impairment	  of	  ventricular	  function	  as	  that	  area	  is	  rendered	  
non	  contractile[12].	  
	  
Such	  events	  clearly	  occur	  and	  lead	  to	  heart	  failure.	  However,	  the	  “index	  event”	  is	  
often	  less	  readily	  identifiable	  and	  the	  development	  of	  left	  ventricular	  systolic	  
dysfunction	  may	  be	  a	  chronic,	  insidious	  process	  which	  at	  some	  point	  tips	  the	  balance	  
towards	  the	  development	  of	  the	  heart	  failure	  syndrome.	  Examples	  of	  these	  “index	  
events”	  would	  include	  systemic	  hypertension	  leading	  to	  pressure	  overload[13],	  
progressive	  valvular	  heart	  disease	  leading	  to	  volume	  overload,	  chronic	  
hyperglycaemia	  in	  diabetes	  resulting	  in	  structural	  changes	  to	  the	  myocardium	  or	  





3.I.ii.	   THE	  CONSEQUENCES	  OF	  LEFT	  VENTRICULAR	  SYSTOLIC	  DYSFUNCTION	  
Left	  ventricular	  dysfunction	  results	  in	  the	  activation	  of	  mechanical	  and	  biochemical	  
homeostatic	  mechanisms	  designed	  to	  compensate	  for	  a	  reduction	  in	  cardiac	  output.	  
Whilst	  these	  mechanisms	  initially	  produce	  their	  required	  effect	  of	  maintaining	  tissue	  
perfusion,	  they	  are	  ultimately	  maladaptive	  and	  result	  in	  the	  development	  of	  heart	  
failure[17].	  The	  progression	  of	  heart	  failure	  is	  determined	  by	  a	  process	  of	  left	  
ventricular	  remodeling	  in	  response	  to	  prolonged	  exposure	  to	  the	  maladaptive	  
internal	  milieu	  consequent	  on	  the	  activation	  of	  various	  neurohormonal	  pathways[18,	  
19]:	  	  
	  	  
a. Renin-­‐angiotensin-­‐aldosterone	  System	  
Decreased	  renal	  perfusion	  as	  a	  consequence	  of	  decreased	  cardiac	  output	  results	  in	  
the	  secretion	  of	  renin	  from	  the	  juxtaglomerular	  apparatus.	  Concurrently,	  production	  
of	  angiotensinogen	  is	  increased	  by	  the	  liver	  and	  there	  is,	  thus,	  an	  increase	  in	  
circulating	  angiotensin	  I.	  The	  action	  of	  the	  angiotensin	  converting	  enzyme	  (ACE)	  in	  
the	  lungs	  converts	  angiotensin	  I	  into	  the	  effector	  hormone	  angiotensin	  II.	  This	  
molecule	  is	  a	  highly	  potent	  vasoconstrictor	  acting	  on	  the	  efferent	  renal	  arterioles	  
and	  the	  systemic	  arteriolar	  bed	  via	  activation	  of	  the	  sympathetic	  nervous	  system	  and	  
stimulation	  of	  endothelin	  release	  from	  the	  vasculature.	  Angiotensin	  II	  also	  stimulates	  
aldosterone	  secretion	  from	  the	  adrenal	  cortex,	  promoting	  salt	  and	  water	  retention	  
(and	  potassium	  loss)[20,	  21].	  High	  levels	  of	  anti-­‐diuretic	  hormone	  (ADH	  /	  
vasopressin)	  are	  also	  seen	  in	  heart	  failure,	  especially	  in	  those	  treated	  with	  diuretics	  




Both	  angiotensin	  II	  and	  aldosterone	  have	  direct	  effects	  on	  cardiac	  myocytes	  which	  
influence	  ventricular	  remodelling.	  Angiotensin	  II	  causes	  myocyte	  hypertrophy	  and	  
fibrosis[23],	  whilst	  aldosterone	  results	  in	  apoptosis	  of	  myocytes	  as	  well	  as	  fibrotic	  
changes[24].	  
	  
b. Sympathetic	  Nervous	  System	  
Angiotensin	  II	  stimulates	  release	  of	  noradrenaline	  (norepinephrine)	  from	  
sympathetic	  nerve	  terminals	  and	  inhibits	  vagal	  tone.	  The	  sympathetic	  nervous	  
system	  is	  also	  directly	  stimulated	  by	  baroreceptors	  in	  response	  to	  a	  fall	  in	  cardiac	  
output.	  Blood	  pressure	  is,	  consequently,	  raised	  by	  peripheral	  vasoconstriction	  and	  
heart	  rate	  rises,	  with	  concomitant	  increased	  myocardial	  oxygen	  demand.	  Prolonged	  
exposure	  has	  a	  toxic	  effect	  on	  the	  myocardium,	  leading	  to	  cell	  death[25].	  Down-­‐
regulation	  of	  heart	  β1	  receptors	  in	  response	  to	  continuous	  stimulation	  does	  not	  
appear	  to	  be	  effective	  at	  preventing	  autonomic	  dysregulation.	  To	  compound	  the	  
situation	  further,	  sympathetic	  activity	  stimulates	  the	  renin-­‐angiotensin-­‐aldosterone	  
system	  (RAAS)	  as	  part	  of	  a	  positive	  feedback	  loop[26].	  
	  
c. Natriuretic	  Peptides	  
Wall	  stress	  in	  the	  atria	  and	  ventricles	  is	  increased	  in	  heart	  failure	  by	  a	  combination	  of	  
increased	  preload	  and	  structural	  changes	  to	  the	  chamber	  walls.	  Stretching	  of	  the	  
atrial	  and	  ventricular	  walls	  results	  in	  the	  secretion	  of	  ANP	  (atrial	  natriuretic	  peptide)	  
and	  BNP	  (brain	  /	  b-­‐type	  natriuretic	  peptide)	  respectively.	  These	  hormones	  act	  to	  
promote	  vasodilatation	  and,	  as	  the	  names	  suggest,	  natriuresis[27].	  In	  such,	  they	  are	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antagonistic	  to	  the	  RAAS	  and	  the	  sympathetic	  nervous	  system	  but	  are	  overwhelmed	  
by	  their	  activity	  in	  heart	  failure.	  	  
Assays	  are	  available	  for	  the	  detection	  of	  BNP	  and	  its	  inactive	  N-­‐terminal	  cleavage	  
fragment	  (NT-­‐proBNP),	  which	  can	  be	  helpful	  in	  identifying	  cases	  of	  heart	  failure	  
where	  there	  is	  diagnostic	  uncertainty[28].	  
	  
d. Cytokines	  
Heart	  failure	  is	  an	  inflammatory	  state.	  Transgenic	  mice,	  bred	  to	  over-­‐express	  tumour	  
necrosis	  factor	  alpha	  (TNF-­‐α)	  in	  cardiac	  myocytes	  develop	  a	  heart	  failure	  syndrome	  
as	  a	  result	  of	  myocarditis	  and	  ventricular	  dilatation[29].	  Levels	  of	  TNF-­‐α,	  interleukin	  
1	  (IL-­‐1)	  and	  interleukin	  6	  (IL-­‐6)	  are	  elevated	  in	  heart	  failure	  and	  can	  result	  in	  myocyte	  
hypertrophy	  and	  apoptosis[30].	  These	  circulating	  cytokines	  not	  only	  affect	  the	  heart	  
but	  are	  felt	  to	  be	  responsible	  for	  the	  cachexia	  associated	  with	  advanced	  heart	  
failure[31].	  	  	  	  
	  	  	  	  	  
The	  End	  Result	  
All	  of	  these	  interlinked	  systems	  act	  on	  a	  heart	  with	  systolic	  left	  ventricular	  
impairment	  to	  influence	  adverse	  remodelling.	  The	  heart	  itself	  is	  dilated	  in	  an	  
attempt	  to	  increase	  ventricular	  pre-­‐load	  –	  the	  Frank-­‐Starling	  mechanism[32]	  –	  and	  
these	  various	  neurohormonal	  mechanisms	  influence	  apoptosis,	  dissolution	  of	  
myocyte	  bridging	  collagen	  struts,	  myocyte	  hyopertrophy,	  and	  increased	  production	  
of	  the	  insterstitial	  matrix[33].	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Uncontrolled	  adverse	  remodelling	  leads	  inexorably	  to	  the	  development	  of	  a	  dilated,	  
globular	  ventricle	  and	  progressive	  pump	  failure.	  Structural	  changes,	  combined	  with	  
the	  abnormal	  internal	  milieu,	  also	  markedly	  increase	  the	  propensity	  for	  malignant	  
dysrhythmia	  –	  both	  atrial[34]	  and	  ventricular[35].	  	  
	  
3.I.iii.	  HEART	  FAILURE	  WITH	  NORMAL	  EJECTION	  FRACTION	  (HFNEF)	  
The	  clinical	  presentation	  of	  HFNEF	  can	  be	  identical	  to	  that	  of	  heart	  failure	  with	  
systolic	  left	  ventricular	  dysfunction.	  	  However,	  as	  an	  entity	  it	  has	  proved	  difficult	  to	  
study	  in	  the	  real	  world	  as	  a	  clear-­‐cut	  diagnosis	  is	  difficult	  without	  invasive	  pressure-­‐
volume	  relationship	  measurements	  –	  ideally	  available	  for	  both	  before	  and	  after	  the	  
onset	  of	  the	  heart	  failure	  syndrome[36].	  The	  quest	  continues	  to	  find	  a	  reliable	  and	  
reproducible	  echocardiographic	  surrogate	  measure	  for	  the	  phenomenon,	  though	  
assessment	  of	  left	  ventricular	  diastolic	  function	  and	  left	  atrial	  size	  are	  recommended	  
in	  establishing	  the	  diagnosis[37].	  	  
	  
The	  pathophysiology	  of	  the	  condition	  is	  typified	  by	  hypertrophy	  of	  myocytes	  and	  
excessive	  fibrosis.	  This	  situation	  results	  in	  ‘stiffening’	  of	  the	  left	  ventricle	  in	  diastole	  
and	  a	  lack	  of	  distensibility,	  with	  consequent	  abnormal	  relaxation	  filling	  of	  the	  
chamber.	  Well	  recognised	  causes	  are	  hypertension,	  chronic	  ischaemia	  and	  diabetes.	  
Pressure	  overload	  hypertrophy	  as	  a	  result	  of	  aortic	  stenosis	  is	  also	  a	  prevalent	  causal	  




3.II.	   DIAGNOSIS	  
	  
Heart	  failure	  is	  a	  triad	  of	  dyspnoea,	  fatigue	  and	  fluid	  retention	  and	  patients	  
presenting	  with	  complaints	  of	  decreased	  exercise	  tolerance	  or	  with	  a	  syndrome	  of	  
fluid	  retention	  should	  be	  considered	  as	  potential	  cases[40,	  41].	  Symptoms,	  however,	  
may	  be	  non-­‐typical	  and	  include	  dizziness,	  confusion,	  anorexia,	  abdominal	  bloating	  or	  
nocturia[42].	  Often,	  a	  careful	  history	  and	  examination	  will	  uncover	  the	  more	  typical	  
signs	  and	  symptoms	  of	  heart	  failure.	  
	  
Various	  models	  have	  been	  employed	  to	  diagnose	  heart	  failure	  in	  the	  research	  setting	  
and	  in	  clinical	  practice.	  Commonly	  cited	  examples	  are	  the	  Framingham	  Criteria[43]	  
and	  the	  Boston	  Criteria[44].	  Such	  models	  rely	  on	  features	  of	  a	  patient’s	  history,	  
examination	  findings	  and	  the	  appearances	  of	  plain	  chest	  radiography,	  and	  have	  been	  
shown	  to	  have	  high	  levels	  of	  specificity	  and	  moderate	  levels	  of	  sensitivity	  for	  
identifying	  persons	  with	  definite	  heart	  failure[45].	  International	  guidelines	  for	  the	  
diagnosis	  of	  heart	  failure	  stipulate	  that	  typical	  symptoms	  and	  signs	  should	  be	  
present	  in	  combination	  with	  objective	  evidence	  of	  cardiac	  dysfunction	  –	  most	  
commonly	  determined	  by	  echocardiographic	  assessment[41,	  46].	  
	  
Where	  symptoms	  and	  signs	  are	  present,	  the	  following	  tests	  are	  recommended	  by	  
the	  UK	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE),	  to	  either	  rule	  out	  




• 12-­‐lead	  surface	  electrocardiogram	  (ECG).	  
o Where	  the	  ECG	  is	  normal,	  heart	  failure	  due	  to	  left	  ventricular	  systolic	  
dysfunction	  is	  highly	  unlikely.	  	  
o Where	  the	  ECG	  is	  abnormal	  it	  may	  provide	  clues	  to	  the	  underlying	  
aetiology	  of	  the	  heart	  failure	  e.g.	  evidence	  of	  previous	  myocardial	  
infarction	  or	  left	  ventricular	  hypertrophy.	  
• Chest	  radiograph	  taken	  in	  the	  postero-­‐anterior	  projection.	  
o May	  demonstrate	  cardiomegaly	  or	  pulmonary	  venous	  congestion	  but	  
is	  most	  useful	  to	  exclude	  significant	  lung	  pathology.	  	  
• Blood	  analyses:	  
o Serum	  electrolytes,	  urea	  and	  creatinine.	  
o Full	  blood	  count.	  
o Thyroid	  function	  tests.	  
o Liver	  function	  tests	  including	  albumin.	  
o Fasting	  glucose	  and	  lipid	  profile.	  
o Assay	  of	  BNP	  or	  NT-­‐proBNP.	   	  
• Urinalysis	  for	  proteinuria	  and	  glycosuria	  
• Cardiac	  imaging	  by	  echocardiography.	  	  
o Information	  should	  be	  provided	  on	  the	  structure	  and	  function	  of	  all	  
four	  cardiac	  chambers,	  all	  valves	  and	  the	  pericardium.	  If	  such	  
information	  cannot	  be	  provided	  then	  alternative	  methods	  of	  cardiac	  
imaging	  may	  be	  required	  (cardiac	  magnetic	  resonance	  imaging	  [cMRI]	  
or	  gated	  radionucleotide	  scanning).	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3.III.	   EPIDEMIOLOGY	  
	  
Chronic	  heart	  failure	  represents	  a	  major	  burden	  of	  disease,	  both	  for	  society	  and	  the	  
individual[47].	  The	  overall	  5	  year	  mortality	  is	  estimated	  to	  be	  in	  the	  region	  of	  
60%[48]	  and	  UK	  data	  suggest	  that	  the	  6	  month	  mortality	  is	  in	  the	  region	  of	  30%,	  with	  
40%	  of	  patients	  not	  surviving	  at	  18	  months	  following	  the	  initial	  diagnosis[49].	  
	  
The	  impact	  of	  the	  syndrome	  in	  health	  economic	  terms	  is	  profound	  and	  estimates	  
from	  the	  early	  years	  of	  the	  21st	  Century	  put	  the	  percentage	  of	  all	  healthcare	  
spending	  on	  heart	  failure	  in	  developed	  nations	  at	  somewhere	  between	  1%	  and	  2%	  
per	  annum[50].	  This	  figure	  is	  set	  to	  increase	  over	  time	  –	  predictions	  made	  in	  2000	  
for	  the	  prevalence	  of	  heart	  failure	  by	  2020	  estimated	  a	  31%	  increase	  in	  men	  and	  a	  
17%	  increase	  in	  women,	  largely	  as	  a	  consequence	  of	  the	  ageing	  population	  as	  a	  
whole[51].	  Overall	  prevalence	  is	  approximately	  2%,	  but	  this	  rises	  markedly	  with	  age,	  
and	  prevalence	  in	  those	  over	  85	  may	  be	  as	  high	  as	  15%[52].	  	  
	  
Life	  expectancy	  is	  markedly	  reduced	  in	  heart	  failure	  and	  mortality	  is	  especially	  high	  
in	  the	  first	  year	  following	  diagnosis	  –	  estimated	  at	  20–30%[53].	  Overall	  in-­‐hospital	  
mortality	  for	  patients	  presenting	  with	  an	  acute	  heart	  failure	  syndrome	  is	  around	  
10%,	  but	  cardiogenic	  shock	  has	  a	  considerably	  poorer	  outlook	  [54].	  Of	  all	  heart	  
failure	  patients	  who	  do	  survive	  to	  discharge	  1	  in	  4	  will	  be	  re-­‐admitted	  within	  12	  




The	  bulk	  of	  the	  economic	  burden	  of	  heart	  failure	  is	  consequent	  on	  hospital	  in-­‐patient	  
care	  –	  60%	  in	  the	  most	  recently	  available	  costing	  analysis	  for	  the	  UK	  National	  Health	  
Service	  (figure	  1)[57]	  –	  and,	  predicting	  increased	  prevalence	  at	  the	  rates	  quoted,	  
estimates	  are	  for	  a	  translation	  into	  increases	  in	  hospitalizations	  of	  34%	  in	  men	  and	  
12%	  in	  women	  by	  2020.	  	  Hospital	  stays	  are	  long	  -­‐	  9.5	  days	  on	  average	  –	  and	  around	  a	  
third	  of	  patients	  will	  be	  re-­‐hospitalized	  within	  12	  months[49].	  
	  
3.IV.	   DEFINING	  HEART	  FAILURE	  
	  
Despite	  these	  statistics,	  one	  of	  the	  difficulties	  of	  working	  in	  this	  area	  is	  that,	  as	  
outlined	  above,	  heart	  failure	  itself	  remains	  difficult	  to	  define	  and	  quantify[58].	  
Specific	  guidelines	  on	  the	  diagnosis	  of	  heart	  failure	  are	  available	  from	  consensus	  
documents	  published	  by	  the	  European	  Society	  of	  Cardiology	  and	  the	  American	  Heart	  
Association	  and	  both	  agree	  that	  the	  diagnosis	  relies	  on	  clinical	  assessment	  coupled	  
with	  objective	  evidence	  of	  cardiac	  dysfunction[41,	  46,	  59].	  In	  the	  UK,	  guidance	  is	  
issued	  by	  the	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE),	  which	  
specifically	  makes	  the	  point	  in	  its	  second	  paragraph	  that:	  “There	  is	  no	  single	  
diagnostic	  test	  for	  heart	  failure…”	  [60].	  	  	  	  
	  
Such	  reliance	  on	  clinical	  diagnosis	  introduces	  an	  element	  of	  subjectivity	  which	  does	  
not	  sit	  well	  in	  the	  arena	  of	  hard	  science.	  This	  is	  made	  all	  the	  more	  difficult	  by	  the	  fact	  
that,	  until	  very	  recently,	  most	  of	  the	  available	  data	  on	  heart	  failure	  has	  come	  from	  
trials	  where	  only	  patients	  with	  markedly	  reduced	  left	  ventricular	  ejection	  fraction	  
(LVEF)	  were	  included	  (‘systolic	  heart	  failure’).	  Up	  to	  date	  guidelines	  recognise	  that	  
	  21	  
the	  syndrome	  is	  equally	  common	  where	  the	  LVEF	  is	  preserved	  above	  a	  ‘normal’	  level	  
of	  45	  –	  50%	  (‘diastolic	  heart	  failure’	  or	  ‘heart	  failure	  with	  normal	  ejection	  fraction’	  
[HFNEF])[37,	  61].	  Developing	  a	  cohort	  to	  accurately	  and	  representatively	  describe	  
the	  relationship	  between	  socioeconomic	  status	  and	  heart	  failure	  is	  therefore	  a	  major	  
challenge.	  	  
	  
3.V.	   DETERMINANTS	  OF	  OUTCOME	  IN	  HEART	  FAILURE	  
	  
Many	  clinical	  factors	  have	  been	  shown	  to	  affect	  prognosis,	  the	  most	  important	  
being[62-­‐65]:	  
• Age	  at	  first	  presentation.	  
• Extent	  of	  co-­‐morbidity.	  
• Severity	  of	  symptoms	  as	  expressed	  by	  New	  York	  Heart	  Association	  (NYHA)	  
grade[66].	  
• Severity	  of	  LV	  dysfunction.	  	  
• Plasma	  BNP	  or	  NT-­‐proBNP	  concentration.	  
• Renal	  function	  and	  plasma	  sodium.	  
• Blood	  pressure	  at	  presentation.	  
• Peak	  oxygen	  consumption	  on	  cardiopulmonary	  exercise	  testing	  [67].	  
	  
In	  addition	  to	  these	  factors,	  outcomes	  have	  been	  powerfully	  mediated	  by	  markedly	  




3.VI.	   MODERN	  MANAGEMENT	  OF	  HEART	  FAILURE	  
	  
3.VI.i.	  DIURETICS	  
Most	  patients	  with	  chronic	  heart	  failure	  will	  require	  some	  oral	  diuretic	  therapy.	  
These	  drugs	  improve	  symptoms	  by	  easing	  fluid	  retention[68].	  However,	  their	  use	  
may	  exacerbate	  neurohormonal	  activation	  by	  decreasing	  circulating	  blood	  
volume[69].	  It	  is	  therefore	  of	  paramount	  importance	  that	  diuretics	  are	  used	  at	  the	  
minimum	  required	  dose	  and	  in	  conjunction	  with	  the	  disease	  modifying	  drugs	  
described	  below[70].	  Periods	  of	  increased	  tendency	  to	  fluid	  retention	  may	  require	  
higher	  dosage	  of	  diuretic,	  but	  this	  can	  be	  reduced	  again	  once	  control	  has	  been	  re-­‐
established[71].	  Higher	  diuretic	  doses	  are,	  therefore,	  often	  taken	  as	  a	  proxy	  of	  
increasing	  disease	  severity,	  where	  control	  of	  the	  syndrome	  is	  more	  difficult[72,	  73].	  	  
Many	  expert	  patients	  adjust	  their	  daily	  dose	  depending	  on	  their	  weight,	  and	  disease	  
management	  programmes,	  specialist	  nursing	  support	  and	  patient	  education	  help	  to	  
facilitate	  this[74].	  
	  
Commonly	  used	  diuretics	  are	  shown	  in	  table	  2.	  Loop	  diuretics	  are	  considered	  first	  
line	  treatment	  as	  they	  are	  most	  effective	  in	  causing	  efficient	  diuresis.	  A	  thiazide	  may	  
be	  added	  in	  cases	  of	  resistant	  fluid	  retention.	  Potassium	  sparing	  diuretics	  can	  be	  
useful	  in	  stimulating	  additional	  fluid	  loss,	  without	  excessive	  kaliuresis[41].	  
	  
Management	  of	  heart	  failure	  has	  improved	  beyond	  the	  relief	  of	  congestion	  by	  
diuretics	  over	  the	  last	  30	  years	  due	  to	  a	  number	  of	  factors:	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3.VI.ii.	   DISEASE	  MODIFYING	  DRUG	  THERAPIES	  
Improved	  understanding	  of	  pathophysiology	  has	  allowed	  for	  the	  increased	  use	  of	  
disease	  modifying	  drug	  therapies	  based	  on	  robust	  clinical	  trial	  evidence	  in	  systolic	  
heart	  failure[75].	  These	  include	  antagonists	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  
axis	  and	  selected	  β-­‐blockers[76-­‐78].	  
	  
Trials	  in	  patients	  with	  systolic	  dysfunction	  have	  repeatedly	  confirmed	  the	  benefits	  of	  
drugs	  which	  antagonise	  the	  maladaptive	  neurohormonal	  mechanisms	  responsible	  
for	  the	  development	  of	  the	  heart	  failure	  syndrome	  as	  discussed	  earlier.	  These	  drugs	  
modify	  disease	  progression	  and	  improve	  prognosis.	  They	  are	  recommended	  in	  all	  
patients	  with	  heart	  failure	  and	  LV	  systolic	  dysfunction	  who	  are	  able	  to	  tolerate	  
them[79].	  Each	  agent	  should	  be	  introduced	  at	  a	  low	  dose	  and	  titrated	  towards	  target	  
doses	  with	  appropriate	  clinical	  supervision	  of	  symptoms,	  renal	  function,	  blood	  
pressure	  and	  side-­‐effects.	  
	  
A	  role	  for	  the	  use	  of	  these	  agents	  in	  HFNEF	  is	  less	  clear-­‐cut,	  with	  large	  randomised	  
trials	  of	  ACE	  inhibitors	  and	  angiotensin	  receptor	  blockers	  being	  neutral[80,	  81].	  This	  
emphasizes	  the	  importance	  of	  echocardiography	  in	  the	  assessment	  of	  heart	  failure	  






Angiotensin	  Converting	  Enzyme	  Inhibitors	  (ACEi)	  
ACEi	  reduce	  the	  relative	  risk	  of	  death	  by	  23%	  and	  the	  relative	  risk	  of	  worsening	  heart	  
failure	  by	  35%[76,	  82].	  Their	  beneficial	  effects	  have	  also	  been	  seen	  in	  asymptomatic	  
LVSD	  and	  heart	  failure	  post-­‐MI[83,	  84].	  
	  
ACEi	  work	  by	  reducing	  the	  production	  of	  angiotensin	  II,	  a	  hormone	  which	  is	  directly	  
toxic	  to	  myocytes	  and	  also	  results	  in	  deleterious	  peripheral	  and	  renal	  
vasoconstriction.	  Several	  preparations	  are	  licensed	  for	  use	  in	  heart	  failure	  and	  are	  
shown	  in	  table	  3.	  	  	  
Angiotensin	  II	  Receptor	  Antagonists	  
These	  drugs	  block	  angiotensin	  II	  at	  its	  receptor	  and	  consequently	  reduce	  the	  effect	  
of	  the	  RAAS.	  Their	  clinical	  effect	  can	  be	  thought	  of	  as	  analogous	  to	  ACEi	  and	  they	  
share	  the	  same	  side	  effect	  profile,	  except	  that	  they	  do	  not	  produce	  rises	  in	  
bradykinin	  and	  so	  do	  not	  result	  in	  troublesome	  cough.	  
	  
Of	  the	  several	  agents	  available,	  the	  evidence	  base	  is	  strongest	  for	  the	  use	  of	  
candesartan	  in	  chronic	  heart	  failure	  [85]	  and	  valsartan	  for	  use	  in	  post-­‐MI	  LV	  systolic	  
dysfunction	  [86].	  	  
	  
β-­‐Blockers	  
β-­‐Blockers	  shown	  to	  have	  beneficial	  effects	  in	  heart	  failure,	  together	  with	  their	  
dosing	  schedules,	  are	  listed	  in	  table	  4[87].	  Well	  designed	  clinical	  trials	  have	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demonstrated	  β-­‐blockers	  reduce	  the	  risk	  of	  all	  cause	  mortality	  and	  death	  due	  to	  
heart	  failure	  by	  25%	  and	  35%,	  respectively	  [77,	  88-­‐90].	  	  
	  
Whilst	  these	  long-­‐term	  benefits	  are	  clear,	  introduction	  of	  β-­‐Blockers	  can	  result	  in	  
acute	  deterioration	  in	  the	  control	  of	  the	  heart	  failure	  syndrome	  due	  to	  abrupt	  
changes	  in	  haemodynamic	  compensatory	  mechanisms.	  	  These	  agents	  should,	  
therefore,	  be	  introduced	  and	  up-­‐titrated	  cautiously,	  paying	  close	  attention	  to	  heart	  
rate,	  blood	  pressure,	  fluid	  status	  and	  renal	  function[91].	  If	  decompensation	  occurs	  
with	  the	  introduction	  of	  β-­‐blockade	  then	  temporary	  increases	  in	  diuretic	  dosing	  may	  
improve	  the	  situation.	  These	  drugs	  are	  generally	  avoided	  in	  the	  acute	  setting	  of	  
decompensation,	  particularly	  if	  the	  patient	  is	  fluid	  overloaded[92].	  
	  
Side	  effects	  of	  β-­‐Blockers	  include	  bradycardia,	  heart	  block	  and	  hypotension.	  Care	  is	  
needed	  when	  considering	  the	  use	  of	  β-­‐Blockers	  in	  patients	  with	  peripheral	  vascular	  
disease	  and	  chronic	  airways	  disease.	  However,	  cardioselective	  agents	  are	  considered	  
safe	  except	  in	  cases	  of	  definite	  asthma[93].	  	  
	  
Aldosterone	  Antagonists	  
Blockade	  of	  the	  aldosterone	  receptor	  is	  achieved	  by	  the	  use	  of	  either	  spironolactone	  
or	  eplerenone.	  Experience	  with	  spironolactone	  in	  patients	  with	  moderate	  to	  severe	  
chronic	  heart	  failure	  (NYHA	  III	  –	  IV)	  has	  revealed	  that	  use	  of	  a	  dose	  of	  25mg	  –	  50mg	  
is	  associated	  with	  a	  30%	  reduction	  in	  the	  relative	  risk	  of	  death[78].	  Eplerenone	  is	  a	  
more	  selective	  aldosterone	  antagonist,	  of	  proven	  benefit	  in	  patients	  with	  low	  
ejection	  fraction	  and	  either	  diabetes	  or	  heart	  failure	  when	  used	  in	  the	  post-­‐MI	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setting[94].	  Evidence	  has	  more	  recently	  emerged	  to	  also	  support	  its	  use	  in	  more	  mild	  
cases	  of	  heart	  failure[95].	  Both	  drugs	  are	  capable	  of	  precipitating	  significant	  
hyperkalaemia	  and	  renal	  dysfunction,	  and	  changes	  in	  fluid	  status	  can	  markedly	  
increase	  this	  effect.	  Consequently,	  close	  monitoring	  of	  electrolytes,	  urea	  and	  
creatinine	  is	  required	  when	  introducing	  these	  drugs	  and	  when	  using	  them	  in	  periods	  
of	  physiological	  instability.	  	  
	  
3.VI.iii.	   ADJUNCTIVE	  DRUG	  THERAPIES	  
Other	  agents	  are	  of	  benefit	  in	  specific	  situations	  in	  heart	  failure,	  particularly	  where	  
comorbid	  conditions	  –	  most	  notably	  atrial	  fibrillation	  –	  complicate	  the	  syndrome.	  
	  
Digoxin	  
Digitalis	  has	  been	  used	  historically	  for	  the	  treatment	  of	  congestive	  syndromes.	  There	  
is	  little	  evidence	  to	  support	  its	  modern	  day	  use	  in	  patients	  with	  sinus	  rhythm	  but	  it	  is	  
often	  added	  to	  conventional	  treatment	  in	  patients	  who	  have	  failed	  to	  respond	  to	  
other	  therapies[96].	  It	  can	  be	  useful	  in	  controlling	  ventricular	  rates	  in	  AF,	  but	  β-­‐
Blockade	  is	  preferable	  and	  digoxin	  is	  recommended	  as	  an	  ‘add	  in’	  agent	  rather	  than	  
first	  line	  therapy[97].	  Toxicity	  can	  arise	  easily	  in	  the	  elderly,	  particularly	  with	  
intercurrent	  illness	  and	  changes	  in	  renal	  function	  or	  electrolytes.	  	  
	  
Anticoagulants	  
Vitamin	  K	  antagonists	  (VKA)	  are	  vital	  in	  heart	  failure	  complicated	  by	  AF	  to	  reduce	  
thromboembolic	  risk.	  Modern	  guidelines	  recommend	  anticoagulation	  in	  AF	  
according	  to	  the	  assessment	  of	  stroke	  risk	  using	  the	  CHA2DS2-­‐VASc	  score	  (see	  table	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5)[98].	  Scores	  ≥	  2	  are	  associated	  with	  adjusted	  stroke	  rates	  of	  2.2%	  or	  greater	  per	  
year	  and	  formal	  anticoagulation	  with	  VKA	  is	  recommended[99].	  	  	  
	  
Such	  anticoagulants	  are	  also	  used	  where	  intra-­‐cardiac	  thrombus	  has	  been	  observed	  
on	  imaging,	  where	  there	  is	  evidence	  of	  left	  ventricular	  aneurysm,	  or	  in	  dilated	  
cardiomyopathy	  with	  a	  history	  of	  thromboembolism[100].	  
	  
Nitrate	  and	  Hydralazine	  Combinations	  
This	  previously	  widely	  used	  combination	  oral	  therapy	  has	  been	  superseded	  by	  ACEi.	  
However,	  benefit	  has	  been	  demonstrated	  when	  this	  combination	  is	  added	  to	  ACEi	  /	  
angiotensin	  II	  receptor	  antagonist	  and	  β-­‐Blocker	  in	  African	  American	  populations	  –	  
probably	  due	  to	  their	  relative	  low	  renin	  phenotype[101].	  	  
	  
3.VI.iv.	   INTEGRATED,	  MULTI-­‐DISCIPLINARY	  DISEASE	  MANAGEMENT[56,	  102]	  
The	  Heart	  Failure	  Association	  (HFA)	  of	  the	  European	  Society	  of	  Cardiology	  (ESC)	  has	  
published	  a	  statement	  setting	  out	  the	  standards	  of	  care	  that	  patients	  with	  heart	  
failure	  should	  expect[103].	  Key	  within	  these	  recommendations	  is	  the	  concept	  that	  
optimal	  management	  should	  involve	  a	  seamless	  system	  of	  care	  throughout	  the	  
journey	  of	  the	  individual	  heart	  failure	  patient.	  To	  achieve	  this,	  a	  high	  degree	  of	  
coordination	  between	  multiple	  services	  within	  a	  health	  care	  system	  is	  required.	  
Evidence	  in	  this	  area	  supports	  the	  benefits	  of	  specialist	  follow-­‐up	  and	  nurse	  led	  heart	  
failure	  services	  to	  facilitate	  the	  adoption	  of	  beneficial	  lifestyle	  measures[104],	  and	  
the	  safe	  and	  timely	  up-­‐titration	  of	  disease	  modifying	  drug	  therapies,	  as	  well	  as	  
improving	  patient	  education	  and	  self	  monitoring[105]	  to	  prevent	  recurrent	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decompensations[56,	  74,	  106-­‐121].	  The	  majority	  of	  these	  data	  are	  based	  on	  small	  
studies	  and	  benefits	  are	  largely	  observed	  in	  the	  prevention	  of	  recurrent	  
hospitalizations.	  However,	  heart	  failure	  is	  a	  long-­‐term,	  complex	  condition	  requiring	  
close	  monitoring	  and	  rapid	  access	  to	  specialist	  treatment	  where	  the	  syndrome	  is	  
unstable.	  The	  characteristics	  of	  a	  management	  programme,	  recommended	  by	  the	  
HFA,	  clearly	  demonstrate	  that	  a	  high	  level	  of	  input	  from	  care	  providers	  with	  an	  
expert	  knowledge	  of	  the	  syndrome,	  and	  the	  treatment	  options	  available,	  is	  a	  
requirement	  for	  optimal	  modern	  management	  of	  the	  heart	  failure	  patient.	  	  
	   	  
	  
3.VI.v.	   IMPLANTABLE	  DEVICE	  THERAPY	  	  
Large,	  randomised	  trials	  of	  implantable	  devices	  have	  demonstrated	  improvements	  in	  
both	  mortality	  and	  morbidity	  in	  subsets	  of	  heart	  failure	  patients	  [122-­‐124].	  	  
The	  benefits	  observed	  are	  the	  result	  of	  one	  or	  both	  of	  the	  following:	  
• Termination	  of	  malignant	  ventricular	  tachyarrhythmia	  by	  implantable	  
cardioverter	  defibrillator	  (ICD)	  technology	  reduces	  sudden	  death[125].	  
• Correction	  of	  electromechanical	  dyssynchrony	  by	  atrio-­‐biventricular	  pacing	  –	  
“cardiac	  resynchronisation	  therapy”	  (CRT)	  –	  improves	  pump	  efficiency.	  
	  
ICD	  therapy	  has	  been	  demonstrated	  to	  benefit	  patients	  with	  ischaemic	  heart	  
disease,	  LVSD	  and	  documented	  evidence	  of	  ventricular	  arrhythmia	  or	  previous	  
cardiac	  arrest[122].	  In	  patients	  with	  no	  documented	  arrhythmia,	  ICD	  implantation	  is	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still	  recommended	  for	  those	  with	  LVEF	  ≤	  35%	  in	  NHYA	  class	  II	  or	  III†.	  Current	  
guidelines	  from	  the	  UK	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE)	  
state	  that	  patients	  should	  have	  a	  reasonable	  expectation	  of	  survival	  with	  good	  
functional	  status	  for	  at	  least	  1	  year[126].	  NHYA	  class	  IV	  patients	  are	  not	  considered	  
eligible	  as	  mortality	  is	  more	  likely	  to	  be	  the	  result	  of	  progressive	  heart	  failure	  than	  
sudden	  cardiac	  death.	  International	  guidelines	  suggest	  that	  the	  indications	  for	  ICD	  
therapy	  in	  patients	  with	  non-­‐ischaemic	  causes	  of	  heart	  failure	  should	  be	  similar[41,	  
59].	  
	  	  
CRT	  can	  exist	  as	  a	  pacing	  system	  alone	  (CRT-­‐P)	  or	  be	  combined	  with	  ICD	  technology	  
(CRT-­‐D)	  for	  those	  at	  particularly	  high	  risk	  of	  sudden	  death.	  Implantation	  is	  as	  for	  a	  
standard	  dual	  chamber	  (atrio-­‐right	  ventricular)	  pacemaker	  but	  with	  a	  lead	  to	  pace	  
the	  left	  ventricle	  introduced	  via	  the	  coronary	  sinus.	  Electromechanical	  dyssynchrony	  
can	  be	  corrected	  by	  adjusting	  the	  timing	  of	  pacing	  by	  the	  atrial	  and	  ventricular	  
leads.	  Dyssynchrony	  is	  best	  predicted	  in	  a	  patient	  with	  a	  QRS	  duration	  prolonged	  
beyond	  120ms	  (left	  bundle	  branch	  block)	  and	  a	  low	  EF.	  	  
	  
Currently,	  CRT-­‐P	  insertion	  is	  recommended	  in	  patients	  with	  LVEF	  ≤35%	  and	  QRS	  
duration	  ≥120ms,	  who	  have	  NYHA	  class	  III-­‐IV	  symptoms,	  despite	  optimal	  medical	  
therapy.	  This	  is	  supported	  by	  robust	  trial	  data	  demonstrating	  the	  effectiveness	  of	  
such	  devices	  in	  reducing	  mortality	  and	  repeat	  hospitalisations[124,	  127]	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
† Not	  within	  40	  days	  of	  an	  acute	  myocardial	  infarction. 
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4.	   INEQUALITY	  IN	  HEART	  FAILURE	  
	  
4.I.	   REASONS	  TO	  SUSPECT	  THE	  OPERATION	  OF	  HEALTH	  INEQUALITY	  IN	  HEART	  FAILURE	  
	  
Where	  increasing	  and	  more	  complex	  options	  are	  available	  for	  the	  management	  of	  a	  
condition,	  as	  outlined	  above	  for	  heart	  failure,	  then	  the	  propensity	  for	  phenomena	  of	  
health	  inequality	  is	  increased[9],	  as	  has	  been	  demonstrated	  in	  ischaemic	  heart	  
disease,	  stroke,	  and	  cancer[128-­‐131].	  The	  importance	  of	  close	  and	  careful	  
monitoring	  in	  the	  condition	  is	  also	  an	  area	  where	  differences	  in	  care	  may	  be	  
observed	  along	  socioeconomic	  lines	  as	  in	  the	  case	  of	  the	  monitoring	  of	  
hypertension[132].	  	  
	  	  	  	  
There	  is	  also	  reason	  to	  believe	  that	  socioeconomic	  factors	  influence	  outcome	  in	  
heart	  failure	  based	  initially	  on	  the	  study	  of	  coronary	  heart	  disease.	  The	  Framingham	  
Heart	  Study	  has	  identified	  those	  factors	  considered	  to	  be	  the	  classical	  risk	  factors	  for	  
cardiovascular	  disease[133].	  However,	  subsequent	  work	  to	  identify	  novel	  risk	  factors	  
has	  resulted	  in	  the	  development	  of	  a	  new,	  validated	  model	  for	  cardiovascular	  risk	  
prediction	  in	  the	  UK	  –	  QRISK	  –	  which	  includes	  assessment	  of	  an	  individuals	  
socioeconomic	  status[134].	  The	  validity	  of	  such	  a	  tool	  is	  not	  surprising,	  given	  the	  
wealth	  of	  data	  which	  has	  been	  accumulated	  relating	  socioeconomic	  status	  to	  
cardiovascular	  risk,	  and	  this	  has	  been	  well	  reviewed	  by	  Kaplan	  and	  Keil[135].	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The	  Whitehall	  Study	  demonstrated	  that	  mortality	  rates	  differed	  markedly	  between	  
UK	  civil	  servants	  depending	  on	  their	  grade.	  Both	  the	  original	  and	  follow	  up	  study,	  
Whitehall	  II,	  demonstrated	  significantly	  higher	  rates	  of	  ischaemic	  heart	  disease	  in	  
those	  of	  lower	  civil	  service	  job	  grades	  when	  compared	  to	  each	  grade	  above,	  even	  
allowing	  for	  obvious	  confounders	  such	  as	  smoking[136].	  This	  demonstrates	  that	  
traditional	  concepts	  of	  health	  inequality,	  simply	  based	  on	  wealth	  and	  poverty,	  are	  
not	  enough	  to	  explain	  the	  whole	  story.	  
	  
This	  evidence	  for	  an	  increased	  cardiovascular	  risk	  in	  general,	  and	  increased	  rates	  of	  
ischaemic	  heart	  disease	  dependent	  on	  socioeconomic	  status	  lend	  weight	  to	  the	  
proposal	  that	  heart	  failure	  outcomes	  might	  be	  associated	  with	  similar	  factors.	  
Estimates	  from	  trial	  and	  registry	  data	  suggest	  that	  anywhere	  between	  50%	  and	  70%	  
of	  heart	  failure	  is	  related	  to	  ischaemic	  heart	  disease[137].	  However,	  these	  figures	  
may	  not	  be	  representative	  of	  a	  “wild-­‐type”	  heart	  failure	  population,	  as	  










4.II.	   A	  CONTEMPORARY	  OVERVIEW	  OF	  HEART	  FAILURE	  MANAGEMENT	  IN	  THE	  UK	  –	  
THE	  NATIONAL	  HEART	  FAILURE	  AUDIT.	  
	  
The	  UK	  National	  Heart	  Failure	  Audit	  was	  established	  in	  July	  2007	  with	  the	  aim	  of	  
monitoring	  the	  care	  and	  treatment	  of	  patients	  admitted	  to	  hospital	  in	  England	  and	  
Wales	  with	  heart	  failure.	  The	  Audit	  is	  commissioned	  by	  the	  Healthcare	  Quality	  
Improvement	  Partnership	  (HQIP),	  managed	  by	  the	  National	  Institute	  for	  
Cardiovascular	  Outcomes	  Research	  (NICOR)	  at	  University	  College	  London	  (UCL)	  and	  
collects	  data	  on	  acute	  patients	  discharged	  from	  hospitals	  in	  England	  and	  Wales	  with	  
a	  coded	  diagnosis	  of	  heart	  failure	  in	  the	  primary	  position,	  reporting	  its	  findings	  on	  a	  
yearly	  basis.	  Specialist	  knowledge	  and	  support	  is	  provided	  by	  the	  British	  Society	  for	  
Heart	  Failure	  (BSH)	  and	  the	  Audit	  is	  part	  of	  the	  National	  Clinical	  Audit	  and	  Patient	  
Outcomes	  Programme	  (NCAPOP).	  
	  
The	  ICD-­‐10	  codes	  used	  to	  select	  patients	  for	  inclusion	  in	  the	  Audit	  are	  the	  same	  as	  
those	  specified	  in	  the	  SUSSEX-­‐HF	  cohort	  (table	  8),	  and	  patients	  admitted	  for	  elective	  
procedures	  are	  excluded.	  Data	  are	  now	  available	  for	  5	  one-­‐year	  periods	  up	  to,	  and	  
including,	  the	  data	  for	  2011/12.	  For	  this	  most	  recent	  report,	  participation	  in	  the	  
Audit	  has	  been	  mandated	  by	  the	  Department	  of	  Health’s	  standard	  terms	  and	  
conditions	  for	  acute	  hospitals	  in	  England,	  but	  not	  for	  those	  in	  Wales[139].	  
Participation	  is	  defined	  as	  an	  acute	  hospital	  trust	  submitting	  a	  minimum	  of	  20	  cases	  
to	  the	  audit	  each	  month,	  or	  all	  cases	  of	  heart	  failure	  for	  a	  given	  month	  if	  the	  total	  
number	  is	  less	  than	  20.	  12	  Trusts	  in	  England	  and	  one	  Health	  Board	  in	  Wales	  failed	  to	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submit	  data	  to	  the	  2011/12	  Audit,	  meaning	  that	  data	  are	  representative	  of	  90%	  of	  
acute	  care	  providers	  in	  England	  and	  Wales,	  and	  are	  based	  on	  59%	  of	  all	  heart	  failure	  
admissions	  nationally.	  
	  
National	  Audit	  data	  are	  not	  available	  for	  the	  period	  over	  which	  the	  cohort	  for	  
SUSSEX-­‐HF	  was	  assembled	  but	  data	  contemporaneous	  with	  the	  end	  of	  the	  follow-­‐up	  
period	  for	  this	  study	  are	  available	  in	  the	  report	  of	  2009/10.	  The	  primary	  aims	  of	  
collecting	  such	  audit	  data	  are	  to	  improve	  standards	  of	  care	  and	  to	  enable	  effective	  
commissioning.	  Therefore,	  with	  each	  iteration	  of	  the	  audit	  one	  would	  expect	  to	  
observe	  improvement	  in	  care	  quality,	  and	  so	  national	  data	  for	  2011/12	  will	  be	  
difficult	  to	  directly	  compare	  with	  data	  from	  SUSSEX-­‐HF.	  However,	  I	  will	  outline	  here	  
the	  findings	  of	  the	  most	  recent	  Audit	  to	  provide	  a	  frame	  of	  reference	  for	  
contemporary	  practice	  in	  the	  UK,	  in	  which	  the	  results	  of	  SUSSEX-­‐HF	  will	  be	  received.	  
	  
4.II.i.	   SUMMARY	  OF	  THE	  FINDINGS	  OF	  THE	  NHFA	  2011/12[140]	  
The	  most	  recent	  National	  Heart	  Failure	  Audit	  data	  have	  demonstrated	  improved	  
outcomes	  for	  patients	  treated	  on	  cardiology	  wards,	  and	  for	  patients	  diagnosed	  with	  
left	  ventricular	  systolic	  dysfunction	  (LVSD)	  as	  an	  in-­‐patient	  and	  prescribed	  disease	  
modifying	  drug	  therapy	  (ACEi/ARB,	  β-­‐blocker,	  mineralocorticoid	  receptor	  
antagonist).	  Survival	  has	  also	  been	  demonstrated	  to	  be	  improved	  by	  specialist	  
follow-­‐up	  by	  a	  consultant	  cardiologist.	  All	  of	  these	  factors	  have	  been	  shown	  to	  be	  
influenced	  by	  the	  age	  and	  sex	  of	  patients	  admitted	  with	  heart	  failure,	  with	  older	  
patients	  and	  women	  less	  likely	  to	  have	  access	  to	  care	  associated	  with	  improved	  
outcome.	  The	  data	  have	  also	  demonstrated	  that	  more	  deprived	  patients	  are	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admitted	  at	  a	  younger	  age.	  These	  findings	  are	  similar	  to	  those	  of	  previous	  audits,	  
although	  rates	  of	  prescription	  of	  medications	  and	  specialist	  care	  have	  improved	  and	  
what	  follows	  is	  an	  outline	  of	  the	  findings	  of	  this	  report.	  	  	  	  
	  
Data	  in	  this,	  most	  recent	  audit	  represent	  findings	  from	  37,076	  submitted	  records	  –	  
32,906	  index	  admissions	  and	  4,170	  readmissions.	  The	  mean	  age	  of	  patients	  on	  their	  
first	  admission	  was	  77.7	  years	  (median	  80.1	  years)	  and	  two	  thirds	  of	  patients	  were	  
over	  75	  at	  the	  time	  of	  first	  admission.	  Men	  were	  significantly	  younger	  than	  women	  
at	  the	  time	  of	  first	  admission	  (75.5	  years	  vs.	  80.3	  years)	  and	  the	  majority	  of	  patients	  
up	  to	  the	  age	  of	  85	  were	  men	  (61.1%).	  In	  those	  over	  85	  there	  was	  a	  higher	  
proportion	  of	  women	  (57.9%)	  but	  overall,	  more	  male	  cases	  of	  heart	  failure	  were	  
submitted	  to	  the	  audit	  (55.2%).	  
	  
Analysis	  of	  the	  age	  of	  patients	  at	  first	  admission	  according	  to	  their	  level	  of	  
deprivation,	  ascertained	  by	  hierarchical	  quintile	  group,	  demonstrated	  a	  mean	  age	  of	  
74.5	  years	  in	  the	  most	  deprived	  group	  vs.	  79.6	  years	  in	  the	  least	  deprived	  group.	  A	  
clear	  trend	  for	  an	  older	  age	  at	  time	  of	  first	  admission	  was	  also	  observed	  across	  the	  
quintiles	  (Q5:	  74.5	  years,	  Q4:	  76.9	  years,	  Q3:	  78.3	  years,	  Q2:	  79.1	  years,	  Q1:	  79.6	  
years).	  The	  authors	  state	  that	  they	  intend	  to	  carry	  out	  further	  analyses	  on	  the	  
treatment	  and	  management	  of	  patients	  according	  to	  their	  level	  of	  deprivation,	  but	  
as	  yet	  no	  such	  data	  are	  available.	  	  	  	  	  
	  
Just	  under	  half	  of	  all	  patients	  (48%)	  were	  treated	  on	  cardiology	  wards,	  and	  these	  
patients	  had	  an	  average	  length	  of	  stay	  of	  12.7	  days	  –	  shorter	  than	  both	  the	  13.1	  day	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average	  length	  of	  stay	  for	  the	  41%	  of	  patients	  managed	  on	  general	  medical	  wards	  
and	  the	  average	  of	  14.7	  days	  spent	  on	  other	  wards	  by	  the	  remaining	  11%	  of	  patients.	  
Treatment	  on	  a	  cardiology	  ward	  was	  associated	  with	  a	  significant	  survival	  advantage	  
(21.8%	  of	  patients	  dying	  over	  a	  median	  follow-­‐up	  period	  of	  242	  days	  vs.	  29.8%	  of	  
those	  treated	  on	  general	  medical	  wards	  and	  33.4%	  of	  those	  treated	  on	  other	  wards	  
over	  similar	  periods	  of	  follow-­‐up).	  Correcting	  for	  confounding	  factors	  of	  age	  >75,	  
NYHA	  class	  III/IV	  and	  previous	  myocardial	  infarction,	  a	  significantly	  lower	  chance	  of	  
survival	  was	  associated	  with	  treatment	  on	  a	  non-­‐cardiology	  ward	  (HR	  =	  1.66	  [95%	  
C.I.	  1.52-­‐1.81;	  p<0.001).	  	  
	  
Women	  were	  more	  likely	  to	  be	  treated	  on	  general	  medical	  wards	  (47.9%	  vs	  36.0%	  of	  
men)	  and	  other	  wards	  (12.4%	  vs.	  9.5%	  of	  men).	  Advancing	  age	  was	  also	  associated	  
with	  a	  decreased	  likelihood	  of	  treatment	  on	  a	  cardiology	  ward	  with	  76.3%	  of	  
patients	  under	  45	  treated	  on	  such	  wards	  compared	  with	  47.1%	  of	  patients	  aged	  74-­‐
84	  years	  and	  32.1%	  of	  patients	  85	  years	  and	  older.	  	  
	  
High	  rates	  of	  access	  to	  in-­‐patient	  echocardiography	  were	  demonstrated	  in	  these	  
audit	  data,	  with	  86%	  of	  patients	  undergoing	  the	  test	  during	  their	  admission.	  Patients	  
were	  more	  likely	  to	  undergo	  assessment	  by	  echocardiography	  if	  they	  were	  male	  
(88.8%)	  than	  if	  they	  were	  female	  (82.6%).	  Age	  was	  also	  an	  important	  determinant	  of	  
access	  to	  echocardiography,	  with	  91.4%	  of	  those	  under	  75	  years	  undergoing	  the	  test	  
compared	  with	  83.3%	  of	  those	  75	  and	  older.	  Treatment	  on	  a	  cardiology	  ward	  was	  
also	  associated	  with	  higher	  rates	  of	  echocardiography	  (92.9%	  vs.	  80.1%	  of	  those	  
treated	  on	  a	  general	  medical	  ward	  and	  77.8%	  of	  those	  on	  other	  wards).	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65%	  of	  patients	  in	  the	  audit	  had	  documented	  left	  ventricular	  systolic	  dysfunction	  
(LVSD)	  and	  84%	  of	  these	  were	  prescribed	  an	  ACE	  inhibitor	  or	  an	  ARB	  on	  discharge.	  
Rates	  of	  prescription	  were	  higher	  in	  those	  treated	  on	  a	  cardiology	  ward	  (87%	  vs.	  80%	  
on	  general	  medical	  wards	  and	  76%	  on	  other	  wards)	  and	  also	  higher	  in	  younger	  
patients	  (89%	  in	  those	  under	  75	  vs.	  80%	  in	  those	  75	  and	  over)	  and	  in	  men	  (85%	  vs	  
83%	  in	  women).	  	  
	  
Similar	  patterns	  were	  observed	  in	  the	  prescription	  of	  β-­‐blockers,	  though	  overall	  rates	  
of	  prescription	  were	  lower	  at	  78%.	  This	  figure	  was	  an	  improvement	  on	  the	  data	  from	  
the	  previous	  years	  audit,	  in	  which	  rates	  of	  β-­‐blocker	  prescription	  were	  65%.	  83%	  of	  
those	  treated	  on	  a	  cardiology	  ward	  received	  a	  β-­‐blocker	  compared	  with	  71%	  of	  
those	  on	  other	  wards.	  Age	  and	  gender	  again	  affected	  the	  likelihood	  of	  prescription	  
with	  84%	  of	  those	  under	  75	  receiving	  this	  class	  of	  medication	  compared	  with	  74%	  of	  
older	  patients,	  and	  79%	  of	  men	  vs.	  76%	  of	  women.	  
	  
The	  same	  patterns	  for	  prescription	  of	  mineralocorticoid	  receptor	  antagonists	  
(spironolactone	  and	  eplerenone)	  were	  observed	  in	  the	  audit	  data.	  Overall	  
prescription	  rates	  were	  45%	  of	  all	  those	  with	  LVSD	  and,	  again,	  rates	  were	  lower	  on	  
non-­‐cardiology	  wards	  (37%	  vs.	  51%),	  lower	  in	  women	  (40%	  vs.	  48%),	  and	  lower	  in	  
patients	  over	  75	  (39%	  vs.	  53%).	  
	  
Rates	  of	  follow-­‐up	  with	  heart	  failure	  liaison	  services	  were	  53.7%	  and	  rates	  of	  follow-­‐
up	  with	  a	  consultant	  cardiologist	  were	  51.7%.	  For	  both	  aspects	  of	  follow-­‐up,	  rates	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were	  higher	  in	  those	  treated	  on	  cardiology	  wards	  as	  an	  in-­‐patient,	  higher	  in	  men,	  
and	  higher	  in	  those	  under	  75	  years	  old	  –	  illustrated	  below.	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4.III.	   ANNOTATED	  REFERENCES	  ON	  HEART	  FAILURE	  AND	  INEQUALITY	  
	  
4.III.i	   GENERAL	  THEMES	  AND	  REFERENCE	  SELECTION	  	  
As	  discussed,	  inequity	  may	  be	  observed	  across	  multiple	  domains.	  To	  inform	  the	  
design	  of	  this	  study,	  and	  set	  it	  in	  the	  context	  of	  the	  existing,	  published	  evidence	  on	  
inequality	  in	  heart	  failure,	  a	  sytematic	  review	  of	  the	  literature	  has	  been	  undertaken.	  	  
	  
A	  thorough	  search	  for	  all	  available	  articles	  on	  the	  subject	  has	  been	  made	  using	  
MEDLINE,	  EMBASE,	  The	  Cochrane	  Database,	  Intute:	  Health	  &	  Life	  Sciences,	  The	  
National	  Electronic	  Library	  for	  Health	  (UK),	  Pubmed	  and	  Stat!Ref.	  Cross	  referencing	  
with	  sources	  quoted	  in	  scholarly	  articles	  generated	  by	  this	  search	  has	  also	  been	  
performed	  and,	  where	  relevant,	  data	  from	  such	  sources	  has	  informed	  this	  chapter.	  
Articles	  considered	  were	  those	  published	  in	  English	  from	  anywhere	  in	  the	  world	  
making	  reference	  to	  socio-­‐economic	  status,	  social	  class,	  deprivation,	  employment,	  
level	  of	  education,	  income,	  or	  inequality,	  in	  combination	  with	  heart	  failure,	  
ventricular	  dysfunction	  or	  congestive	  cardiac	  failure.	  
	  	  
This	  chapter	  comprises	  a	  review	  of	  the	  relationships	  observed	  between	  the	  clinical	  
syndrome	  of	  heart	  failure	  and	  various	  measures	  of	  socioeconomic	  status.	  Key	  
themes,	  identified	  on	  review	  of	  the	  available	  literature,	  were	  of	  the	  existence	  of	  
social	  gradients	  operating	  to	  determine	  differences	  in:	  
1. Heart	  failure	  incidence	  
2. Mortality	  rates	  in	  established	  heart	  failure	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3. Readmission	  rates	  for	  heart	  failure	  
4. Access	  to	  various	  therapies	  and	  disease	  management	  programmes	  identified	  
as	  beneficial	  in	  established	  heart	  failure.	  
	  
What	  follows	  comprises	  a	  list	  of	  references	  which	  have	  explored	  each	  of	  these	  
relationships.	  Each	  reference	  is	  accompanied	  by	  a	  description	  of	  the	  study	  
population,	  the	  method	  used	  to	  determine	  socioeconomic	  status	  and	  the	  basis	  on	  
which	  heart	  failure	  was	  diagnosed.	  Any	  significant	  relationship	  identified,	  as	  well	  as	  
the	  authors’	  conclusions	  are	  presented	  here	  also.	  
	  
Research	  in	  this	  area,	  by	  its	  very	  nature,	  tends	  to	  be	  centred	  around	  analyses	  of	  
wealthy,	  industrialized	  nations.	  The	  majority	  of	  the	  available	  literature	  comes	  from	  
the	  United	  States,	  Scotland,	  and	  the	  Scandinavian	  Countries	  of	  Sweden	  and	  Norway.	  	  
Other	  data	  are	  available	  from	  studies	  performed	  in	  England	  and	  Australasia.	  
Analyses	  of	  these	  data	  require	  an	  appreciation	  of	  the	  differing	  systems	  of	  health	  
insurance	  and	  patterns	  of	  access	  to	  healthcare	  which	  exist	  between	  these	  nations.	  
	  
4.III.ii.	   A	  starting	  point	  for	  considering	  the	  relationship	  between	  socioeconomic	  
status	  and	  heart	  failure	  
Eriksson	  et	  al.	  writing	  in	  the	  European	  Heart	  Journal	  in	  1989,	  were	  the	  first	  to	  
observe	  a	  link	  between	  SES	  and	  incident	  heart	  failure.	  Their	  study	  of	  men	  born	  in	  
Sweden	  in	  1913	  was	  designed	  to	  characterize	  risk	  factors	  for	  chronic	  heart	  
failure[141].	  They	  screened	  a	  sample	  drawn	  at	  random	  from	  the	  population	  of	  
Gothenburg	  using	  census	  data	  to	  identify	  individuals	  born	  in	  1913.	  In	  1963	  they	  were	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examined	  by	  the	  investigators	  and	  the	  examination	  was	  repeated	  in	  95%	  of	  cases	  in	  
1967.	  A	  second	  sample	  was	  drawn	  in	  1973	  using	  an	  identical	  method.	  These	  men	  
were	  examined	  and	  that	  examination	  repeated	  in	  1980.	  	  
	  
SES	  was	  characterized	  in	  both	  the	  ‘63	  and	  ’73	  cohorts	  using	  the	  official	  Swedish	  
classification	  which	  ranks	  individuals	  into	  three	  groups	  –	  1	  being	  the	  highest	  and	  3	  
the	  lowest.	  Essentially	  this	  classification	  system	  relies	  on	  employment	  to	  rank	  
individuals	  into:	  
1. Employers	  
2. Non-­‐manual	  employees	  
3. Manual	  workers	  
	  
However,	  a	  closer	  look	  at	  the	  system	  reveals	  that	  there	  are	  subsets	  of	  individuals	  in	  
each	  class.	  Farmers,	  for	  example,	  by	  virtue	  of	  being	  employers,	  are	  in	  the	  highest	  
social	  class,	  whereas	  upper	  level	  executives	  in	  major	  companies	  are	  in	  Class	  2.	  
Specific	  statements	  regarding	  highest	  level	  of	  educational	  achievement	  are	  also	  
made	  to	  subdivide	  the	  three	  classes,	  but	  these	  cannot	  trump	  the	  main	  class	  
boundaries	  dependent	  on	  employment.	  Thus	  it	  is	  the	  case	  that	  a	  highly	  educated	  
individual	  with	  a	  manual	  job	  is	  classed	  lower	  than	  an	  assistant	  non-­‐manual	  employee	  
with	  less	  than	  2	  years	  post-­‐comprehensive	  school	  education.	  
	  
Heart	  failure	  in	  this	  study	  was	  defined	  on	  the	  basis	  of	  a	  scoring	  system	  validated	  
previously	  in	  a	  publication	  by	  the	  same	  authors[142].	  The	  main	  inclusion	  criterion	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was	  dyspnoea	  on	  exertion	  and	  patients	  were	  then	  subdivided	  into	  5	  categories	  –	  CHF	  
0-­‐4	  (see	  table	  6).	  
	  	  
In	  their	  discussion	  the	  authors	  address	  the	  definition	  of	  heart	  failure,	  especially	  as	  an	  
end-­‐point	  in	  studies,	  and	  the	  problems	  inherent	  therein.	  Certainly,	  the	  argument	  for	  
a	  graded	  definition	  in	  an	  attempt	  to	  represent	  the	  heterogeneity	  of	  the	  condition	  is	  a	  
persuasive	  one.	  However,	  some	  of	  their	  scoring	  system	  is	  based	  on	  ischaemic	  
symptoms	  or	  dysrhythmia	  	  +/-­‐	  dyspnoea	  and	  in	  such	  they	  may	  have	  included	  purely	  
ischaemic	  patients	  or	  even	  those	  with	  lone	  atrial	  fibrillation.	  
	  
The	  authors	  found	  the	  prevalence	  of	  CHF	  among	  their	  67	  year	  old	  cohort	  in	  1980	  to	  
be	  13%.	  They	  analyzed	  multiple	  risk	  factors	  in	  an	  attempt	  to	  target	  avenues	  for	  
intervention	  to	  prevent	  the	  development	  of	  CHF	  and	  comment	  that	  social	  class	  at	  
the	  ages	  of	  50	  and	  60	  correlated	  positively	  with	  CHF	  development.	  In	  their	  
regression	  analysis	  of	  social	  class	  they	  found	  statistically	  significant	  differences	  in	  the	  
number	  of	  men	  who	  developed	  CHF	  over	  the	  course	  of	  both	  17	  and	  7	  years	  of	  
follow-­‐up	  (regression	  coefficient	  15.42	  [p=0.0001]	  and	  0.006	  [p=0.02]	  respectively).	  
Despite	  these	  convincing	  data	  the	  authors	  make	  no	  comment	  in	  their	  conclusions	  
about	  the	  likely	  effect	  of	  social	  class	  on	  predicting	  incident	  heart	  failure.	  
	  
This	  study	  is	  a	  useful	  starting	  point	  for	  considering	  the	  problems	  inherent	  in	  
exploring	  the	  relationship	  between	  SES	  and	  heart	  failure,	  as	  it	  demonstrates	  both	  
the	  difficulties	  in	  defining	  heart	  failure	  itself	  and	  the	  reliance	  on	  specific	  proxy	  
measures	  when	  determining	  individual	  SES	  –	  in	  this	  case	  hierarchical	  employment	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status.	  Women	  were	  not	  studied	  in	  this	  cohort,	  thus	  avoiding	  potential	  difficulty	  in	  
characterising	  female	  SES	  in	  relation	  to	  spousal	  employment.	  
	  
4.III.iii.	   INCIDENT	  HEART	  FAILURE	  AND	  SES	  
	  
MacIntyre	  K,	  Capewell	  S,	  Stewart	  S,	  Chalmers	  JW,	  Boyd	  J,	  Finlayson	  A,	  Redpath	  A,	  
Pell	  JP,	  McMurray	  JJ.	  Evidence	  of	  improving	  prognosis	  in	  heart	  failure:	  trends	  in	  
case	  fatality	  in	  66	  547	  patients	  hospitalized	  between	  1986	  and	  1995.	  Circulation	  
2000;	  102:	  1126	  –	  1131.	  	  
This	  Scottish-­‐wide	  retrospective	  cohort	  study	  examined	  case	  fatality	  rates	  per	  year	  in	  
patients	  hospitalized	  for	  the	  first	  time	  with	  heart	  failure	  according	  to	  ICD	  9	  coding	  of	  
admissions.	  Data	  on	  SES	  were	  collected	  according	  to	  Carstairs	  Deprivation	  category	  
based	  on	  postcode	  data	  and	  ranked	  1	  –	  5.	  
	  
Though	  the	  primary	  aim	  of	  the	  study	  was	  to	  assess	  case	  fatality	  rates	  over	  time,	  the	  
collection	  of	  SES	  data	  provide	  evidence	  of	  higher	  incidence	  of	  heart	  failure	  in	  more	  
deprived	  individuals.	  44%	  of	  cases	  came	  from	  the	  lowest	  two	  deprivation	  quintiles	  
and	  the	  admission	  rate	  was	  56%	  higher	  in	  the	  most	  deprived	  quintile	  compared	  with	  







He	  J,	  Ogden	  LG,	  Bazzano	  LA,	  et	  al.	  Risk	  Factors	  for	  Congestive	  Heart	  Failure	  in	  US	  
Men	  and	  Women:	  NHANES	  I	  Epidemiologic	  Follow-­‐up	  Study.	  Arch	  Intern	  Med.	  
2001;	  161:	  996-­‐1002.	  
The	  First	  National	  Health	  and	  Nutrition	  Examination	  Survey	  (NHANES	  I)	  allowed	  the	  
authors	  to	  examine	  the	  population	  attributable	  risk	  for	  incident	  heart	  failure	  of	  
various	  baseline	  characteristics	  in	  a	  cohort	  of	  5545	  men	  and	  8098	  women	  aged	  25	  to	  
74	  years,	  recruited	  in	  the	  initial	  phase	  of	  the	  study	  in	  1971-­‐1975.	  The	  relative	  risk	  for	  
incident	  heart	  failure	  associated	  with	  each	  factor	  was	  also	  examined.	  Follow-­‐up	  data	  
were	  collected	  in	  1982-­‐1984	  and	  1986,	  1987	  and	  1992.	  Incident	  heart	  failure	  was	  
based	  on	  one	  or	  more	  hospital	  or	  nursing	  home	  stays	  with	  a	  discharge	  diagnosis	  with	  
ICD-­‐9	  code	  428.0	  –	  428.9,	  or	  on	  a	  death	  certificate	  report	  with	  cause	  of	  death	  listed	  
as	  one	  of	  the	  same	  codes.	  
	  
A	  less	  than	  high	  school	  education	  was	  associated	  with	  a	  population	  attributable	  risk	  
of	  8.9%	  for	  incident	  heart	  failure	  and	  the	  relative	  risk	  for	  incident	  heart	  failure	  was	  
1.35	  (95%	  C.I.	  1.16-­‐1.57;	  p<0.001)	  overall,	  with	  the	  effect	  apparently	  slightly	  more	  
marked	  in	  women	  compared	  with	  men.	  In	  multivariate	  analysis	  –	  simultaneously	  
including	  all	  the	  significant	  factors	  identified	  in	  the	  age,	  race	  and	  time	  dependent	  
history	  of	  coronary	  heart	  disease	  adjusted	  model	  –	  the	  risk	  associated	  with	  a	  less	  
than	  high	  school	  education	  remained	  statistically	  significant	  (RR	  1.22	  [95%	  C.I.	  1.04-­‐
1.42]	  p=0.01).	  
	  
The	  authors	  conclude	  that	  less	  education	  is	  an	  independent	  risk	  factor	  for	  congestive	  
heart	  failure[144].	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McAlister	  FA,	  Murphy	  NF,	  Simpson	  CR,	  Stewart	  S,	  MacIntyre	  K,	  Kirkpatrick	  M,	  
Chalmers	  J,	  Redpath	  A,	  Capewell	  S,	  McMurray	  JJ.	  Influence	  of	  socioeconomic	  
deprivation	  on	  the	  primary	  care	  burden	  and	  treatment	  of	  patients	  with	  a	  diagnosis	  
of	  heart	  failure	  in	  general	  practice	  in	  Scotland:	  population	  based	  study.	  BMJ	  2004;	  
328:1110.	  	  
This	  Scottish	  study	  utilised	  the	  continuous	  morbidity	  recording	  project	  to	  explore	  
rates	  of	  contact	  with	  general	  practitioners	  amongst	  a	  cohort	  representative	  of	  the	  
Scottish	  population	  as	  a	  whole.	  The	  authors	  used	  a	  quintile	  measure	  of	  SES	  based	  on	  
postcode	  of	  residence	  –	  the	  Carstairs	  deprivation	  category	  –	  and	  a	  diagnosis	  of	  heart	  
failure	  was	  based	  on	  Read	  coding	  of	  face	  to	  face	  consultations	  with	  general	  
practitioners.	  The	  aim	  of	  the	  study	  was	  to	  determine	  whether	  there	  are	  
socioeconomic	  gradients	  in	  the	  incidence,	  prevalence,	  treatment	  and	  follow-­‐up	  of	  
patients	  with	  heart	  failure	  in	  primary	  care.	  	  
	  
Incident	  heart	  failure	  was	  determined	  by	  the	  modifier	  ‘first’	  being	  associated	  with	  a	  
diagnosis	  of	  heart	  failure	  entered	  at	  the	  time	  of	  the	  consultation.	  This	  gave	  results	  
demonstrating	  a	  highly	  significant	  trend	  for	  increased	  incidence	  of	  heart	  failure	  
when	  moving	  from	  the	  most	  affluent	  quintile	  of	  the	  cohort	  to	  the	  most	  deprived,	  
when	  adjusted	  for	  age	  and	  sex.	  The	  odds	  ratio	  for	  the	  incidence	  of	  heart	  failure	  
between	  the	  most	  affluent	  and	  most	  deprived	  quintile	  was	  1.44	  (p	  for	  trend	  across	  
groups	  =	  0.003).	  
	  
One	  of	  the	  authors’	  conclusions	  is,	  therefore,	  that	  socioeconomically	  deprived	  
patients	  were	  44%	  more	  likely	  to	  develop	  heart	  failure[145].	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Ingelsson	  E,	  Lind	  L,	  Ärnlöv	  J,	  Sundström	  J.	  Socioeconomic	  Factors	  as	  Predictors	  of	  
Incident	  Heart	  Failure.	  Journal	  of	  Cardiac	  Failure.	  2006;	  12:	  540-­‐5.	  
The	  Swedish	  study	  made	  use	  of	  the	  USLAM	  (Uppsala	  Longitudinal	  Study	  of	  Adult	  
Men)	  cohort[146]	  of	  2322	  men	  aged	  50	  at	  the	  time	  of	  enrolment	  and	  with	  no	  
previous	  diagnosis	  of	  heart	  failure.	  	  Men	  with	  prior	  myocardial	  infarction	  or	  known	  
valvular	  heart	  disease	  at	  baseline	  were	  excluded	  from	  the	  cohort	  (7	  and	  1	  cases	  
respectively).	  Occupational	  classification,	  education	  level	  and	  marital	  status	  were	  
recorded	  as	  socioeconomic	  variables,	  with	  each	  variable	  having	  three	  possible	  
hierarchical	  values.	  Individuals	  were	  examined	  at	  the	  time	  of	  entry	  into	  the	  study	  
and	  were	  followed	  for	  a	  median	  of	  29.6	  years.	  Heart	  failure	  cases	  were	  identified	  by	  
linkage	  with	  the	  nationwide	  hospital	  discharge	  register,	  where	  ICD-­‐8	  codes	  for	  heart	  
failure	  in	  any	  of	  the	  six	  diagnostic	  positions	  were	  accepted	  as	  evidence	  of	  heart	  
failure.	  
	  
Unadjusted	  Cox	  proportional	  hazard	  analyses	  revealed	  that	  lower	  occupational	  
classification	  (HR	  1.55	  [95%	  C.I.	  1.03-­‐2.35]),	  lower	  education	  level	  (HR	  1.98	  [95%	  C.I.	  
1.07-­‐3.68])	  and	  being	  unmarried	  (HR	  1.44	  [95%	  C.I.	  0.99-­‐3.68])	  increased	  the	  risk	  of	  
heart	  failure.	  A	  clear	  trend	  across	  hierarchical	  levels	  of	  occupational	  class	  and	  
education	  was	  not,	  however,	  evident.	  Adjustment	  for	  established	  risk	  factors	  for	  the	  
development	  of	  heart	  failure,	  and	  for	  interim	  myocardial	  infarction	  reduced	  the	  
apparent	  hazard	  associated	  with	  lower	  socioeconomic	  status	  and	  being	  unmarried.	  
There	  were	  low	  numbers	  of	  men	  in	  the	  highest	  occupational	  class	  (14.6%),	  and	  with	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higher	  than	  elementary	  school	  education	  (16.7%).	  The	  proportion	  of	  married	  men	  in	  
the	  cohort	  was	  high	  at	  84.8%.	  
	  
The	  authors	  conclude	  that	  high	  occupational	  classification	  and	  education	  level	  	  
decreased	  the	  risk	  of	  subsequent	  heart	  failure	  in	  middle	  aged	  men,	  and	  being	  
unmarried	  increased	  the	  risk,	  via	  mechanisms	  largely	  independent	  of	  established	  risk	  
factors[147].	  	  	  	  	  	  
	  
Stewart	  S,	  Murphy	  NF,	  McMurray	  JJ,	  Jhund	  P,	  Hart	  CL,	  Hole	  D.	  Effect	  of	  socio-­‐	  
economic	  deprivation	  on	  the	  population	  risk	  of	  incident	  heart	  failure	  
hospitalisation:	  an	  analysis	  of	  the	  Renfrew/Paisley	  Study.	  Eur	  J	  Heart	  Fail	  2006;	  8:	  
856–863.	  
This	  large,	  prospective,	  population	  based	  study	  recruited	  15402	  individuals	  (45.8%	  
male)	  between	  the	  ages	  of	  45	  and	  64	  years	  from	  the	  industrial	  areas	  of	  Renfrew	  and	  
Paisley	  in	  Western	  Scotland	  –	  representing	  an	  estimated	  80%	  of	  the	  population	  in	  
this	  age	  range.	  Baseline	  assessment	  of	  cardio-­‐respiratory	  health	  status	  was	  carried	  
out	  in	  all	  subjects	  and	  they	  were	  subsequently	  followed	  for	  a	  period	  of	  20	  years	  for	  
the	  development	  of	  incident	  heart	  failure	  based	  on	  discharge	  diagnostic	  coding	  of	  
ICD	  9	  (ICD	  8	  in	  a	  small	  number	  of	  cases)	  codes	  for	  heart	  failure	  in	  the	  primary	  
position.	  
	  
SES	  in	  this	  study	  was	  based	  on	  the	  Carstairs-­‐Morris	  Deprivation	  category.	  This	  index	  
is	  based	  upon	  census	  data	  at	  the	  postcode	  level	  and	  uses	  levels	  of	  employment,	  
living	  conditions,	  car	  ownership,	  and	  social	  class	  to	  rank	  postcode	  sectors	  into	  seven	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deprivation	  categories	  (1=least	  deprived,	  7=most	  deprived).	  Data	  were	  also	  collected	  
on	  occupation	  at	  baseline	  according	  to	  the	  Registrar	  General’s	  classification,	  but	  
preliminary	  analyses	  indicated	  that	  the	  Carstairs-­‐Morris	  Deprivation	  category	  was	  
most	  sensitive	  to	  heart	  failure	  related	  outcomes	  and	  was	  available	  in	  a	  larger	  
number	  of	  cases,	  and	  so	  it	  was	  chosen	  as	  the	  primary	  measure	  of	  SES.	  Comparison	  
was	  made	  of	  the	  results	  using	  the	  Carstairs-­‐Morris	  Deprivation	  category	  with	  those	  
using	  individual	  social	  class	  to	  examine	  the	  robustness	  of	  using	  this	  composite	  
measure.	  
	  
A	  total	  of	  628	  study	  participants	  (4.1%)	  were	  hospitalised	  with	  a	  primary	  diagnosis	  of	  
heart	  failure	  over	  the	  20-­‐year	  follow-­‐up	  period.	  Analyses	  of	  the	  baseline	  
cardiovascular	  risk	  profile	  of	  all	  participants	  revealed	  a	  marked	  gradient	  according	  to	  
SES,	  with	  a	  significant	  trend	  for	  those	  in	  the	  most	  deprived	  categories	  to	  have	  
multiple	  markers	  of	  increased	  risk.	  A	  statistically	  significant	  gradient	  was	  observed	  in	  
the	  rates	  of	  hospitalization	  for	  heart	  failure	  according	  to	  Carstairs-­‐Morris	  Deprivation	  
category	  (Log	  rank	  test:	  p=0.003)	  –	  6.4%	  of	  those	  in	  category	  7	  hospitalized	  vs.	  3.5%	  
of	  those	  in	  categories	  1,	  3	  and	  4*,	  with	  an	  intermediate	  rate	  of	  hospitalization	  in	  
categories	  5	  (4.2%)	  and	  6	  (4.7%).	  Cox	  proportional	  hazards	  models	  demonstrated	  
that	  lower	  SES	  at	  baseline	  was	  associated	  with	  a	  higher	  risk	  of	  subsequent	  heart	  
failure	  hospitalizations	  independent	  of	  age,	  sex	  and	  baseline	  cardiovascular	  risk	  
(p<0.001	  overall).	  In	  the	  study	  population	  as	  a	  whole,	  the	  risk	  of	  heart	  failure	  
admission	  in	  the	  most	  deprived	  cohort	  was	  around	  40%	  greater	  than	  in	  the	  most	  
affluent	  cohort	  (RR	  1.39	  [95%	  C.I.	  1.04-­‐2.01]	  p=0.044).	  The	  risk	  associated	  with	  the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  No	  cases	  were	  defined	  in	  category	  2.	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highest	  level	  of	  deprivation	  appeared	  to	  be	  greater	  in	  men	  than	  in	  women	  (64%	  vs.	  
53%),	  though	  specific	  comparison	  between	  the	  most	  and	  least	  deprived	  categories	  in	  
each	  sex	  did	  not	  reach	  statistical	  significance.	  Subgroup	  analysis	  of	  initially	  “healthy”	  
subjects	  (those	  without	  appreciable	  cardiovascular	  risk	  at	  baseline)	  revealed	  that	  
those	  in	  the	  most	  deprived	  cohorts	  (categories	  6	  and	  7)	  were	  close	  to	  five	  times	  
more	  likely	  to	  be	  admitted	  for	  heart	  failure	  than	  those	  in	  categories	  1	  and	  2	  (least	  
deprived)	  –	  3.8%	  vs.	  0.8%	  0ver	  20	  years	  of	  follow-­‐up	  (p=0.016).	  
	  
The	  authors	  conclude	  that	  these	  data	  show	  a	  link	  between	  social	  deprivation	  and	  the	  
risk	  of	  developing	  heart	  failure,	  irrespective	  of	  baseline	  cardio-­‐respiratory	  status	  and	  
cardiovascular	  risk	  factors[148].	  	  
	  
Schaufelberger	  M,	  Rosengren	  A.	  Heart	  failure	  in	  different	  occupational	  classes	  in	  
Sweden.	  Eur	  Heart	  J.	  2007;	  28:	  212-­‐8.	  
Occupation	  was	  used	  in	  this	  observational	  case-­‐control	  study	  of	  6999	  men,	  drawn	  
from	  the	  population	  of	  9998	  men	  in	  the	  interventional	  cohort	  of	  the	  multifactor	  
Primary	  Prevention	  Study	  in	  Goteborg,	  Sweden[149].	  Five	  occupational	  classes	  were	  
identified	  to	  stratify	  the	  sample	  by	  socioeconomic	  status	  –	  unskilled	  workers	  through	  
to	  high	  officials	  /	  professionals.	  	  Notably,	  individuals	  were	  excluded	  from	  analysis	  if	  
they	  could	  not	  be	  classified	  by	  occupation	  due	  to	  having	  taken	  early	  retirement	  (405	  
of	  those	  eligible	  by	  other	  criteria).	  Of	  the	  6999	  men	  studied,	  1004	  developed	  heart	  
failure	  over	  the	  course	  of	  the	  28-­‐year	  follow-­‐up	  period.	  Diagnosis	  was	  based	  on	  
linkage	  with	  the	  Swedish	  National	  Register	  on	  Cause	  of	  Death,	  and	  the	  Swedish	  
Hospital	  Discharge	  Register.	  All	  of	  the	  men	  studied	  returned	  an	  initial	  questionnaire	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on	  occupation,	  smoking	  habits,	  physical	  activity	  and	  known	  hypertension	  or	  diabetes	  
mellitus.	  The	  men	  were	  also	  examined	  for	  height,	  weight	  and	  resting	  blood	  pressure,	  
and	  had	  blood	  taken	  for	  analysis	  of	  serum	  cholesterol	  concentration.	  	  
	  
A	  clear	  trend	  was	  observed	  across	  the	  strata	  of	  occupational	  class	  in	  both	  age	  
adjusted	  hazard	  ratio	  (HR	  for	  lowest	  vs.	  highest	  =	  1.92	  [1.50-­‐2.45])	  and	  multiple	  
adjusted	  hazard	  ratio	  (HR	  for	  lowest	  vs.	  highest	  =	  1.42	  [1.17-­‐1.72])	  for	  incident	  heart	  
failure.	  The	  trend	  was	  less	  clear	  when	  considering	  those	  with	  a	  previous	  diagnosis	  of	  
non-­‐fatal	  MI	  or	  prior	  coronary	  revascularization	  procedure.	  The	  highest	  occupational	  
class	  was	  used	  as	  the	  reference	  group	  and	  the	  number	  of	  men	  in	  this	  group	  was	  low	  
in	  comparison	  to	  those	  in	  the	  other	  four	  groups	  (e.g.	  802	  men	  vs.	  1671	  men	  in	  the	  
unskilled	  workers	  group).	  
	  
The	  authors	  conclude	  that	  low	  SES	  is	  an	  independent	  risk	  factor	  for	  long	  term	  risk	  of	  
heart	  failure	  in	  men[150].	  	  	  
	  
Bahrami	  H,	  Kronmal	  R,	  Bluemke	  DA,	  Olson	  J,	  Shea	  S,	  Liu	  K,	  Burke	  G,	  Lima	  JAC.	  
Differences	  in	  the	  Incidence	  of	  Congestive	  Heart	  Failure	  by	  Ethnicity:	  The	  Multi-­‐
Ethnic	  Study	  of	  Atherosclerosis.	  Arch	  Intern	  Med.	  2008;	  168(19):	  2138	  –	  2145.	  
In	  a	  similar	  US	  study	  Bahrami	  et	  al.	  investigated	  the	  incidence	  of	  heart	  failure	  in	  the	  
Multi-­‐Ethnic	  Study	  of	  Atherosclerosis	  (MESA)	  cohort	  of	  6814	  individuals	  from	  four	  
ethnicities	  (White	  [38.5%],	  African	  American	  [27.8%],	  Hispanic	  [21.9%,	  Chinese	  
American	  [11.8%]),	  recruited	  between	  July	  2000	  and	  August	  2002.	  After	  excluding	  
those	  with	  a	  history	  of	  cardiovascular	  disease	  at	  baseline,	  participants	  were	  followed	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for	  a	  median	  period	  of	  4.0	  years	  and	  incident	  heart	  failure	  in	  this	  period	  was	  defined	  
by:	  
a. congestive	  heart	  failure	  diagnosed	  by	  a	  physician	  and	  patient	  receiving	  medical	  
treatment	  for	  heart	  failure,	  
b. pulmonary	  oedema	  /	  congestion	  seen	  on	  chest	  radiograph,	  and	  
c. dilated	  ventricle	  /	  poor	  LV	  systolic	  function	  /	  evidence	  of	  LV	  diastolic	  function	  on	  
echocardiography.	  
Participants	  meeting	  criteria	  “a”	  alone	  were	  considered	  to	  have	  met	  a	  soft	  criterion	  
for	  incident	  heart	  failure	  but	  these	  individuals	  were	  included	  in	  the	  analyses.	  
Socioeconomic	  status	  was	  examined	  in	  this	  study	  according	  to	  educational	  level	  (6	  
hierarchical	  categories	  from	  less	  than	  high	  school	  to	  graduate/professional	  school	  
training)	  and	  median	  annual	  household	  income	  (<$25000,	  $25000	  -­‐	  $49999,	  $50000	  
-­‐	  $75000,	  and	  >$75000).	  
	  
The	  authors	  explore	  the	  interaction	  of	  race	  with	  the	  various	  potential	  mediating	  
factors	  in	  the	  development	  of	  incident	  heart	  failure	  and	  give	  us	  insight	  into	  the	  
complexity	  of	  the	  interplay	  between	  SES	  and	  heart	  failure	  within	  populations.	  White	  
race	  is	  taken	  as	  the	  reference	  population	  and	  hazard	  ratios	  for	  incident	  heart	  failure	  
in	  the	  other	  three	  racial	  groups	  are	  calculated	  and	  the	  effect	  of	  the	  addition	  of	  other	  
covariates	  to	  the	  model	  is	  examined.	  Hazard	  ratios	  for	  incident	  heart	  failure	  in	  
Chinese	  Americans	  and	  Hispanics	  suggest	  no	  significant	  differences	  in	  rates	  of	  
incident	  heart	  failure	  in	  these	  races	  compared	  to	  whites,	  though	  there	  is	  a	  trend	  for	  
lower	  rates	  in	  Chinese	  Americans	  and	  higher	  rates	  in	  Hispanics.	  However,	  the	  results	  
signal	  that	  higher	  median	  household	  income	  is	  associated	  with	  a	  lower	  risk	  of	  heart	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failure	  in	  Chinese	  Americans,	  and	  that	  the	  addition	  of	  household	  income	  to	  the	  
model	  abolishes	  the	  increased	  hazard	  associated	  with	  black	  race	  as	  well	  as	  reducing	  
the	  non-­‐significant	  hazard	  associated	  with	  Hispanic	  race.	  Educational	  level,	  however,	  
appears	  to	  be	  associated	  with	  no	  significant	  change	  in	  the	  risk	  of	  incident	  heart	  
failure	  in	  any	  racial	  group[151].	  
	  
Kalogeropoulos	  A.	  et	  al.	  Epidemiology	  of	  Incident	  Heart	  Failure	  in	  a	  Contemporary	  
Elderly	  Cohort:	  the	  Health,	  Aging,	  and	  Body	  Composition	  Study.	  Arch	  Intern	  Med.	  
2009;	  169(7):	  708-­‐715	  
This	  US	  study	  examined	  2934	  participants	  without	  heart	  failure	  enrolled	  in	  the	  
Health,	  Aging,	  and	  Body	  Composition	  Study	  (Health	  ABC	  Study)	  –	  a	  population	  based	  
study	  enrolling	  community	  dwelling	  white	  Medicare	  beneficiaries	  and	  all	  eligible	  
blacks,	  between	  the	  ages	  of	  70	  and	  79	  years	  from	  April	  1997	  to	  June	  1998.	  The	  mean	  
age	  was	  73.6	  years,	  52.1%	  of	  those	  studied	  were	  women,	  41.4%	  were	  black,	  and	  the	  
median	  follow-­‐up	  was	  7.1	  years.	  
	  
Incident	  heart	  failure	  was	  classified	  on	  the	  basis	  of	  all	  first	  admissions	  with	  an	  
overnight	  stay	  confirmed	  to	  be	  related	  to	  heart	  failure	  on	  the	  basis	  of	  symptoms,	  
signs,	  chest	  radiograph	  and	  echocardiographic	  findings.	  The	  criteria	  required	  at	  least	  
a	  diagnosis	  of	  heart	  failure	  from	  a	  physician	  and	  treatment	  for	  heart	  failure	  	  (diuretic	  
/	  digitalis	  or	  vasodilator)	  prior	  to	  screening	  of	  the	  admission	  by	  a	  local	  adjudicator.	  
Educational	  status	  (<high	  school,	  high	  school,	  >high	  school)	  was	  used	  as	  a	  potential	  
mediator	  of	  incident	  heart	  failure	  and	  no	  association	  with	  the	  outcome	  was	  
indentified	  in	  this	  study.	  Black	  race	  was	  associated	  with	  a	  higher	  risk	  of	  incident	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heart	  failure	  and,	  in	  both	  blacks	  and	  whites,	  male	  sex	  was	  associated	  with	  more	  
incident	  heart	  failure.	  White	  men	  were,	  however,	  at	  less	  risk	  of	  incident	  heart	  failure	  
than	  black	  women.	  Risk	  factors	  in	  those	  of	  black	  race	  were	  all	  more	  prevalent	  than	  in	  
whites	  and	  carried	  higher	  population	  attributable	  risk.	  No	  significant	  differences	  in	  
risk	  factor	  profiles	  were	  seen,	  however,	  between	  sexes	  within	  each	  race.	  
	  
This	  paper	  concludes	  that	  incident	  heart	  failure	  is	  common	  in	  older	  persons	  and	  that	  
a	  large	  proportion	  of	  risk	  is	  attributable	  to	  modifiable	  factors.	  No	  mention	  is	  made	  of	  
the	  lack	  of	  observed	  effect	  of	  education	  level	  on	  incident	  heart	  failure,	  though	  for	  
the	  purposes	  of	  this	  review,	  these	  are	  interesting	  negative	  data[152].	  
	  
Christensen	  S,	  Mogelvang	  R,	  Heitmann	  M,	  Prescott	  E.	  Level	  of	  education	  and	  risk	  of	  
heart	  failure:	  a	  prospective	  cohort	  study	  with	  echocardiography	  evaluation.	  Eur	  
Heart	  J	  2011;32:450–458.	  	  
This	  Danish,	  prospective	  cohort	  study	  examined	  the	  effects	  of	  level	  of	  educational	  
achievement	  (<8	  years,	  8-­‐10	  years	  and	  >10	  years)	  and	  median	  household	  income	  
(low,	  medium	  and	  high)	  on	  the	  risk	  of	  incident	  heart	  failure,	  determined	  by	  survival	  
time	  free	  of	  an	  admission	  for	  congestive	  heart	  failure,	  in	  participants	  in	  the	  
Copenhagen	  City	  Heart	  Study.	  18616	  participants	  (both	  men	  and	  women)	  were	  
followed	  until	  July	  2007,	  with	  the	  initial	  cohort,	  recruited	  between	  1976	  and	  1978,	  
numbering	  14223.	  Subsequent	  examinations	  were	  made	  in	  the	  years	  1981-­‐1983,	  
1991-­‐1994,	  and	  2001-­‐2003.	  At	  the	  time	  of	  each	  subsequent	  examination,	  new	  
participants	  were	  recruited,	  primarily	  of	  younger	  age,	  in	  an	  attempt	  to	  generate	  a	  
study	  population	  with	  representatives	  from	  all	  age	  groups.	  All	  individuals	  included	  in	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the	  analysis	  were	  free	  from	  prior	  MI	  or	  congestive	  heart	  failure	  at	  the	  time	  of	  entry	  
into	  the	  study.	  	  
	  
Primary	  endpoint	  was	  first-­‐ever	  hospitalization	  with	  a	  diagnosis	  of	  congestive	  heart	  
failure,	  based	  on	  ICD8	  codes	  until	  1st	  January	  1994	  and	  ICD10	  codes	  thereafter.	  
Analyses	  were	  restricted	  to	  age	  below	  80	  at	  the	  time	  of	  study	  entry,	  as	  the	  
assumption	  of	  proportional	  hazards	  was	  violated	  with	  regard	  to	  the	  effect	  of	  
education	  on	  the	  primary	  outcome	  above	  this	  age.	  Individuals,	  therefore,	  
contributed	  to	  the	  total	  time	  at	  risk	  of	  developing	  heart	  failure	  in	  the	  model	  until	  
reaching	  the	  endpoint,	  death,	  emigration,	  or	  age	  80.	  
	  
A	  subset	  of	  participants	  were	  recruited,	  by	  random	  sampling,	  at	  the	  time	  of	  the	  final	  
interval	  examination	  (2001-­‐2003)	  for	  an	  echocardiography	  sub-­‐study	  (n=3589).	  Five	  
indices	  were	  used	  to	  examine	  echocardiographic	  abnormalities	  according	  to	  level	  of	  
educational	  achievement	  –	  LV	  hypertrophy,	  LV	  dilatation,	  LVEF	  <	  50%,	  mild	  diastolic	  
dysfunction,	  and	  severe	  diastolic	  dysfunction.	  
	  
All	  analyses	  were	  adjusted	  for	  age,	  gender	  and	  family	  history	  as	  potential	  
confounders,	  and	  potentially	  modifiable	  cardiovascular	  risk	  factors	  were	  examined	  
and	  treated	  as	  mediating	  covariates.	  
	  
The	  authors	  found	  that	  participants	  with	  the	  lowest	  level	  of	  education	  were	  1.5	  
times	  more	  likely	  to	  be	  admitted	  with	  congestive	  heart	  failure	  over	  the	  course	  of	  the	  
study	  when	  compared	  to	  those	  with	  the	  highest	  level	  of	  education.	  These	  individuals	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were,	  on	  average,	  older	  at	  the	  time	  of	  entry	  into	  the	  study	  and	  generally	  had	  a	  worse	  
risk	  factor	  profile	  than	  those	  with	  the	  highest	  level	  of	  education.	  Following	  
adjustment	  for	  all	  potentially	  mediating	  variables	  found	  to	  be	  associated	  with	  
admission	  for	  congestive	  heart	  failure	  in	  the	  multivariable	  model,	  however,	  the	  
hazard	  ratio	  for	  heart	  failure	  admission	  associated	  with	  higher	  levels	  of	  education	  
remained	  similar	  to	  that	  seen	  in	  the	  unadjusted	  and	  age/sex	  adjusted	  analyses.	  	  	  	  
Higher	  median	  household	  incomes	  were	  also	  associated	  with	  decreased	  hazard	  
ratios	  for	  heart	  failure	  admission	  in	  both	  men	  and	  women,	  but	  the	  effect	  was	  less	  
pronounced.	  	  	  	  	  	  	  	  
	  
The	  findings	  of	  the	  echocardiography	  sub-­‐study	  were	  less	  clear-­‐cut,	  but	  LV	  dilatation	  
and	  severe	  diastolic	  dysfunction	  appeared	  to	  be	  significantly	  correlated	  with	  lower	  
levels	  of	  educational	  achievement	  after	  adjustment	  for	  all	  other	  variables.	  There	  was	  
also	  a	  significant	  trend	  for	  lower	  rates	  of	  LVEF	  <	  50%	  and	  any	  abnormal	  
echocardiography	  in	  those	  with	  higher	  levels	  of	  education.	  
	  
The	  authors	  conclude	  that	  level	  of	  education	  was	  associated	  with	  cardiac	  
dysfunction	  and	  predicted	  future	  hospital	  admissions	  for	  congestive	  heart	  failure,	  






4.III.iv	  .	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McAlister	  FA,	  Murphy	  NF,	  Simpson	  CR,	  Stewart	  S,	  MacIntyre	  K,	  Kirkpatrick	  M,	  
Chalmers	  J,	  Redpath	  A,	  Capewell	  S,	  McMurray	  JJ.	  Influence	  of	  socioeconomic	  
deprivation	  on	  the	  primary	  care	  burden	  and	  treatment	  of	  patients	  with	  a	  diagnosis	  
of	  heart	  failure	  in	  general	  practice	  in	  Scotland:	  population	  based	  study.	  BMJ	  2004;	  
328:1110.	  
This,	  previously	  described,	  study	  addressed	  not	  only	  incidence,	  but	  also	  prevalence	  
of	  heart	  failure	  according	  to	  deprivation	  category.	  Prevalence	  was	  estimated	  by	  
examination	  of	  the	  number	  of	  individual	  patient	  attendances	  for	  heart	  failure	  over	  
the	  year	  1st	  April	  1999	  –	  31st	  March	  2000.	  When	  adjusted	  for	  age	  and	  sex	  prevalence	  
was	  6.4/1000	  in	  the	  most	  affluent	  group	  and	  7.2%	  in	  the	  most	  deprived	  group	  (OR	  












4.III.v.	   MORTALITY	  IN	  HEART	  FAILURE	  AND	  SES	  
	  
MacIntyre	  K,	  Capewell	  S,	  Stewart	  S,	  Chalmers	  JW,	  Boyd	  J,	  Finlayson	  A,	  Redpath	  A,	  
Pell	  JP,	  McMurray	  JJ.	  Evidence	  of	  improving	  prognosis	  in	  heart	  failure:	  trends	  in	  
case	  fatality	  in	  66	  547	  patients	  hospitalized	  between	  1986	  and	  1995.	  Circulation	  
2000;	  102:	  1126	  –	  1131.	  	  
This,	  previously	  described,	  study	  provided	  evidence	  of	  increased	  incidence	  of	  heart	  
failure	  with	  increasing	  deprivation.	  The	  primary	  aim,	  however,	  was	  to	  describe	  the	  
case	  fatality	  rate	  for	  incident	  heart	  failure.	  Deprivation,	  described	  by	  Carstairs-­‐Morris	  
quintile,	  principally	  increased	  the	  short	  term	  case	  fatality	  rate	  in	  an	  adjusted	  logistic	  
regression	  analysis	  at	  30	  days,	  with	  the	  effect	  more	  marked	  in	  men	  than	  in	  women.	  	  
	  
A	  convincing	  trend	  was	  seen	  for	  increased	  early	  mortality	  with	  increasing	  quintile	  of	  
deprivation	  and	  the	  case	  fatality	  rate	  at	  30	  days	  was	  26%	  higher	  in	  men	  and	  11%	  
higher	  in	  women	  for	  the	  most	  deprived	  quintile	  compared	  with	  the	  least	  deprived.	  
Long	  term	  mortality	  (30	  days	  to	  the	  end	  of	  follow	  up)	  was	  affected	  to	  a	  lesser	  extent,	  
though	  an	  excess	  mortality	  of	  10%	  in	  men	  and	  6%	  in	  women	  was	  observed	  in	  the	  
most	  deprived	  quintile[143]	  	  	  	  	  
	  
Blackledge	  HM,	  Tomlinson	  J,	  Squire	  IB.	  Prognosis	  for	  patients	  newly	  admitted	  to	  
hospital	  with	  heart	  failure:	  survival	  trends	  in	  12	  220	  index	  admissions	  in	  
Leicestershire	  1993–2001.	  Heart	  2003;	  89:	  615–620.	  	  
This	  UK	  based	  retrospective	  cohort	  study	  made	  use	  of	  the	  comprehensive	  record	  
linkage	  system	  of	  Leicestershire	  Health	  Authority	  and	  data	  from	  the	  Office	  of	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National	  Statistics,	  which	  allow	  for	  follow-­‐up	  of	  all	  patients	  registered	  with	  primary	  
care	  in	  the	  region	  for	  hospitalization	  and	  mortality	  events.	  Data	  were	  obtained	  on	  
residents,	  40	  years	  and	  older,	  admitted	  with	  a	  first	  presentation	  of	  heart	  failure	  
according	  to	  ICD	  9	  or	  ICD	  10	  codes	  for	  heart	  failure	  in	  any	  discharge	  coding	  position.	  
Mortality	  was	  identified	  using	  death	  certification	  records	  and	  survival	  was	  measured	  
from	  the	  date	  of	  admission	  to	  the	  date	  of	  death	  or	  the	  end	  of	  follow-­‐up	  (30th	  
September	  2001),	  or	  to	  the	  date	  of	  migration	  outside	  of	  the	  study	  area.	  Comorbidity	  
was	  assessed	  on	  the	  basis	  of	  admissions	  in	  the	  5	  years	  prior	  to	  heart	  failure	  
hospitalization	  for	  the	  management	  of	  conditions	  associated	  with	  the	  development	  
of	  heart	  failure.	  Average	  length	  of	  stay	  for	  these	  prior	  admissions	  was	  also	  used	  as	  a	  
proxy	  for	  level	  of	  comorbidity.	  
	  
SES	  was	  determined	  for	  members	  of	  the	  cohort	  using	  the	  index	  of	  multiple	  
deprivation	  (IMD	  2000)	  at	  the	  electoral	  ward	  level	  according	  to	  the	  patient’s	  
postcode	  of	  residence.	  Each	  member	  of	  the	  cohort	  was	  assigned	  a	  quintile	  of	  
deprivation	  according	  to	  this	  multi-­‐domain	  measure	  of	  deprivation.	  
	  
All	  cause	  mortality	  and	  cardiovascular	  mortality	  reduced	  significantly	  over	  the	  course	  
of	  the	  study.	  Advancing	  age,	  male	  sex,	  and	  comorbidity	  were	  strongly	  associated	  
with	  higher	  mortality.	  No	  association	  was	  found	  between	  deprivation	  and	  either	  all	  
cause	  or	  cardiovascular	  mortality	  in	  this	  cohort,	  either	  in	  the	  univariate	  or	  
multivariate	  analyses.	  The	  authors	  do	  note,	  however,	  that	  a	  disproportionate	  
number	  of	  index	  cases	  came	  from	  the	  most	  deprived	  quintiles	  (62%	  of	  cases	  from	  Q4	  
and	  Q5).	  They	  hypothesize	  that	  the	  lack	  of	  any	  appreciable	  social	  gradient	  in	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mortality	  might	  be	  the	  result	  of	  a	  lower	  threshold	  for	  hospital	  referral	  in	  these	  
patients	  from	  the	  more	  deprived	  quintiles[154].	  	  	  	  	  	  	  	  	  	  
	  
	  
Riddell	  T.	  Heart	  failure	  hospitalisations	  and	  deaths	  in	  New	  Zealand:	  patterns	  by	  
deprivation	  and	  ethnicity.	  New	  Zealand	  Medical	  Journal	  2005;	  118(1208):1254-­‐
1263.	  	  	  
This	  retrospective	  analysis	  of	  heart	  failure	  deaths	  and	  hospitalizations	  in	  New	  
Zealand	  used	  the	  National	  Minimum	  Data	  Set	  of	  the	  New	  Zealand	  Health	  
Information	  Service	  in	  the	  period	  1988	  –	  1998	  to	  identify	  admissions	  and	  deaths	  
according	  to	  ICD	  9	  codes	  for	  heart	  failure.	  A	  small	  area	  based	  measure	  of	  deprivation	  
was	  used	  according	  to	  the	  domicile	  of	  residence	  associated	  with	  each	  record	  –	  the	  
New	  Zealand	  Index	  of	  Deprivation	  (NZDep)	  –	  and	  the	  cohort	  was	  arranged	  by	  decile	  
of	  deprivation.	  Deciles	  1-­‐4	  (least	  deprived)	  were	  collapsed	  to	  form	  a	  single	  group	  as	  
the	  principal	  aim	  of	  the	  study	  was	  to	  investigate	  outcomes	  in	  Maori	  vs.	  non-­‐Maori	  
individuals,	  and	  there	  was	  an	  under	  representation	  of	  Maori	  in	  the	  least	  deprived	  
deciles.	  
	  
8079	  heart	  failure	  deaths	  and	  66416	  heart	  failure	  hospitalizations	  were	  recorded	  in	  
individuals	  over	  the	  age	  of	  45	  during	  the	  period	  of	  interest.	  Poisson	  regression	  
analysis	  of	  relative	  risk	  of	  heart	  failure	  death	  and	  hospitalization	  revealed	  an	  11%	  
increase	  in	  both	  deaths	  [95%	  C.I.	  1.06-­‐1.16]	  and	  hospitalizations	  [95%	  C.I.	  1.09-­‐1.14]	  
for	  each	  decile	  of	  increasing	  deprivation.	  Within	  deprivation	  strata	  Maori	  rates	  of	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death	  and	  hospitalization	  were	  considerably	  higher	  than	  non-­‐Maori	  rates	  at	  all	  
levels.	  
	  
These	  data	  were	  an	  unadjusted	  measure	  of	  the	  risk	  of	  heart	  failure	  death	  and	  
hospitalization	  according	  to	  increasing	  deprivation	  from	  a	  study	  primarily	  designed	  
to	  address	  the	  interaction	  between	  socioeconomic	  status	  and	  race	  on	  outcomes.	  The	  
author	  concludes	  that	  deprivation	  was	  associated	  with	  an	  increased	  chance	  of	  death	  
and	  hospitalization	  from	  heart	  failure	  in	  New	  Zealand	  and	  acknowledges	  the	  
limitations	  of	  the	  study	  in	  identifying	  the	  factors	  underpinning	  this	  gradient[155].	  	  	  	  	  	  	  	  	  	  	  
	  
Wen	  M	  &	  Christakis	  NA.	  Correlates	  of	  Ambulatory	  Care.	  Neighborhood	  Effects	  on	  
Posthospitalization	  Mortality:	  A	  Population-­‐based	  Cohort	  Study	  of	  the	  Elderly	  in	  
Chicago.	  Health	  Service	  Research	  2005;	  40(4):	  1108	  
This	  US	  retrospective	  cohort	  study	  merged	  three	  data	  sources	  to	  ascribe	  
neighbourhood	  SES	  (based	  on	  census	  data)	  and	  neighbourhood	  social	  environment	  
(based	  on	  the	  Project	  on	  Human	  Development	  in	  Chicago	  Neighbourhoods	  –	  
Community	  Survey	  [PHDCN-­‐CS])	  to	  individuals	  in	  the	  Care	  after	  the	  Onset	  of	  Serious	  
Illness	  (COSI)	  dataset,	  according	  to	  ZIP	  code	  of	  residence	  (akin	  to	  UK	  postcode).	  
The	  primary	  outcome	  of	  interest	  was	  survival	  time	  after	  the	  index	  admission.	  The	  
study	  examined	  10557	  patients	  admitted	  in	  1993	  for	  the	  fist	  presentation	  of	  acute	  
myocardial	  infarction,	  congestive	  heart	  failure,	  hip	  fracture,	  lung	  cancer,	  or	  stroke.	  
29%	  of	  patients	  in	  the	  study	  were	  admitted	  with	  congestive	  heart	  failure.	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Complex	  analyses	  demonstrated	  that	  better	  neighbourhood	  SES	  and	  social	  
environment	  were	  predictors	  of	  better	  outcome	  overall,	  but	  this	  effect	  was	  most	  
marked	  where	  individual	  income	  was	  adequate.	  Analyses	  of	  individual	  diseases	  in	  
the	  cohort	  seemed	  to	  show	  that	  neighbourhood	  SES	  and	  social	  environment	  were	  
potent	  predictors	  of	  mortality	  following	  myocardial	  infarction	  but	  had	  little	  effect	  in	  
the	  other	  conditions	  studied,	  including	  heart	  failure.	  The	  work	  therefore	  implies	  that	  
the	  effect	  of	  better	  neighbourhood	  related	  factors	  on	  mortality	  was	  principally	  to	  
improve	  prognosis	  following	  myocardial	  infarction[156].	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Am	  Heart	  J	  2006;	  152:371–378.	  	  
This	  retrospective	  study	  from	  the	  USA	  examined	  medical	  records	  of	  a	  national	  
sample	  of	  25086	  Medicare	  beneficiaries,	  aged	  65	  and	  over,	  hospitalized	  with	  heart	  
failure	  in	  a	  single	  year	  March	  1998	  –	  April	  1999.	  The	  aim	  was	  to	  assess	  the	  
association	  of	  SES	  with	  treatments	  and	  outcomes	  in	  heart	  failure.	  Heart	  failure	  was	  
defined	  by	  principle	  discharge	  diagnosis	  of	  heart	  failure	  according	  to	  ICD	  9	  code	  and	  
chart	  review	  of	  identified	  admissions	  was	  undertaken	  to	  exclude	  cases	  without	  any	  
clear	  documentation	  of	  heart	  failure.	  SES	  was	  determined	  using	  a	  commercially	  
available	  database	  linking	  ZIP	  code-­‐level	  residential	  demographic	  characteristics	  to	  
individual	  patients.	  The	  index	  used	  (ZIP	  Quality	  rating)	  was	  a	  composite	  measure	  
derived	  from	  median	  household	  income,	  educational	  achievement	  of	  persons	  25	  
years	  and	  over,	  occupation	  of	  employed	  persons,	  and	  home	  value	  within	  each	  ZIP	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code.	  Patients	  were	  allocated	  to	  one	  of	  four	  groups	  according	  to	  this	  index	  in	  a	  
hierarchical	  manner	  based	  on	  their	  score	  relative	  to	  the	  national	  mean	  score.	  
The	  principal	  outcome	  measures	  were	  mortality	  at	  30	  days	  and	  1	  year	  post	  
admission.	  All-­‐cause	  readmissions	  within	  1	  year	  of	  discharge	  were	  also	  examined,	  as	  
was	  quality	  of	  care,	  determined	  by	  documentation	  of	  left	  ventricular	  systolic	  
function	  and	  prescription	  of	  ACE	  inhibitors	  to	  ideal	  candidates.	  
	  
Crude	  mortality	  rates	  at	  30	  days	  and	  1	  year	  did	  not	  differ	  between	  socioeconomic	  
groups.	  Following	  adjustment	  for	  a	  wide	  range	  of	  factors	  identified	  as	  being	  
associated	  with	  patient	  outcomes	  1	  year	  mortality	  rates	  demonstrated	  a	  significant	  
trend	  for	  higher	  rates	  with	  decreasing	  SES.	  One	  of	  the	  conclusions	  offered	  by	  the	  
authors	  is	  that	  SES	  may	  influence	  outcomes	  after	  hospitalization	  for	  heart	  
failure[157].	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Struthers	  AD,	  Anderson	  G,	  Donnan	  PT,	  MacDonald	  T.	  Social	  deprivation	  increases	  
cardiac	  hospitalisations	  in	  chronic	  heart	  failure	  independent	  of	  disease	  severity	  and	  
diuretic	  non-­‐adherence.	  Heart	  2000;83:12–16.	  
This	  retrospective	  cohort	  study	  included	  patients	  admitted	  to	  an	  acute	  hospital	  in	  
the	  Tayside	  region	  of	  Scotland	  with	  an	  ICD	  9	  coded	  diagnosis	  of	  myocardial	  infarction	  
between	  1st	  January	  1989	  and	  31st	  December	  1992,	  and	  then	  subsequently	  admitted	  
with	  an	  ICD	  9	  coded	  diagnosis	  of	  chronic	  heart	  failure	  in	  the	  same	  period.	  The	  
authors	  hypothesized	  that	  diuretic	  adherence	  might	  give	  an	  insight	  into	  the	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assumption	  that	  more	  socially	  deprived	  individuals	  are	  less	  health	  conscious	  if	  
adherence	  were	  less	  in	  more	  deprived	  groups.	  Therefore,	  three	  or	  more	  
prescriptions	  for	  diuretics	  had	  to	  have	  been	  dispensed	  to	  each	  patient	  in	  the	  year	  
from	  January	  1993	  –	  January	  1994	  for	  them	  to	  be	  included	  in	  the	  study.	  Total	  daily	  
diuretic	  dose	  was	  used	  as	  a	  proxy	  marker	  of	  disease	  severity.	  
	  
In	  total,	  478	  patients	  were	  included	  (52%	  male,	  age	  46	  –	  90	  years,	  80%	  >	  65	  years	  
old)	  and	  information	  on	  all	  emergency	  admissions	  and	  deaths	  in	  the	  two	  years	  1st	  
January	  1993	  –	  31st	  December	  1994	  was	  recorded.	  Cardiac	  admissions	  were	  based	  
on	  ICD	  9	  coding	  for	  cardiac	  disease	  in	  the	  primary	  diagnostic	  position.	  SES	  was	  
determined	  by	  Carstairs	  score	  from	  1	  (most	  affluent)	  to	  7	  (most	  deprived)	  according	  
to	  postcode	  of	  residence.	  No	  patients	  in	  this	  study	  had	  a	  Carstairs	  score	  of	  7.	  
The	  main	  findings	  of	  the	  study	  were	  that	  social	  deprivation	  was	  independently	  
associated	  with	  an	  increase	  in	  cardiac	  hospitalizations	  in	  individuals	  who	  have	  had	  a	  
previous	  myocardial	  infarction	  and	  an	  admission	  for	  congestive	  heart	  failure,	  and	  
that	  this	  effect	  was	  independent	  of	  disease	  severity,	  measured	  by	  average	  diuretic	  
dose,	  death	  rate,	  and	  duration	  of	  each	  hospital	  stay.	  The	  increase	  in	  hospitalization	  
observed	  was	  driven	  by	  admission	  of	  a	  higher	  proportion	  of	  individuals	  admitted	  in	  
more	  deprived	  groups	  rather	  than	  increased	  frequency	  of	  admission	  for	  individuals.	  
The	  relative	  risk	  of	  emergency	  cardiac	  admission	  across	  all	  six	  deprivation	  categories	  
was	  1.11	  (1.002	  –	  1.224)	  when	  adjusted	  for	  age	  and	  sex.	  All	  cause	  hospitalization	  in	  
this	  cohort	  was	  not	  significantly	  affected	  by	  deprivation	  and	  rates	  of	  diuretic	  
adherence	  did	  not	  appear	  to	  influence	  hospitalization.	  It	  is	  also	  worth	  noting	  that	  
this	  study	  did	  not	  demonstrate	  any	  effect	  of	  deprivation	  on	  mortality[158].	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2001;	  87:1367	  –	  1371.	  	  
This	  US	  Study	  retrospectively	  analysed	  hospital	  discharge	  data	  collected	  
prospectively	  in	  New	  York	  State.	  All	  patients	  discharged	  at	  least	  once	  in	  the	  period	  
1st	  January	  –	  31st	  December	  1995,	  with	  an	  ICD	  9	  code	  for	  heart	  failure	  in	  the	  principal	  
diagnostic	  position	  on	  the	  discharge	  abstract,	  were	  included	  in	  the	  study.	  The	  cohort	  
totalled	  41776	  patients	  with	  a	  mean	  age	  of	  74	  years	  (43%	  male,	  18%	  African	  
American).	  Median	  household	  income	  in	  the	  ZIP	  code	  of	  each	  patient’s	  residential	  
address	  (based	  on	  1990	  census	  data)	  was	  used	  to	  define	  socioeconomic	  status,	  with	  
patients	  assigned	  to	  one	  of	  four	  income	  quartiles	  for	  analysis	  purposes.	  
	  
Baseline	  differences	  in	  the	  propensity	  for	  readmission	  were	  accounted	  for	  by	  use	  of	  
a	  published	  prediction	  rule	  by	  the	  same	  first	  author[159].	  In	  all,	  21.5%	  of	  patients	  
experienced	  at	  least	  1	  readmission	  for	  recurrent	  heart	  failure.	  	  	  	  	  	  
	  
Patients	  in	  the	  lowest	  income	  quartile	  were	  significantly	  younger	  than	  those	  in	  the	  
highest	  income	  quartile	  (71	  ±	  14	  years	  vs.	  75	  ±	  13	  years;	  p<0.05)	  and	  more	  likely	  to	  
be	  female	  (59%	  vs.	  54%;	  p<0.05)	  or	  African	  American	  (39%	  vs.	  8%;	  p<0.05).	  They	  
were	  also	  significantly	  less	  likely	  to	  be	  treated	  by	  a	  cardiologist	  (19%	  vs.	  22%;	  
p<0.05).	  
	  
There	  was	  a	  stepwise	  decrease	  in	  the	  crude	  frequency	  of	  hospital	  readmission	  for	  
heart	  failure	  from	  the	  lowest	  quartile	  of	  income	  (23.2%)	  to	  the	  highest	  (20%)	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(p<0.0001	  for	  trend	  and	  for	  difference	  between	  highest	  and	  lowest	  income	  
quartiles).	  Adjusted	  odds	  ratios	  for	  heart	  failure	  related	  admissions	  in	  each	  income	  
quartile	  demonstrated	  a	  similar	  stepwise	  progression	  for	  increasing	  risk	  of	  
readmission	  with	  decreasing	  income	  with	  the	  highest	  income	  quartile	  used	  as	  the	  
reference	  population,	  though	  the	  differences	  between	  the	  top	  income	  quartile	  and	  
the	  next	  lowest	  failed	  to	  reach	  statistical	  significance.	  	  
	  
The	  authors	  conclude	  that,	  whilst	  important	  clinical	  and	  demographic	  differences	  
exist	  between	  patients	  with	  higher	  and	  lower	  incomes	  in	  New	  York,	  lower	  income	  




Tsuchihashi	  M,	  Tsutsui	  H,	  Kodama	  K,	  Kasagi	  F,	  Setoguchi	  S,	  Mohr	  M,	  Kubota	  T,	  
Takeshita	  A.	  Medical	  and	  socioenvironmental	  predictors	  of	  hospital	  readmission	  in	  
patients	  with	  congestive	  heart	  failure.	  Am	  Heart	  J	  2001;142:E7.	  	  
This	  prospective	  study	  of	  230	  consecutive	  patients	  discharged	  from	  5	  teaching	  
hospitals	  in	  Fukoka,	  Japan	  used	  medical	  record	  review	  to	  identify	  cases	  of	  heart	  
failure,	  based	  on	  principal	  discharge	  diagnosis	  in	  the	  year	  1st	  January	  1997	  –	  31st	  
December	  1997.	  The	  validity	  of	  the	  diagnosis	  of	  congestive	  heart	  failure	  was	  
ascertained	  by	  thorough	  case	  note	  review	  and	  use	  of	  the	  Framingham	  criteria.	  	  
	  
Presence	  of	  at	  least	  2	  major	  criteria	  or	  1	  major	  criterion	  in	  conjunction	  with	  2	  minor	  
criteria	  were	  accepted	  as	  evidence	  of	  definite	  heart	  failure.	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Socioenvironmental	  factors	  considered	  were	  occupation,	  financial	  resources	  
(financial	  support	  for	  physician	  visits	  and	  medications),	  marital	  status,	  family	  
caregiver,	  professional	  support	  (weekly	  or	  biweekly	  home	  visits),	  and	  follow-­‐up	  visits	  
(outpatient	  attendances	  per	  month).	  	  	  	  	  
	  
Mean	  follow-­‐up	  was	  2.4	  years	  and	  the	  mean	  age	  of	  participants	  was	  69	  years	  (21%	  ≥	  
80	  years).	  60%	  of	  patients	  were	  male	  and	  no	  differences	  were	  observed	  in	  
readmission	  rates	  according	  to	  age	  or	  gender.	  Rates	  of	  death	  at	  6	  months,	  1	  year	  and	  
2	  years	  were	  6.1%,	  8.3%,	  and	  16.5%	  respectively.	  
	  
Readmission	  rates	  were	  high	  at	  35%	  within	  1	  year.	  Independent	  predictors	  of	  
hospital	  admission	  were:	  less	  than	  1	  follow-­‐up	  visit	  per	  month,	  prior	  admission	  for	  
heart	  failure,	  no	  occupation,	  longer	  hospital	  stay	  during	  the	  index	  admission,	  and	  a	  
history	  of	  hypertension.	  A	  significantly	  higher	  percentage	  of	  patients	  in	  the	  non-­‐
readmitted	  group	  received	  professional	  support,	  but	  on	  multivariate	  analysis	  this	  
significance	  was	  lost.	  
	  
The	  only	  significant	  socioeconomic	  variable	  considered	  in	  this	  study	  was	  occupation,	  
treated	  as	  a	  binomial	  categorical	  variable	  	  -­‐	  occupation	  or	  no	  occupation.	  The	  
authors	  make	  the	  point	  that	  it	  was	  not	  possible	  to	  exclude	  an	  interaction	  between	  
medical	  and	  socio-­‐environmental	  variables	  and	  that	  there	  was	  a	  significant	  
relationship	  between	  older	  age	  and	  no	  occupation.	  Whilst	  longer	  hospital	  stays	  were	  
associated	  with	  increased	  likelihood	  of	  readmission,	  other	  markers	  of	  disease	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severity	  –	  NYHA	  class	  and	  ejection	  fraction	  –	  were	  not	  associated	  with	  higher	  
readmission	  rates[161].	  
	  
Riddell	  T.	  Heart	  failure	  hospitalisations	  and	  deaths	  in	  New	  Zealand:	  patterns	  by	  
deprivation	  and	  ethnicity.	  New	  Zealand	  Medical	  Journal	  2005;	  118(1208):1254-­‐
1263.	  	  	  
The	  details	  and	  findings	  of	  this	  New	  Zealand	  based	  study	  are	  outlined	  above	  in	  the	  
mortality	  section.	  Similar	  risks	  were	  noted	  for	  crude	  readmission	  and	  mortality	  
according	  to	  SES[155].	  
	  
Rathore	  SS,	  Masoudi	  FA,	  Wang	  Y,	  Curtis	  JP,	  Foody	  JM,	  Havranek	  EP,	  Krumholz	  HM.	  
Socioeconomic	  status,	  treatment,	  and	  outcomes	  among	  elderly	  patients	  
hospitalized	  with	  heart	  failure:	  findings	  from	  the	  National	  Heart	  Failure	  Project.	  
Am	  Heart	  J	  2006;152:371–378.	  
This	  previously	  described	  study	  examined	  readmission	  rates	  as	  well	  as	  mortality	  
according	  to	  SES.	  Crude	  readmission	  rates	  within	  1	  year	  of	  discharge	  demonstrated	  a	  
significant	  trend	  for	  higher	  rates	  of	  readmission	  with	  decreasing	  socioeconomic	  
status.	  Those	  in	  the	  lowest	  SES	  group	  remained	  at	  an	  increased	  risk	  of	  readmission	  
compared	  with	  those	  in	  the	  highest	  group	  after	  multivariable	  adjustment	  (RR	  1.08	  
[1.03-­‐1.12]).	  However,	  after	  such	  adjustment	  those	  in	  the	  lower	  middle	  and	  higher	  
middle	  SES	  groups	  (between	  the	  highest	  and	  lowest	  groups)	  appeared	  to	  show	  no	  




Antonelli-­‐Incalzi	  R,	  Ancona	  C,	  Forastiere	  F,	  Belleudi	  V,	  Corsonello	  A,	  Perucci	  C	  A.	  
Socioeconomic	  status	  and	  hospitalization	  in	  the	  very	  old:	  a	  retrospective	  study.	  
BMC	  Public	  Health	  2007;	  7:227.	  	  
This	  Italian	  retrospective	  cohort	  study	  examined	  the	  rate	  of	  hospitalizations	  for	  
common	  medical	  conditions	  amongst	  residents	  of	  Rome,	  aged	  75	  years	  or	  older,	  in	  
the	  period	  1997	  –	  2000.	  Income	  data	  were	  provided	  by	  using	  the	  median	  income	  for	  
each	  census	  tract	  of	  Rome,	  applied	  to	  the	  individual	  by	  means	  of	  linkage	  with	  their	  
residential	  address.	  For	  analysis	  purposes,	  individuals	  were	  categorized	  into	  deciles	  
of	  income	  –	  1	  =	  very	  underprivileged,	  10	  =	  very	  well	  off.	  
	  
Age	  standardized	  rates	  of	  hospitalization	  (per	  1000	  inhabitants)	  by	  gender	  and	  
income	  decile	  were	  calculated	  for	  the	  entire	  cohort	  and	  also	  for	  patients	  75	  –	  84	  
years	  old	  and	  those	  85	  and	  over	  (22%	  of	  the	  cohort).	  	  There	  was	  only	  a	  marginal	  
increase	  in	  the	  hospitalization	  rate	  between	  those	  aged	  75-­‐84	  and	  those	  in	  the	  older	  
group	  in	  both	  men	  and	  women,	  and	  rates	  were	  generally	  lower	  in	  women.	  However,	  
the	  rate	  of	  hospitalization	  dramatically	  increased	  with	  decreasing	  income	  in	  both	  
sexes	  and	  age	  groups,	  and	  rates	  of	  hospitalization	  increased	  between	  age	  groups	  to	  
a	  greater	  extent	  with	  increasing	  poverty.	  	  Amongst	  those	  hospitalized,	  higher	  income	  
was	  associated	  with	  lower	  Charleson’s	  comorbidity	  index,	  but	  this	  was	  not	  explored	  
further	  in	  the	  analyses.	  	  	  
	  
Analysis	  of	  admission	  rates	  for	  individual	  conditions	  revealed	  the	  same	  pattern	  for	  
heart	  failure	  related	  admissions	  but,	  interestingly,	  not	  for	  the	  sudden	  acute	  
condition	  of	  hip	  fracture.	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The	  authors	  conclude	  that	  income	  deprivation	  is	  a	  more	  appropriate	  measure	  to	  
target	  interventions	  to	  prevent	  hospital	  admission	  than	  age	  per-­‐se	  in	  elderly	  men	  
and	  women[162].	  
	  
Saxena	  S,	  George	  J,	  Barber	  J,	  Fitzpatrick	  J,	  Majeed	  A.	  Association	  of	  population	  and	  
practice	  factors	  with	  potentially	  avoidable	  admission	  rates	  for	  chronic	  diseases	  in	  
London:	  cross	  sectional	  analysis.	  J.RSM	  2008;	  99:81-­‐89.	  
This	  UK	  based	  study	  pooled	  routinely	  collected	  cross	  sectional	  data	  sources	  from	  all	  
primary	  care	  trusts	  in	  London	  for	  the	  year	  2001.	  The	  fields	  examined	  to	  accurately	  
describe	  each	  trust	  were	  taken	  from	  census	  data;	  IMD	  2000	  score;	  condition	  specific	  
mortality	  rates	  from	  the	  Office	  for	  National	  Statistics;	  prescription	  dispensing	  data	  
from	  the	  Department	  of	  Health,	  according	  to	  the	  Prescription	  Pricing	  Authority’s	  
Prescribing	  Analysis	  and	  Cost	  scheme	  data;	  information	  on	  individual	  primary	  care	  
trust	  list	  sizes	  and	  services;	  data	  on	  hospital	  admissions	  from	  Hospital	  Episodes	  
Statistics	  for	  five	  chronic	  diseases,	  including	  heart	  failure	  (ICD	  10	  code	  I50	  alone).	  
There	  were	  wide	  variations	  in	  hospital	  admission	  rates	  between	  the	  31	  primary	  care	  
trusts	  in	  question	  for	  all	  conditions	  studied,	  including	  heart	  failure.	  These	  variations	  
in	  heart	  failure	  appeared	  to	  be	  mediated	  by	  deprivation,	  increased	  percentage	  of	  
elderly	  living	  alone	  and	  higher	  levels	  of	  ethnic	  minority	  patients.	  No	  significant	  
associations	  were	  noted	  between	  prescription	  rates	  and	  rate	  of	  admission.	  GP	  
factors	  such	  as	  practice	  size	  and	  list	  size	  were	  not	  apparently	  associated	  with	  
differences	  in	  rates	  of	  admission	  for	  any	  of	  the	  conditions	  studied.	  Interestingly,	  the	  
provision	  of	  specialist	  services	  for	  diabetes	  management	  in	  primary	  care	  was	  
associated	  with	  decreased	  hospital	  admission	  rates,	  although	  the	  same	  was	  not	  true	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of	  asthma.	  No	  analysis	  of	  specialist	  heart	  failure	  services	  in	  primary	  care	  is	  
commented	  upon[163].	  	  	  	  	  	  	  	  	  	  	  
	  
	  
4.III.vii.	   TREATMENT	  IN	  HEART	  FAILURE	  AND	  SES	  
	  
McAlister	  FA,	  Murphy	  NF,	  Simpson	  CR,	  Stewart	  S,	  MacIntyre	  K,	  Kirkpatrick	  M,	  
Chalmers	  J,	  Redpath	  A,	  Capewell	  S,	  McMurray	  JJ.	  Influence	  of	  socioeconomic	  
deprivation	  on	  the	  primary	  care	  burden	  and	  treatment	  of	  patients	  with	  a	  diagnosis	  
of	  heart	  failure	  in	  general	  practice	  in	  Scotland:	  population	  based	  study.	  BMJ	  2004;	  
328:1110.	  	  
This	  study,	  described	  in	  detail	  previously,	  examined	  rates	  of	  follow-­‐up	  (total	  contacts	  
in	  the	  year	  1st	  April	  1999	  –	  31st	  March	  2000)	  in	  general	  practice	  for	  patients	  
identified	  as	  having	  heart	  failure	  on	  the	  basis	  of	  Read	  coding.	  Prescribing	  data	  were	  
also	  available	  in	  46%	  of	  patients	  in	  the	  cohort	  from	  a	  priori	  selected	  GP	  practices,	  
and	  this	  sub-­‐cohort	  had	  a	  similar	  age,	  sex	  and	  deprivation	  distribution	  when	  
compared	  with	  the	  full	  cohort.	  Drugs	  considered	  were	  loop	  diuretics,	  angiotensin	  
converting	  enzyme	  inhibitors,	  β-­‐blockers,	  spironolactone,	  and	  digoxin.	  Drugs	  were	  
judged	  to	  have	  been	  given	  if	  they	  were	  prescribed	  at	  least	  twice	  during	  the	  12	  
months	  of	  the	  study.	  
	  
Age	  and	  sex	  standardised	  overall	  rates	  of	  contact	  with	  general	  practitioners	  differed	  
between	  deprivation	  strata	  but	  without	  a	  significant	  trend	  from	  least	  to	  most	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deprived	  as	  there	  was	  little	  difference	  between	  categories	  1-­‐4.	  There	  was	  however,	  a	  
significantly	  reduced	  rate	  of	  contact	  in	  the	  most	  deprived	  group	  when	  compared	  to	  
the	  other	  4	  groups.	  	  Contact	  rates	  did	  not	  differ	  across	  age	  groups	  or	  by	  gender.	  
Contact	  rates	  per	  individual	  patient	  did	  vary	  markedly	  with	  deprivation,	  and	  in	  this	  
case	  a	  highly	  significant	  trend	  for	  reduced	  number	  of	  annual	  contacts	  per	  patient	  
was	  observed	  as	  deprivation	  increased	  (2.6	  contacts	  per	  year	  in	  the	  most	  affluent	  
group	  vs.	  2.0	  contacts	  per	  year	  in	  the	  most	  deprived	  group).	  	  
	  
Rates	  of	  prescription	  of	  diuretics	  were	  relatively	  high	  at	  80.6%,	  but	  rates	  of	  
prescription	  of	  other	  medications	  was	  low	  in	  the	  cohort	  where	  information	  was	  
available	  (ACEi	  39.3%;	  β-­‐blockers	  21.4%;	  digoxin	  20.7%;	  spironolactone	  8.5%).	  No	  
differential	  prescribing	  rates	  were	  observed	  according	  to	  deprivation	  category	  but	  
age	  and	  sex	  appeared	  to	  strongly	  influence	  prescription	  rates.	  The	  authors	  give	  the	  
example	  of	  ACEi	  prescription	  where	  male	  sex	  was	  associated	  with	  a	  42%	  higher	  
likelihood	  of	  prescription	  and	  the	  odds	  ratio	  for	  receiving	  this	  class	  of	  drug	  was	  0.60	  
in	  patients	  aged	  75	  –	  84	  years	  and	  0.39	  for	  patients	  over	  85	  years,	  when	  compared	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  Heart	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  Heart	  J	  
2006;	  152:371–378.	  	  
This	  study	  has	  again	  been	  described	  in	  detail	  earlier.	  As	  well	  as	  investigating	  
mortality	  and	  readmission	  rates,	  the	  authors	  also	  examined	  rates	  of	  assessment	  of	  
LV	  systolic	  function	  and	  prescription	  of	  ACE	  inhibitors	  /	  ARB.	  
	  
Crude	  rates	  of	  LV	  systolic	  function	  assessment	  followed	  a	  significant	  trend	  of	  higher	  
rates	  according	  to	  higher	  SES	  (58.8%	  through	  to	  75%,	  p<0.001).	  This	  trend	  was,	  
however,	  only	  seen	  in	  white	  patients,	  and	  no	  differential	  rates	  of	  assessment	  were	  
seen	  in	  black	  patients.	  This	  pattern	  of	  lower	  rates	  of	  LV	  systolic	  function	  assessment	  
in	  those	  of	  lower	  SES	  persisted	  after	  multivariable	  adjustment.	  
	  
Rates	  of	  ACEi	  /	  ARB	  prescription	  were	  not	  related	  to	  socioeconomic	  status	  as	  
assessed	  in	  this	  study[157].	  	  	  
	  
Bongers	  FJ,	  Schellevis	  FG,	  Bakx	  C,	  van	  den	  Bosch	  WJ,	  van	  der	  ZJ.	  Treatment	  of	  heart	  
failure	  in	  Dutch	  general	  practice.	  BMC	  Fam	  Pract	  2006;7:40.	  	  
This	  survey	  collected	  data	  from	  195	  Dutch	  general	  practitioners	  in	  104	  practices	  with	  
patient	  lists	  equating	  to	  2.5%	  of	  the	  population	  of	  the	  Netherlands.	  Demographic	  
data	  on	  patients	  were	  derived	  from	  the	  administration	  of	  practices	  but	  
socioeconomic	  data	  were	  collected	  directly	  by	  return	  of	  mailed	  questionnaire	  
(response	  rate	  76.5%).	  Data	  regarding	  occupational	  and	  educational	  level	  were	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aggregated	  to	  subdivide	  the	  cohort	  into	  3	  hierarchical	  social	  classes,	  with	  the	  
occupational	  level	  used	  as	  the	  primary	  marker	  for	  social	  class.	  
	  
Patients	  in	  the	  study	  were	  identified	  as	  having	  heart	  failure	  on	  the	  basis	  of	  at	  least	  
one	  contact	  with	  the	  GP	  coded	  K77	  (heart	  failure)	  using	  the	  International	  
Classification	  of	  Primary	  Care	  (ICPC).	  Comorbidity	  was	  based	  on	  contacts	  in	  the	  same	  
year	  with	  the	  relevant	  ICPC	  codes.	  	  
	  
Information	  on	  drug	  prescription	  was	  obtained	  and	  prescription	  rates	  were	  
calculated	  as	  proportions	  of	  patients	  with	  heart	  failure.	  	  
	  
The	  prevalence	  of	  heart	  failure	  was	  calculated	  at	  7.4/1000	  (6.7/1000	  in	  males	  and	  
8.1/1000	  in	  females)	  and	  the	  mean	  age	  of	  patients	  was	  77.7	  years.	  Women	  were	  
significantly	  older	  (79.7	  years	  vs	  75.2	  years)	  and	  68%	  of	  all	  patients	  were	  75	  or	  older.	  
The	  authors	  defined	  optimal	  heart	  failure	  treatment	  as	  a	  triple	  combination	  of	  a	  
diuretic,	  an	  inhibitor	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  system	  (RAAS-­‐I),	  and	  a	  β-­‐
blocker.	  RAAS-­‐I	  were	  defined	  as	  ACE	  inhibitors	  or	  angiotensin	  II	  receptor	  antagonists	  
(ARBs).	  Analyses	  were	  based	  on	  rates	  of	  triple	  treatment,	  rates	  of	  treatment	  with	  
two	  of	  the	  three	  drug	  classes	  together,	  or	  monotherapy	  with	  one	  of	  the	  three	  drug	  
classes.	  Data	  were	  also	  presented	  on	  rates	  of	  prescription	  of	  every	  drug	  class	  
separately	  and	  rates	  of	  prescription	  of	  digoxin	  and	  spironolactone.	  
	  
Triple	  treatment	  was	  observed	  in	  18%	  of	  the	  cohort.	  There	  was	  no	  observable	  
difference	  in	  the	  frequency	  of	  triple	  treatment	  by	  gender,	  but	  rates	  in	  patients	  under	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75	  years	  were	  significantly	  higher	  than	  those	  in	  patients	  75	  years	  and	  older	  (23.7%	  
vs.	  15.4%;	  p<0.05).	  Rates	  of	  triple	  treatment	  were	  also	  significantly	  higher	  in	  patients	  
of	  high	  SES	  than	  those	  of	  low	  SES	  (22.1%	  vs.	  16.7%;	  p<0.05).	  The	  authors	  do	  not	  
provide	  any	  data	  on	  prescription	  rates	  for	  those	  1283	  patients	  who	  were	  in	  the	  
middle	  stratum	  of	  SES.	  	  
	  
Where	  two	  drugs	  were	  prescribed	  the	  combination	  of	  diuretic	  and	  RAAS-­‐I	  was	  most	  
common	  (28.2%	  in	  total),	  and	  in	  this	  case	  older	  patients	  had	  significantly	  higher	  rates	  
of	  this	  prescription.	  No	  SES	  or	  gender	  related	  prescription	  differential	  was	  noted.	  
Older	  patients	  were	  also	  significantly	  more	  commonly	  prescribed	  diuretic	  
monotherapy,	  and	  younger	  patients	  significantly	  more	  commonly	  prescribed	  RAAS-­‐I	  
monotherapy.	  
	  
Consideration	  of	  each	  drug	  as	  a	  separate	  prescription	  revealed	  significantly	  higher	  
prescription	  rates	  of	  diuretics	  and	  digoxin	  in	  older	  patients.	  β-­‐blocker	  prescription	  
rates	  were	  significantly	  higher	  in	  those	  under	  75	  (40%	  vs.	  29%;	  p<0.05)	  and	  in	  those	  
of	  higher	  SES	  (39%	  vs.	  31%;	  p<0.05).	  
	  
The	  authors	  concluded	  that	  the	  influence	  of	  gender	  and	  SES	  on	  prescription	  rates	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This	  UK	  survey	  used	  repeated	  cross-­‐sectional	  analysis	  of	  a	  previously	  validated,	  
nationally	  representative	  primary	  care	  database	  from	  152	  practices	  using	  a	  specific	  
software	  programme	  to	  record	  patient	  data.	  Morbidity	  and	  prescription	  data	  in	  the	  
database	  were	  coded	  using	  Read	  codes	  and	  the	  database	  included	  a	  commercially	  
available	  sociodemographic	  indicator,	  based	  on	  available	  means	  and	  linked	  to	  
patient	  postcode	  –	  the	  ACORN	  index.	  
	  
Patients	  aged	  50	  years	  and	  over	  in	  the	  database	  were	  included	  in	  the	  study	  and	  
heart	  failure	  was	  identified	  by	  a	  Read	  code	  using	  the	  definition	  of	  heart	  failure	  from	  
the	  2006	  revision	  of	  the	  Quality	  and	  Outcomes	  Framework	  (QOF).	  Only	  patients	  
considered	  to	  be	  actively	  managed	  for	  heart	  failure	  were	  included	  in	  the	  study,	  and	  
this	  was	  defined	  as	  the	  receipt	  of	  two	  prescriptions	  of	  and	  ACEi/ARB	  during	  the	  
calendar	  year	  around	  the	  date	  of	  cross-­‐sectional	  sampling.	  Sampling	  occurred	  in	  the	  
years	  2000	  –	  2005.	  
	  
Age	  adjusted	  use	  of	  recommended	  β-­‐blockers	  rose	  sharply	  between	  2000	  and	  2005	  
but	  a	  gender	  gap	  in	  rates	  of	  prescription	  persisted	  (6.2%	  to	  27%	  in	  men	  vs.	  4.2%	  to	  
21.5%	  in	  women).	  Other	  determinants	  of	  β-­‐blocker	  prescription	  included	  age	  (OR	  for	  
those	  aged	  60-­‐64	  years	  3.87	  vs.	  those	  aged	  >85	  years)	  and	  residence	  in	  a	  postcode	  
defined	  in	  the	  ACORN	  index	  as	  “Hard	  pressed”	  (the	  lowest	  sociodemographic	  
stratum)	  –	  OR	  0.79	  for	  prescription	  of	  β-­‐blocker	  compared	  with	  those	  in	  the	  most	  
affluent	  stratum.	  A	  record	  of	  recent	  echocardiography	  also	  predicted	  β-­‐blocker	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prescription	  in	  a	  multivariable	  model	  in	  which	  age	  remained	  the	  dominant	  predictor	  
of	  prescription	  rates.	  Reduced	  prescription	  rates	  in	  those	  of	  lowest	  SES	  persisted	  




















4.IV.	   SUMMARY	  OF	  CURRENT	  KNOWLEDGE	  
	  
The	  National	  Heart	  Failure	  Audit	  for	  England	  and	  Wales	  has	  recurrently	  reported	  that	  
patients	  from	  more	  deprived	  backgrounds	  have	  been	  admitted	  at	  an	  earlier	  age	  than	  
those	  with	  lower	  levels	  of	  deprivation.	  This	  tallies	  with	  numerous	  reports,	  cited	  
above,	  confirming	  a	  higher	  incidence	  of	  heart	  failure	  in	  patients	  of	  lower	  
socioeconomic	  status.	  
	  
What	  is	  not	  clear	  from	  the	  available	  published	  data	  is	  to	  what	  extent	  socioeconomic	  
status	  affects	  mortality	  in	  heart	  failure	  with	  conflicting	  reports	  from	  studies	  in	  
different	  geographies,	  employing	  different	  methods	  to	  assess	  this	  issue.	  
	  
Evidence	  for	  higher	  rates	  of	  readmission	  amongst	  heart	  failure	  patients	  of	  lower	  
socioeconomic	  status	  does	  appear	  to	  be	  available	  from	  several	  studies,	  but	  these	  are	  
isolated,	  historical	  reports	  form	  the	  UK	  combined	  with	  data	  from	  the	  USA	  and	  Italy	  
where	  welfare	  systems	  and	  health	  economies	  are	  markedly	  different.	  
	  
Lower	  socioeconomic	  status	  has	  been	  shown	  to	  predict	  lower	  rates	  of	  LV	  function	  
assessment	  in	  the	  USA	  and	  lower	  rates	  of	  β-­‐blocker	  prescription	  in	  the	  Netherlands	  
and	  the	  UK.	  Lower	  rates	  of	  contact	  with	  general	  practitioners	  in	  UK	  heart	  failure	  
patients	  has	  also	  been	  demonstrated	  in	  more	  deprived	  groups.	  There	  is,	  however,	  
far	  more	  evidence	  from	  international	  published	  data	  and	  from	  the	  UK	  National	  Heart	  
Failure	  Audit	  for	  the	  existence	  of	  lower	  quality	  care	  associated	  with	  older	  age	  and	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female	  gender,	  than	  for	  lower	  quality	  care	  associated	  with	  lower	  socioeconomic	  



















5.	   HYPOTHESES	  
	  
	  
On	  the	  basis	  of	  the	  available	  evidence	  several	  questions	  remain	  regarding	  the	  impact	  
of	  socioeconomic	  status	  on	  heart	  failure	  outcomes	  and	  the	  factors	  which	  might	  
underpin	  any	  such	  association.	  There	  is	  strong	  historical	  evidence	  for	  a	  link	  between	  
incidence	  of	  heart	  failure	  and	  socioeconomic	  status,	  but	  in	  those	  with	  known	  heart	  
failure	  there	  are	  no	  contemporary	  published	  data	  for	  the	  NHS	  in	  England	  for	  the	  
effect	  of	  socioeconomic	  status	  on	  mortality,	  rates	  of	  re-­‐hospitalization,	  or	  quality	  of	  
care.	  	  
	  
This	  thesis	  is	  designed	  to	  test	  the	  following	  hypotheses:	  
	  
1. Lower	  socioeconomic	  status,	  indicated	  by	  lower	  ranking	  in	  the	  IMD	  2007	  for	  
an	  individual’s	  postcode	  of	  residence	  is	  associated	  with	  higher	  mortality	  in	  
patients	  admitted	  to	  hospital	  with	  a	  new	  diagnosis	  of	  heart	  failure.	  
	  
2. In	  patients	  admitted	  to	  hospital	  with	  a	  new	  diagnosis	  of	  heart	  failure	  the	  
readmission	  rate	  is	  higher	  in	  those	  of	  lower	  socioeconomic	  status	  measured	  
in	  the	  same	  way.	  
	  
3. Frequency	  of	  contacts	  with	  hospital	  services	  and	  with	  community	  heart	  
failure	  services	  prior	  to	  and	  following	  an	  initial	  admission	  with	  heart	  failure	  is	  
related	  to	  socioeconomic	  status	  measured	  in	  the	  same	  way.	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4. Quality	  of	  care	  –	  assessed	  by	  prescription	  of	  evidence-­‐based	  medication,	  
access	  to	  echocardiography	  and	  rates	  of	  specialist	  follow-­‐up	  –	  is	  related	  to	  




















6.	   METHODS	  
	  
6.I.	   OVERVIEW	  OF	  THE	  STUDY	  DESIGN	  
	  
The	  project	  has	  been	  conducted	  as	  a	  historical	  cohort	  study.	  The	  cohort	  has	  been	  
identified	  by	  retrospective	  identification	  of	  individuals	  admitted	  with	  heart	  failure	  
over	  a	  designated	  historical	  period,	  and	  data	  pertaining	  to	  these	  individuals	  have	  
been	  extracted	  from	  health	  records	  created	  at	  the	  time	  of	  that	  admission.	  Health	  
records	  and	  other	  sources	  of	  data	  have	  subsequently	  been	  examined	  to	  identify	  use	  
of	  secondary	  care	  services	  in	  the	  period	  2	  years	  prior	  to,	  and	  following,	  the	  date	  of	  
the	  identified	  heart	  failure	  admission	  and	  also	  for	  the	  outcome	  variables	  of	  death	  
and	  readmission	  to	  hospital	  in	  the	  2	  years	  following	  the	  initial	  admission.	  
	  
6.II.	   SETTING	  
	  
6.II.i.	   LOCAL	  HEALTH	  SERVICES	  &	  INFRASTRUCTURE	  
The	  cohort	  was	  assembled	  by	  collection	  of	  data	  from	  a	  single	  district	  general	  hospital	  
on	  the	  South-­‐East	  coast	  of	  England	  –	  The	  Conquest	  Hospital,	  Hastings.	  The	  hospital	  
forms	  part	  of	  the	  East	  Sussex	  Hospitals	  NHS	  Trust	  (ESHT),	  created	  by	  the	  merger	  of	  
the	  Eastbourne	  Hospitals	  NHS	  Trust	  (EHT)	  and	  the	  Hastings	  and	  Rother	  NHS	  Trust	  
(HART)	  in	  April	  2002.	  Acute,	  in-­‐patient	  services	  are	  provided	  at	  both	  Conquest	  
Hospital	  and	  Eastbourne	  District	  General	  Hospital	  (EDGH).	  Outpatient	  services,	  as	  
well	  as	  some	  day-­‐surgeries	  and	  physiotherapy	  are	  provided	  by	  the	  Trust	  at	  several	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community	  hospitals	  operated	  by	  two	  local	  primary	  care	  trusts	  (PCT)	  as	  shown	  in	  
table	  7.	  
	  	  	  	  	  
Hastings	  &	  Rother	  PCT	  was	  formed	  by	  the	  amalgamation	  of	  Hastings	  &	  St.	  Leonards	  
PCT	  and	  Bexhill	  &	  Rother	  PCT	  following	  consultation	  in	  2005	  in	  response	  to	  the	  NHS	  
Improvement	  Plan.	  Since	  that	  time	  it	  has	  been	  responsible	  for	  the	  provision	  of	  
health	  services	  for	  the	  population	  resident	  in	  the	  area	  around	  Conquest	  Hospital,	  
numbering	  170,	  457	  people	  in	  the	  2001	  census[166].	  The	  geographic	  context	  of	  
Conquest	  Hospital	  is	  demonstrated	  in	  the	  map	  –	  figure	  2.	  
	  
It	  can	  be	  appreciated	  from	  figure	  2	  that	  the	  geography	  and	  road	  network	  limit	  the	  
propensity	  for	  health	  migration.	  This	  supposition	  has	  been	  supported	  by	  data	  
demonstrating	  that	  76%	  of	  all	  PCT	  spending	  on	  acute	  services	  in	  2008	  was	  directed	  
towards	  ESHT.	  98%	  of	  the	  remaining	  expenditure	  on	  acute	  services	  was	  for	  tertiary	  
care,	  not	  available	  at	  the	  hospitals	  within	  ESHT[167].	  There	  has	  also	  been	  evidence	  
of	  significant	  local	  opposition	  to	  the	  relocation	  of	  services	  from	  Conquest	  Hospital	  to	  
Eastbourne[168],	  suggesting	  that	  residents	  of	  Hastings	  &	  Rother	  PCT	  are	  most	  likely	  
to	  access	  secondary	  care	  at	  Conquest	  Hospital	  for	  the	  reasons	  outlined	  above.	  
	  
6.II.ii.	  DEFINING	  THE	  STUDY	  PERIOD	  
The	  historical	  period	  defined	  for	  the	  identification	  of	  admitted	  heart	  failure	  cases	  
was	  01/01/2005	  –	  31/12/2007.	  Cases	  identified	  during	  this,	  three	  year,	  period	  were	  
selected	  for	  inclusion	  according	  to	  the	  criteria	  outlined	  below.	  The	  paper	  and	  
electronic	  hospital	  records	  of	  those	  included	  in	  the	  final	  cohort	  were	  retrospectively	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examined	  for	  each	  hospital	  admission	  and	  out-­‐patient	  contact	  in	  the	  2	  years	  
immediately	  prior	  to	  and	  immediately	  subsequent	  to	  the	  date	  of	  the	  identified	  
admission.	  Thus,	  the	  earliest	  date	  for	  which	  prior	  contact	  with	  secondary	  care	  
services	  was	  identified	  and	  collected	  in	  the	  study	  was	  01/01/2003	  and	  the	  latest	  
date	  for	  which	  a	  subsequent	  admission	  or	  out-­‐patient	  appointment	  could	  be	  
recorded	  was	  31/12/2009.	  The	  database	  was	  closed	  on	  01/08/2010	  and	  all	  deaths	  
were	  recorded	  up	  to	  and	  including	  this	  date.	  
	  
6.III.	   ASSEMBLING	  THE	  COHORT	  
	  
An	  historical	  cohort	  of	  patients	  admitted	  with	  a	  first	  episode	  of	  heart	  failure	  
requiring	  admission	  to	  hospital	  was	  defined	  according	  to	  the	  method	  outlined	  
below.	  
	  
Data	  on	  all	  admissions	  to	  Conquest	  Hospital	  are	  continuously	  collected	  for	  inclusion	  
in	  the	  Hospital	  Episode	  Statistics	  (HES)	  and	  Admitted	  Patient	  Care	  (APC)	  datasets.	  A	  
search	  of	  the	  APC	  dataset	  of	  all	  admissions	  in	  the	  period	  01/01/2005	  –	  31/12/2007	  
was	  performed	  to	  identify	  all	  episodes	  where	  heart	  failure	  appeared	  in	  the	  primary	  
or	  secondary	  diagnostic	  positions.	  Diagnoses	  in	  the	  APC	  for	  the	  period	  in	  question	  
were	  coded	  by	  hospital	  coding	  department	  staff,	  to	  determine	  the	  tariff	  associated	  
with	  the	  admission,	  according	  to	  the	  International	  Classification	  of	  Diseases	  version	  
10	  (ICD-­‐10)[169].	  The	  codes	  selected	  to	  identify	  heart	  failure	  in	  this	  study	  were	  the	  
same	  as	  those	  used	  in	  the	  National	  Heart	  Failure	  Audit[170]	  and	  are	  shown	  in	  table	  
8.	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As	  a	  result	  of	  this	  search,	  a	  dataset	  was	  constructed	  which	  contained	  all	  consecutive	  
admissions	  for	  heart	  failure	  in	  the	  period	  in	  question.	  Using	  the	  unique	  hospital	  
identifier	  for	  each	  patient,	  this	  dataset	  was	  then	  examined	  for	  cases	  of	  multiple	  
admissions	  related	  to	  a	  single	  individual.	  Where	  more	  than	  one	  admission	  with	  heart	  
failure	  was	  identified	  for	  a	  single	  individual	  in	  the	  period	  of	  interest,	  these	  
admissions	  were	  considered	  with	  reference	  to	  the	  formal	  written	  discharge	  
summary	  for	  each	  episode.	  In	  such	  cases,	  the	  earliest	  recorded	  admission	  was	  
considered	  to	  be	  the	  index	  admission	  unless	  the	  discharge	  summary	  clearly	  stated	  
that	  this	  admission	  was	  solely	  as	  a	  day-­‐case	  for	  a	  specific	  investigation	  or	  therapy	  
other	  than	  for	  the	  primary	  treatment	  of	  heart	  failure.	  If	  the	  earliest	  admission	  in	  the	  
dataset	  was	  such	  a	  day-­‐case	  admission	  then	  that	  episode	  was	  excluded	  as	  an	  index	  
case	  and	  the	  next	  earliest	  admission	  in	  the	  period	  in	  question	  was	  considered	  in	  the	  
same	  way	  until	  an	  admission	  with	  heart	  failure	  was	  identified.	  Where	  multiple	  
admissions	  of	  the	  same	  individual	  were	  identified	  then	  all	  admissions	  subsequent	  to	  
that	  episode	  accepted	  as	  the	  index	  case	  were	  designated	  re-­‐admissions	  and	  
removed	  from	  the	  initial	  cohort.	  Because	  the	  APC	  defines	  episodes	  of	  care	  in	  the	  
same	  was	  as	  the	  HES	  dataset,	  duplicate	  admissions	  which	  ran	  over	  consecutive	  dates	  
were	  also	  scrutinised	  at	  this	  stage,	  with	  reference	  to	  the	  hospital	  notes	  and	  
electronic	  discharge	  summaries.	  Where	  the	  duplication	  was	  found	  to	  be	  due	  to	  a	  
transfer	  of	  care	  from	  one	  consultant/speciality	  to	  another	  then	  the	  admissions	  were	  
amalgamated	  into	  a	  single	  episode.	  
	  
The	  dataset	  generated	  as	  a	  result	  of	  these	  procedures	  was	  compared	  against	  a	  
similar	  dataset,	  generated	  again	  from	  APC	  data,	  in	  which	  all	  admissions	  for	  heart	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failure	  in	  the	  period	  01/01/2000	  –	  31/12/2004	  were	  identified	  using	  the	  ICD-­‐10	  
codes	  listed	  in	  table	  8	  in	  the	  first	  and	  second	  positions.	  Where	  an	  individual	  was	  
identified	  as	  appearing	  in	  both	  datasets	  they	  were	  excluded	  from	  the	  final	  cohort.	  By	  
use	  of	  this	  method	  to	  exclude	  all	  those	  hospitalized	  for	  heart	  failure	  in	  the	  preceding	  
five	  years,	  the	  final	  cohort	  was	  designed	  to	  contain	  only	  cases	  of	  first	  admission	  with	  
a	  coded	  diagnosis	  of	  heart	  failure.	  	  	  	  
	  
Following	  the	  identification	  of	  all	  consecutive	  patients	  newly	  admitted	  with	  a	  
diagnosis	  of	  heart	  failure	  in	  the	  primary	  or	  secondary	  position	  as	  detailed	  above,	  
data	  from	  the	  medical	  record	  and	  the	  electronic	  discharge	  summary	  were	  examined	  
for	  each	  patient	  in	  this	  final	  dataset	  to	  corroborate	  the	  diagnosis	  of	  heart	  failure.	  The	  
criteria	  used	  were	  based	  on	  the	  contemporary	  recommendations	  of	  the	  European	  
Society	  of	  Cardiology[41].	  However,	  measurement	  of	  natriuretic	  peptides	  was	  not	  
routine	  at	  Conquest	  Hospital,	  or	  in	  the	  UK,	  during	  the	  period	  in	  question.	  Therefore,	  
the	  following	  algorithm	  was	  used	  to	  exclude	  cases	  of	  unlikely	  heart	  failure:	  
	  
1. A	  Boston	  Heart	  Failure	  Score	  (see	  table	  9)[44]	  was	  calculated	  for	  each	  
individual	  on	  the	  basis	  of	  the	  records	  of	  symptoms,	  physical	  examination	  
and	  chest	  x-­‐ray	  report1	  at	  the	  time	  of	  the	  admission.	  
2. Evidence	  of	  cardiac	  dysfunction	  (both	  systolic	  and	  diastolic)	  from	  any	  
echocardiogram	  performed	  during	  the	  four-­‐year	  period	  of	  interest	  was	  
recorded.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Consultant radiologist report – available from electronic records in all cases where chest x-ray 
performed 
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3. Evidence	  of	  response	  to	  heart	  failure	  treatment	  (diuretics	  &	  vasodilators)	  
was	  recorded.2	  
	  
Where	  the	  Boston	  Heart	  Failure	  Score	  was	  0	  –	  4	  the	  case	  was	  excluded	  from	  the	  
cohort	  unless	  there	  was	  clear	  evidence	  of	  cardiac	  dysfunction	  and	  response	  to	  
treatment	  directed	  against	  heart	  failure.	  	  
	  
Following	  the	  above	  method	  resulted	  in	  the	  generation	  of	  a	  cohort	  of	  patients	  
admitted	  for	  the	  first	  in-­‐patient	  management	  of	  an	  episode	  of	  heart	  failure,	  coded	  as	  
such	  and	  confirmed	  on	  review	  of	  all	  of	  the	  clinical	  evidence	  recorded.	  Because	  the	  
primary	  focus	  of	  the	  study	  was	  to	  describe	  and	  explore	  the	  associations	  between	  
socioeconomic	  status	  and	  contact	  with	  secondary	  care	  services	  and	  the	  quality	  of	  
that	  care,	  confident	  assessment	  of	  the	  number	  and	  type	  of	  contacts	  for	  each	  
individual	  was	  required.	  As	  discussed,	  there	  is	  strong	  evidence	  from	  available	  data	  
that	  residents	  of	  the	  geographic	  area	  covered	  by	  Hastings	  &	  Rother	  PCT	  access	  
secondary	  care	  almost	  exclusively	  via	  the	  Conquest	  Hospital.	  However,	  the	  region	  of	  
the	  South	  Coast	  encompassing	  Hastings	  and	  its	  environs	  is	  a	  popular	  holiday	  
destination,	  and	  the	  area	  contains	  several	  holiday	  camps	  and	  caravan	  parks,	  
anecdotally	  more	  popular	  with	  elderly	  holidaymakers.	  Specific	  data	  to	  support	  this	  
are	  limited,	  but	  certainly	  an	  average	  of	  119,	  6000	  holiday	  nights	  were	  spent	  in	  
Hastings	  alone	  in	  2006-­‐2008[171].	  For	  this	  reason,	  it	  was	  predicted	  that	  a	  degree	  of	  
seasonal	  health	  migration	  would	  be	  operating	  within	  the	  cohort	  of	  interest	  for	  the	  
study.	  Individuals	  were	  only	  considered	  eligible	  for	  inclusion	  in	  the	  final	  study	  cohort	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 For this criterion a statement in the discharge summary of “responded well to / improved with 
treatment for heart failure” (or similar) was taken as evidence.  
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if	  their	  primary	  postcode	  of	  residence,	  recorded	  on	  the	  hospital’s	  clinical	  information	  
system,	  was	  located	  in	  the	  area	  defined	  by	  Hastings	  &	  Rother	  PCT,	  and	  if	  they	  were	  
registered	  with	  a	  general	  practitioner	  operating	  within	  the	  PCT	  at	  the	  time	  of	  the	  
index	  admission.	  
	  
Patients	  were	  also	  excluded	  from	  the	  final	  cohort	  if	  there	  was	  no	  evidence	  of	  
registration	  with	  the	  hospital	  prior	  to	  the	  index	  admission.	  This	  was	  estimated	  by	  the	  
absence	  of	  an	  historic	  patient	  number	  associated	  with	  the	  individual’s	  hospital	  
records.	  Such	  numbers	  contained	  an	  H	  as	  the	  first	  character	  (H-­‐numbers)	  and	  were	  
replaced	  by	  numbers	  containing	  an	  X	  as	  the	  first	  character	  (X-­‐numbers)	  in	  May	  2004.	  
All	  patients	  registered	  with	  the	  Conquest	  hospital	  prior	  to	  May	  2004	  had	  individual	  
X-­‐numbers	  associated	  with	  their	  records	  in	  addition	  to	  the	  historic	  H-­‐number.	  All	  
patients	  newly	  registered	  after	  May	  2004	  had	  a	  novel	  X-­‐number	  generated	  for	  
association	  with	  their	  records	  and	  had	  no	  H-­‐number	  associated	  with	  those	  same	  
records.	  By	  excluding	  from	  the	  cohort	  those	  individuals	  with	  no	  H-­‐number	  
associated	  with	  their	  medical	  records,	  those	  patients	  migrating	  into	  the	  study	  
population	  during	  the	  period	  of	  interest	  for	  the	  study	  were	  not	  included	  in	  the	  
analysis,	  as	  their	  prior	  contacts	  with	  secondary	  care,	  and	  their	  socioeconomic	  status	  
could	  not	  be	  confidently	  assessed.	  Finally,	  as	  contacts	  with	  the	  health	  service	  were	  
under	  study	  it	  was	  necessary	  to	  exclude	  patients	  if	  it	  were	  clear	  from	  review	  of	  the	  
medical	  record	  that	  their	  care	  was	  mainly	  managed	  by	  a	  tertiary	  centre	  or	  in	  the	  




6.IV.	   DATA	  EXTRACTION	  
	  
All	  data	  were	  extracted	  from	  the	  continuous	  medical	  record	  either	  in	  its	  electronic	  or	  
paper	  notes	  form.	  The	  electronic	  record	  at	  the	  Conquest	  Hospital,	  known	  as	  JOE,	  has	  
been	  in	  continuous	  operation	  since	  1998.	  Over	  this	  period,	  all	  correspondence,	  
blood	  results,	  radiology	  and	  echocardiogram	  reports3,	  and	  the	  results	  of	  all	  special	  
investigations	  have	  been	  recorded	  on	  JOE	  and	  were	  therefore	  available	  for	  
immediate	  review	  at	  the	  time	  of	  data	  collection.	  No	  other	  system	  has	  been	  used	  for	  
generating	  letters	  and	  where	  investigation	  results	  were	  delivered	  by	  alternative	  
software	  systems,	  all	  such	  systems	  have	  been	  integrated	  with	  JOE	  so	  that	  a	  











	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Echocardiogram reports available from 2001 onwards. 
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6.V.	   VARIABLES	  
	  
6.V.i.	   OUTCOME	  MEASURES	  
The	  primary	  outcome	  variable	  was	  death	  from	  any	  cause.	  Death	  was	  determined	  as	  
having	  occurred	  on	  a	  specific	  date	  by	  interrogation	  of	  the	  JOE	  clinical	  system,	  which	  
is	  in	  turn	  linked	  to	  the	  PAS	  system	  of	  ESHT.	  Where	  deaths	  occurred	  in	  the	  Conquest	  
Hospital,	  these	  were	  immediately	  recorded	  on	  these	  systems	  and	  were	  corroborated	  
by	  interrogation	  of	  the	  database	  of	  in-­‐patient	  deaths,	  maintained	  by	  the	  
bereavement	  service	  at	  the	  Conquest	  Hospital.	  The	  PAS	  system	  has	  continuously	  
been	  linked	  to	  the	  Office	  for	  National	  Statistics,	  by	  means	  of	  the	  unique	  patient	  NHS	  
number,	  and	  is	  updated	  on	  a	  three	  monthly	  basis	  to	  identify	  deaths	  occurring	  
outside	  the	  Conquest	  Hospital.	  A	  final	  interrogation	  of	  this	  system	  was	  carried	  out	  on	  
08/11/2010	  to	  minimise	  the	  risk	  of	  any	  out	  of	  hospital	  deaths	  in	  the	  cohort	  not	  being	  
recorded	  as	  a	  result	  of	  these	  events	  occurring	  near	  the	  database	  closure	  date	  of	  
01/08/2010.	  
	  
Mortality	  at	  30	  days	  and	  at	  one	  year	  was	  defined	  from	  the	  date	  of	  the	  start	  of	  the	  
index	  admission.	  
	  
The	  secondary	  outcome	  measures	  were	  of	  all	  cause	  readmission	  and	  readmission	  
with	  heart	  failure.	  All	  admissions	  subsequent	  to	  that	  used	  to	  include	  the	  case	  in	  the	  
final	  cohort	  were	  identified	  by	  interrogation	  of	  the	  APC	  in	  the	  period	  730	  days	  
following	  the	  date	  of	  the	  start	  of	  that	  index	  admission,	  using	  the	  unique	  hospital	  
	  89	  
number	  for	  each	  patient.	  In	  this	  way,	  a	  list	  of	  admissions	  for	  any	  cause	  in	  the	  period	  
two	  years	  from	  the	  start	  of	  the	  index	  admission	  was	  generated	  for	  each	  member	  of	  
the	  cohort.	  The	  primary	  and	  secondary	  coded	  diagnoses	  for	  each	  of	  the	  indentified	  
readmissions	  were	  recorded	  in	  every	  case.	  Where	  one	  of	  the	  ICD-­‐10	  codes	  used	  to	  
include	  the	  case	  in	  the	  original	  cohort	  (listed	  in	  table	  8)	  appeared	  in	  either	  the	  
primary	  or	  secondary	  position,	  then	  that	  readmission	  was	  determined	  to	  be	  a	  heart	  
failure	  readmission.	  Readmissions	  where	  ICD-­‐10	  codes	  other	  than	  those	  used	  to	  
identify	  heart	  failure	  cases	  appeared	  in	  both	  the	  primary	  and	  secondary	  positions	  
were	  determined	  to	  be	  non-­‐heart	  failure	  admissions	  and	  were	  combined	  with	  heart	  
failure	  readmissions	  to	  generate	  the	  list	  of	  all	  cause	  readmissions.	  
	  
	  
6.V.ii.	  ASSIGNING	  SOCIOECONOMIC	  STATUS	  
The	  exposure	  variable	  of	  interest	  was	  socioeconomic	  status	  of	  individuals	  in	  the	  
cohort,	  determined	  by	  use	  of	  the	  Index	  of	  Multiple	  Deprivation	  2007	  (IMD	  
2007)[172].	  This	  index	  is	  a	  measure	  of	  multiple	  deprivation	  at	  the	  small	  area	  level	  in	  
England,	  constructed	  by	  the	  Social	  Disadvantage	  Research	  Centre	  at	  the	  Department	  
of	  Social	  Policy	  and	  Social	  Work	  at	  the	  University	  of	  Oxford.	  Data	  on	  deprivation	  –	  
combined	  across	  seven,	  weighted	  domains	  –	  are	  available	  at	  the	  lower	  layer	  super	  
output	  area	  (LSOA)	  level	  (table	  10).	  Data	  used	  to	  calculate	  the	  IMD	  2007	  were,	  in	  the	  
main,	  collected	  in	  2005,	  or	  represented	  the	  average	  of	  data	  collected	  up	  to	  2005.	  For	  
a	  minority	  of	  the	  determinants	  in	  certain	  domains,	  data	  were	  taken	  from	  the	  most	  
contemporaneous	  (2001)	  census.	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LSOA	  were	  designated	  to	  improve	  the	  reporting	  of	  small	  area	  statistics	  in	  England	  
and	  Wales	  and	  are	  part	  of	  a	  geographical	  hierarchy	  for	  which	  population	  statistics	  
are	  available[173].	  Each	  LSOA	  is	  composed	  of	  four	  to	  six	  contiguous	  output	  areas,	  
and	  they	  were	  generated	  by	  the	  ONS	  to	  be	  as	  consistent	  in	  population	  size	  and	  social	  
homogeneity	  as	  possible.	  The	  minimum	  population	  within	  an	  LSOA	  is	  1000	  persons	  
and	  the	  mean	  is	  reported	  as	  1500	  persons.	  The	  Organisation	  Data	  Service,	  provided	  
by	  NHS	  Connecting	  for	  Health,	  has	  linked	  each	  individual	  postcode	  in	  England	  and	  
Wales	  with	  a	  specific	  LSOA.	  In	  England	  alone,	  there	  are	  32,	  482	  individual	  LSOA.	  Each	  
of	  these	  has	  been	  assigned	  a	  specific	  IMD	  2007	  score,	  and	  subsequently	  ranked	  
relative	  to	  all	  other	  LSOA	  in	  the	  country	  on	  the	  basis	  of	  this	  score.	  Thus,	  the	  most	  
deprived	  LSOA	  in	  England	  has	  a	  rank	  of	  1,	  and	  the	  least	  deprived	  has	  a	  rank	  of	  
32,482.	  
	  
The	  score	  and	  rank	  of	  the	  LSOA	  associated	  with	  the	  postcode	  of	  each	  individual	  
member	  of	  the	  final	  cohort	  was	  recorded	  and	  these	  ranks	  were	  used	  to	  divide	  the	  
cohort	  into	  quintiles	  of	  deprivation,	  according	  to	  their	  overall	  rank	  within	  England	  
(table	  11).	  
	  
6.V.iii.	   EFFECT	  MODIFIERS	  
	  
Demographic	  Factors	  
Age	  and	  gender	  of	  members	  of	  the	  cohort	  were	  considered	  as	  potential	  effect	  
modifiers	  and	  were	  routinely	  recorded	  from	  the	  APC	  dataset	  in	  each	  case.	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Care	  Quality	  	  	  	  
Several	  markers	  of	  high	  quality	  care	  were	  defined	  for	  the	  study	  on	  the	  basis	  of	  what	  
information	  could	  be	  reliably	  gathered	  retrospectively.	  These	  markers	  are	  based	  on	  
guidelines	  from	  the	  UK	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  
(NICE)[60]	  and	  have	  also	  been	  informed	  by	  the	  National	  Service	  Framework	  for	  
Coronary	  Heart	  Disease[174]	  as	  well	  as	  recommendations	  by	  the	  European	  Society	  
of	  Cardiology[41].	  The	  variables	  felt	  to	  be	  related	  to	  care	  quality	  were	  
echocardiography,	  prescription	  of	  medications,	  investigations	  performed,	  and	  
specialist	  care	  (prior	  to,	  during,	  and	  subsequent	  to	  the	  admission).	  Details	  of	  the	  
methods	  used	  to	  collect	  these	  data	  are	  outlined	  below.	  	  
	  
Echocardiography	  
The	  JOE	  system	  was	  interrogated	  for	  evidence	  of	  echocardiography	  having	  been	  
performed	  in	  the	  period	  two	  years	  prior	  to	  and	  two	  years	  following	  the	  date	  of	  the	  
index	  admission.	  Echocardiogram	  reports	  were	  identified	  by	  accessing	  each	  
individual	  patient	  record	  and	  opening	  the	  following	  subdirectory	  tree:	  
	  RESULTS	  
	   	   	   	   	  CARDIAC	  
	   	   	   	   	   	  ECHO	  
This	  generated	  a	  list	  of	  all	  available,	  typed	  echocardiogram	  reports	  in	  date	  order.	  
Where	  echocardiography	  was	  found	  to	  have	  been	  performed	  during	  the	  period	  
between	  the	  admission	  and	  discharge	  dates	  of	  the	  index	  episode,	  this	  was	  recorded	  
as	  an	  echocardiogram	  performed	  as	  an	  in-­‐patient	  during	  a	  first	  admission	  for	  the	  
management	  of	  heart	  failure.	  If	  no	  echocardiogram	  report	  was	  identified	  at	  the	  time	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of	  the	  index	  episode,	  but	  a	  report	  was	  available	  from	  the	  period	  of	  interest	  then	  the	  
number	  of	  days	  (either	  positive	  or	  negative)	  between	  this	  report	  and	  the	  index	  
admission	  was	  recorded.	  Where	  more	  than	  one	  echocardiogram	  had	  been	  
performed	  in	  the	  period	  of	  interest,	  the	  date	  of	  the	  report	  most	  contemporary	  with	  
the	  index	  admission	  was	  recorded.	  
	  
Once	  the	  timing	  of	  echocardiography	  had	  been	  determined	  in	  this	  manner,	  the	  
measurements	  of	  interest	  were	  extracted	  from	  the	  identified	  report.	  All	  reports	  
were	  for	  trans-­‐thoracic	  studies	  and	  were	  prepared	  by	  a	  British	  Society	  of	  
Echocardiography	  certified	  technician	  or	  by	  a	  Consultant	  Cardiologist	  or	  Specialist	  
Registrar	  in	  Cardiology	  training.	  The	  following	  measurements	  were	  recorded:	  
1. Left	  Ventricular	  Ejection	  Fraction	  (LVEF),	  measured	  using	  either	  Teichholz	  
method[175]	  or	  the	  method	  of	  discs	  (modified	  Simpson’s	  rule)[176].	  
Where	  LVEF	  was	  calculated	  using	  both	  methods,	  the	  value	  given	  by	  the	  
method	  of	  discs	  was	  recorded	  as	  it	  was	  considered	  to	  be	  more	  
reliable[177].	  
2. Left	  Ventricular	  End	  Systolic	  and	  End	  Diastolic	  Diameter	  (LVESD	  &	  LVEDD),	  
measured	  in	  centimeters	  (cm),	  from	  the	  trailing	  edge	  of	  the	  
interventricular	  septum	  to	  leading	  edge	  of	  the	  posterior	  wall	  by	  M-­‐mode	  
echocardiography,	  just	  beyond	  the	  tips	  of	  the	  mitral	  valve	  leaflets.	  
3. Left	  Atrial	  Internal	  Diameter	  (LAID),	  measured	  by	  m-­‐mode	  
echocardiography,	  in	  cm	  at	  end	  systole.	  The	  measurement	  was	  taken	  
from	  the	  trailing	  edge	  of	  the	  posterior	  aortic	  wall	  to	  the	  leading	  edge	  of	  
the	  posterior	  wall	  of	  the	  left	  atrium,	  at	  the	  level	  of	  the	  aortic	  valve.	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4. Subjective	  left	  ventricular	  systolic	  function,	  recorded	  according	  to	  any	  
statement	  made	  in	  the	  free	  text	  summary	  provided	  with	  each	  
echocardiogram	  report.	  The	  measure	  was	  treated	  as	  a	  discrete	  variable,	  
with	  the	  following	  possible	  values:	  
a. Good	  /	  Normal.	  
b. Mild	  systolic	  dysfunction.	  
c. Mild	  –	  moderate	  systolic	  dysfunction.	  
d. Moderate	  systolic	  dysfunction.	  
e. Moderate	  –	  severe	  systolic	  dysfunction.	  
f. Severe	  systolic	  dysfunction.	  	  	  
	  	  
Prescription	  of	  Medications	  
The	  electronic	  discharge	  summary,	  created	  at	  the	  end	  of	  the	  index	  admission	  for	  
each	  member	  of	  the	  cohort,	  was	  examined	  for	  details	  of	  the	  medications	  prescribed	  
on	  discharge.	  Such	  summaries	  were	  only	  available	  for	  those	  patients	  who	  survived	  to	  
discharge,	  and	  no	  data	  were	  collected	  on	  the	  prescription	  of	  medications	  to	  patients	  
who	  died	  during	  the	  index	  admission.	  Prescription	  of	  each	  medication	  was	  
considered	  to	  have	  occurred	  according	  to	  the	  presence	  or	  absence	  of	  a	  member	  of	  
that	  class	  of	  drug	  on	  the	  discharge	  summary.	  The	  following	  classes	  of	  medication	  
were	  recorded:	  
1. Loop	  Diuretics	  –	  record	  was	  taken	  of	  the	  total	  daily	  dose	  of	  diuretic	  
prescribed	  in	  furosemide	  equivalents4.	  	  
2. Angiotensin	  Converting	  Enzyme	  Inhibitors	  (ACEi).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 1mg bumetanide = 40mg furosemide = 20mg torasemide. 
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3. Angiotensin	  II	  Receptor	  Antagonists	  (ARB).	  
4. β-­‐blockers	  –	  record	  was	  taken	  of	  the	  specific	  agent	  where	  this	  class	  of	  
medication	  was	  prescribed,	  according	  to	  whether	  or	  not	  the	  agent	  was	  
licensed	  for	  the	  treatment	  of	  heart	  failure.	  
5. Aldosterone	  antagonists	  (spironolactone	  or	  eplerenone	  at	  any	  dose).	  
6. Anti-­‐platelet	  agents	  –	  record	  was	  taken	  of	  prescription	  of	  aspirin	  
(acetylsalicylic	  acid),	  clopidogrel	  and	  dipyridamole,	  and	  also	  of	  situations	  
where	  combinations	  of	  these	  drugs	  were	  prescribed.	  
7. Vitamin-­‐K	  antagonists.	  
8. Nitrate	  preparations.	  
9. HMG-­‐CoA	  Reductase	  Inhibitors	  (“statins”).	  
10. Calcium	  channel	  antagonists	  (CCB)	  –	  record	  was	  taken	  of	  whether	  
dihydropyridine	  or	  non-­‐dihydropyridine	  type.	  
11. Non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  other	  than	  acetylsalicylic	  
acid.	  
12. Thiazide	  diuretics.	  	  	  
	  
Specialist	  Care	  
The	  clinician	  responsible	  for	  the	  care	  of	  the	  patient	  during	  the	  index	  admission	  was	  
determined	  to	  be	  the	  consultant	  named	  on	  the	  electronic	  discharge	  summary.	  
Patients	  may	  have	  been	  recorded	  as	  having	  been	  admitted	  initially	  under	  the	  care	  of	  
another	  clinician,	  but	  the	  speciality	  of	  the	  clinician	  responsible	  for	  the	  patient	  on	  
discharge	  was	  felt	  to	  be	  the	  best	  proxy	  for	  the	  speciality	  which	  had	  most	  impact	  on	  
determining	  the	  in-­‐patient	  and	  future	  management.	  Where	  patients	  died	  prior	  to	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discharge	  from	  the	  index	  admission,	  then	  the	  consultant	  recorded	  as	  responsible	  for	  
the	  admission	  on	  the	  JOE	  system	  was	  used	  to	  determine	  the	  speciality	  of	  care	  for	  the	  
admission.	  The	  speciality	  of	  in-­‐patient	  care	  was	  classified	  as	  a	  discrete	  variable	  with	  
three	  possible	  values:	  
1. Cardiology	  
2. General	  Medicine	  (any	  consultant	  physician	  other	  than	  one	  with	  a	  CCST	  in	  
cardiology	  or	  elderly	  medicine).	  
3. Elderly	  care	  /	  geriatrics.	  
One	  of	  the	  geriatricians	  responsible	  for	  the	  care	  of	  in-­‐patients	  (HFM)	  was	  recognised	  
as	  having	  a	  specialist	  interest	  in	  heart	  failure.	  However,	  during	  the	  period	  of	  the	  
study,	  no	  specialist	  service	  for	  elderly	  in-­‐patients	  with	  heart	  failure	  existed	  at	  the	  
Conquest	  Hospital	  and	  so,	  for	  the	  purposes	  of	  defining	  the	  speciality	  of	  care	  of	  in-­‐
patient	  members	  of	  the	  cohort,	  those	  admitted	  under	  HFM	  were	  recorded	  as	  having	  
received	  care	  from	  a	  geriatrician.	  	  	  	  
	  
Investigations	  
The	  JOE	  system	  was	  interrogated	  for	  evidence	  of	  the	  following	  investigations	  having	  
been	  performed	  during	  the	  index	  admission:	  
• Full	  Blood	  Count	  (FBC).	  
• Plasma	  urea,	  creatinine	  and	  electrolytes	  (U&E).	  
• Liver	  Function	  Tests	  (LFT).	  
• Plasma	  glucose	  testing.	  
• Serum	  lipid	  profile	  testing.	  
• Thyroid	  function	  tests	  (TFT).	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Note	  was	  also	  taken	  as	  to	  whether	  these	  final	  three	  investigations	  were	  performed	  
at	  any	  time	  in	  the	  6	  weeks	  prior	  to	  the	  date	  of	  the	  index	  admission,	  as	  it	  was	  
considered	  that	  clinicians	  reviewing	  such	  results	  at	  the	  time	  of	  the	  admission	  would	  
not	  feel	  that	  repeating	  the	  tests	  would	  provide	  additional	  useful	  information	  
regarding	  the	  diagnosis	  and	  management	  of	  heart	  failure.	  Once	  collected,	  these	  data	  
were	  treated	  as	  discrete	  variables	  with	  the	  possible	  values:	  
1. Test	  performed	  during	  index	  admission	  (or	  in	  the	  6	  weeks	  prior	  to	  the	  
admission	  date	  for	  TFT	  and	  plasma	  glucose	  and	  lipid	  testing).	  
2. Test	  not	  performed.	  
	  
Record	  was	  also	  taken	  of	  the	  performance	  of	  a	  chest	  X-­‐ray	  (CXR)	  during	  the	  index	  
admission.	  All	  chest	  radiographs	  are	  formally	  reported	  at	  the	  hospital	  and	  so	  this	  was	  
determined	  by	  the	  presence	  on	  the	  JOE	  system	  of	  a	  formal	  report,	  by	  a	  radiology	  
consultant	  or	  trainee,	  pertaining	  to	  a	  CXR	  performed	  during	  the	  period	  of	  the	  index	  
admission.	  
	  
Prior	  contacts	  with	  secondary	  care	  
Prior	  contacts	  with	  secondary	  care	  were	  collected	  for	  both	  admissions	  and	  out-­‐
patient	  visits	  in	  the	  two	  years	  prior	  to	  the	  date	  of	  admission	  for	  the	  index	  episode.	  
For	  prior	  admissions,	  the	  APC	  dataset	  was	  interrogated	  for	  all	  admissions	  in	  the	  
period	  of	  interest	  using	  the	  unique	  hospital	  number	  for	  each	  member	  of	  the	  cohort,	  
and	  the	  total	  number	  of	  admissions	  was	  recorded.	  
For	  out-­‐patient	  visits,	  the	  PAS	  system	  was	  interrogated	  in	  a	  similar	  manner,	  using	  the	  
unique	  hospital	  number	  for	  each	  member	  of	  the	  cohort.	  All	  appointments	  were	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identified	  in	  the	  period	  of	  interest	  and	  the	  date	  of	  the	  appointment,	  as	  well	  as	  the	  
speciality	  of	  the	  clinic	  was	  recorded	  in	  each	  case.	  Data	  were	  available	  for	  patients	  
who	  failed	  to	  attend	  scheduled	  outpatient	  appointments	  and	  attendance	  at	  an	  
outpatient	  clinic	  was	  considered	  to	  have	  occurred	  if	  the	  outcome	  record	  of	  the	  clinic	  
was	  one	  other	  than	  DNA	  (did	  not	  attend).	  	  
	  
Follow-­‐up	  
Details	  of	  all	  out-­‐patient	  appointments	  in	  the	  follow-­‐up	  period	  were	  collected	  using	  
the	  same	  method	  used	  to	  record	  prior	  clinic	  visits,	  outlined	  above.	  	  
	  
Contacts	  with	  primary	  care	  
When	  designing	  the	  study	  initially,	  data	  on	  contacts	  with	  primary	  care	  were	  planned	  
to	  be	  collected	  for	  all	  members	  of	  the	  cohort.	  However,	  when	  applying	  for	  ethical	  
approval	  of	  the	  original	  study	  design,	  it	  was	  felt	  by	  the	  committee	  that	  access	  to	  
such	  records	  without	  formal	  written	  consent	  would	  not	  be	  ethically	  acceptable.	  
Application	  to	  conduct	  the	  study	  under	  Section	  60	  of	  the	  Health	  and	  Social	  Care	  Act	  
was	  explored	  but	  not	  considered	  appropriate	  for	  data	  confined	  to	  a	  single	  centre,	  as	  
well	  as	  being	  too	  lengthy	  a	  process	  to	  embark	  upon	  given	  the	  time	  constraints	  of	  this	  






6.V.iv.	   CONFOUNDERS	  
Factors	  known	  to	  be	  associated	  with	  outcome,	  in	  terms	  of	  death	  and	  hospital	  
readmission	  in	  the	  published	  literature,	  in	  heart	  failure	  were	  recorded,	  as	  completely	  
as	  possible,	  for	  each	  member	  of	  the	  cohort.	  Where	  results	  of	  blood	  tests	  were	  
recorded,	  all	  tests	  were	  performed	  by	  the	  pathology	  services	  of	  the	  study	  site	  –	  the	  
Conquest	  Hospital,	  Hastings	  –	  in	  either	  the	  biochemistry	  or	  haematology	  
laboratories.	  All	  values	  were	  taken	  from	  the	  results	  available	  on	  the	  JOE	  system.	  
Results	  of	  blood	  tests	  on	  the	  system	  are	  recorded	  in	  chronological	  order,	  and	  the	  
first	  result	  appearing	  within	  the	  date	  range	  of	  the	  index	  admission	  was	  taken	  for	  the	  
admission	  value.	  Where	  discharge	  values	  were	  included,	  they	  were	  taken	  to	  be	  those	  
of	  the	  last	  recorded	  result	  within	  the	  date	  range	  of	  the	  admission	  –	  i.e.	  the	  last	  result	  
known	  by	  the	  responsible	  admitting	  clinician.	  	  
	  
Renal	  Function	  and	  Serum	  Sodium	  
Both	  admission	  and	  discharge	  measures	  of	  sodium,	  potassium,	  urea	  and	  creatinine	  
(collectively	  U&E)	  were	  recorded.	  	  
	  
Renal	  function	  was	  determined	  by	  estimated	  glomerular	  filtration	  rate	  (eGFR),	  
calculated	  from	  the	  simplified	  Modification	  of	  Diet	  in	  Renal	  Disease	  (MDRD)	  
formula[178].	  No	  adjustment	  for	  race	  was	  made	  when	  calculating	  these	  values,	  as	  
this	  information	  was	  not	  collected	  in	  the	  study.	  Available	  data	  on	  the	  demography	  of	  
the	  population	  from	  which	  the	  cohort	  was	  drawn	  suggests	  that	  the	  accuracy	  of	  this	  
method	  was	  unlikely	  to	  have	  been	  significantly	  impaired	  by	  discounting	  race	  when	  
calculating	  the	  eGFR[166].	  Renal	  function	  was	  analyzed	  as	  a	  continuous	  variable	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using	  the	  eGFR	  and	  the	  plasma	  creatinine	  concentration[179],	  but	  also	  as	  a	  
categorical	  variable	  using	  the	  stages	  of	  chronic	  kidney	  disease	  (CKD)	  to	  sort	  the	  
cohort	  into	  groups	  according	  to	  their	  eGFR	  (table	  12).	  
	  
Plasma	  sodium	  was	  recorded	  as	  a	  continuous	  variable.	  Members	  of	  the	  cohort	  were	  
also	  dichotomized	  into	  groups	  according	  to	  the	  presence	  or	  absence	  of	  
hyponatraemia	  (plasma	  sodium	  <	  130mmol/l).	  
	  
Anaemia	  
Admission	  full	  blood	  count	  results	  were	  examined	  and	  the	  haemoglobin	  
concentration	  (Hb),	  total	  white	  cell	  count	  (WCC),	  platelet	  count	  and	  mean	  
corpuscular	  volume	  (MCV)	  were	  recorded	  for	  each	  member	  of	  the	  cohort.	  	  
	  
Haemoglobin	  concentration	  was	  analyzed	  as	  a	  continuous	  variable	  but	  anaemia	  was	  
also	  examined	  as	  a	  discrete	  variable.	  The	  definition	  of	  anaemia	  used	  was	  that	  of	  the	  
World	  Health	  Organization	  –	  Hb	  <	  13g/dl	  in	  men	  and	  Hb	  <	  12g/dl	  in	  women.	  
	  
Serum	  Albumin	  
Liver	  function	  tests	  measured	  on	  admission	  were	  examined	  and	  results	  of	  plasma	  
bilirubin,	  alkaline	  phosphatase	  (ALP),	  alanine	  aminotransferase	  (ALT)	  and	  albumin	  
were	  recorded.	  Plasma	  albumin	  concentration	  was	  analyzed	  as	  both	  a	  continuous	  





Evidence	  of	  myocardial	  ischaemia	  during	  the	  index	  admission	  was	  determined	  by	  
reference	  to	  the	  result	  of	  any	  troponin-­‐T	  assay	  performed	  during	  the	  in-­‐patient	  stay.	  
A	  maximum	  of	  two	  troponin-­‐T	  results	  were	  recorded	  as	  part	  of	  the	  study	  and	  any	  
result	  at	  a	  level	  greater	  that	  0.10µg/l	  was	  taken	  to	  be	  representative	  of	  significant	  
myocardial	  ischaemia.	  Myocardial	  ischaemia	  was	  analyzed	  as	  a	  discrete	  variable	  
designated	  either	  present	  or	  absent	  on	  the	  basis	  of	  the	  troponin-­‐T	  result.	  Where	  no	  
measure	  of	  troponin-­‐T	  was	  made	  during	  the	  index	  admission	  myocardial	  ischemia	  
was	  designated	  as	  having	  been	  absent	  at	  the	  time	  of	  the	  index	  admission.	  
	  
Comorbidity	  
The	  presence	  or	  absence	  of	  various	  comorbidities	  were	  considered	  as	  candidate	  
confounding	  variables.	  A	  comorbidity	  was	  defined	  as	  having	  been	  present	  if	  it	  was	  
noted	  in	  the	  admission	  documentation,	  discharge	  summary	  or	  in	  any	  previous	  
correspondence,	  or	  if	  it	  was	  coded	  at	  any	  position	  in	  the	  APC	  dataset	  record	  of	  the	  
index	  admission	  or	  any	  prior	  admission	  in	  the	  preceding	  two	  years.	  The	  comorbid	  
conditions	  of	  interest	  were:	  
• Documented	  history	  of	  atrial	  fibrillation	  (AF)	  –	  ICD-­‐10	  I48X.	  Where	  AF	  was	  
identified	  as	  a	  comorbidity,	  demographic	  data	  and	  the	  presence	  of	  other	  
comorbid	  conditions	  were	  considered	  to	  generate	  a	  CHA2DS2VASc	  score	  
(see	  table	  5)	  for	  the	  patient	  in	  order	  to	  determine	  the	  recommended	  
strategy	  for	  the	  prevention	  of	  arterial	  thromboembolism,	  according	  to	  the	  
guidelines	  of	  the	  ESC.	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• Documented	  history	  of	  systemic	  hypertension:	  The	  ICD-­‐10	  codes	  used	  to	  
examine	  the	  APC	  dataset	  for	  systemic	  hypertension	  were	  I10,	  I11,	  I12,	  I13,	  
I14,	  I15.	  
• Documented	  history	  of	  ischaemic	  heart	  disease:	  Defined	  as	  present	  if	  any	  
history	  of	  previous	  myocardial	  infarction,	  percutaneous	  coronary	  
intervention	  (PCI)	  or	  coronary	  artery	  bypass	  grafting	  (CABG)	  procedure	  
was	  recorded	  in	  the	  admission	  documentation,	  discharge	  summary	  or	  in	  
any	  previous	  correspondence.	  Also	  defined	  as	  present	  if	  any	  ICD-­‐10	  code	  
for	  myocardial	  infarction	  I24,	  I25	  was	  recorded	  in	  any	  position	  in	  any	  
admission	  in	  the	  two	  years	  up	  to	  and	  including	  the	  index	  admission,	  or	  if	  
any	  of	  these	  admissions	  was	  for	  the	  purposes	  of	  either	  PCI	  or	  CABG.	  
• Documented	  history	  of	  chronic	  lung	  disease:	  Use	  of	  inhalers	  alone	  was	  not	  
taken	  to	  be	  evidence	  of	  chronic	  lung	  disease	  without	  other	  mention	  of	  the	  
diagnosis	  of	  asthma,	  chronic	  obstructive	  pulmonary	  disease	  (COPD)	  or	  
emphysema.	  The	  ICD-­‐10	  codes	  used	  to	  examine	  the	  APC	  dataset	  for	  
evidence	  of	  chronic	  lung	  disease	  were	  J40,	  J41,	  J42,	  J43,	  J44,	  J459,	  and	  J47.	  	  
• Documented	  history	  of	  drug-­‐treated	  diabetes	  mellitus	  (DM):	  The	  ICD-­‐10	  
codes	  used	  to	  examine	  the	  APC	  dataset	  were	  E10,	  E11,	  E12,	  E13,	  E14.	  DM	  
was	  also	  defined	  as	  having	  been	  present	  if	  there	  was	  record	  on	  the	  
discharge	  summary	  for	  the	  index	  admission	  of	  treatment	  with	  oral	  
hypoglycaemic	  agents	  or	  insulin.	  	  
• Documented	  history	  of	  ischaemic	  stroke	  or	  transient	  ischaemic	  attack	  
(TIA):	  The	  ICD-­‐10	  codes	  used	  to	  examine	  the	  APC	  dataset	  were	  G46,	  I63,	  
I64,	  I67,	  and	  G459.	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6.VI.	   SAMPLE	  SIZE	  CALCULATION	  
	  
For	  a	  predictive	  power	  of	  80%	  to	  test	  the	  primary	  hypothesis	  at	  a	  5%	  level	  of	  
significance,	  an	  average	  mortality	  rate	  of	  30%	  at	  2	  years	  and	  a	  hazard	  ratio	  between	  
quintiles	  of	  socioeconomic	  status	  of	  1.10	  was	  assumed,	  based	  on	  figures	  in	  the	  
available	  literature.	  These	  assumptions	  suggested	  a	  requirement	  for	  a	  minimum	  
















6.VII.	   ANALYSIS	  
	  
6.VII.i.	   GENERAL	  ANALYSES	  
All	  statistical	  analyses	  were	  performed	  using	  PASW	  Statistics	  18	  (SPSS	  version	  18,	  
IBM	  Corporation,	  release	  date	  30	  July	  2009)	  or	  STATA	  version	  10.0	  (StataCorp	  LP,	  
release	  date	  2009).	  The	  analyses	  were	  conducted	  by	  myself	  –	  Dr	  Paul	  Haydock	  –	  with	  	  
advice	  from	  Professor	  Martin	  Cowie.	  Mr	  Winston	  Banya	  (statistician)	  provided	  
assistance	  with	  the	  use	  of	  the	  STATA	  software,	  used	  for	  modeling	  proportional	  
hazards	  and	  generating	  standardized	  mortality	  ratios	  for	  the	  cohort.	  
	  
The	  distributions	  of	  continuous	  data	  were	  explored	  for	  evidence	  of	  normality	  by	  eye,	  
and	  by	  the	  use	  of	  both	  Normal	  and	  Detrended	  Normal	  Q-­‐Q	  plots.	  	  
	  
Where	  the	  distribution	  of	  data	  was	  normal,	  then	  mean	  and	  standard	  deviation	  (SD)	  
for	  the	  variable	  in	  question	  were	  quoted	  and	  data	  were	  compared	  across	  2	  groups	  
using	  the	  Student’s	  t-­‐-­‐test	  for	  equality	  of	  means,	  or	  one	  way	  analysis	  of	  variance	  
(ANOVA)	  for	  multiple	  groups.	  Non-­‐parametric	  data	  were	  quoted	  as	  median	  and	  
either	  range	  or	  inter-­‐quartile	  range	  (IQR).	  Such	  variables	  were	  analysed	  for	  
differences	  between	  2	  groups	  using	  the	  Mann-­‐Whitney	  U	  test	  and	  for	  differences	  
across	  multiple	  groups	  using	  the	  Kruskal-­‐Wallis	  test.	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Discrete	  data	  were	  analysed	  as	  proportions	  in	  each	  group	  using	  contingency	  tables,	  
and	  comparison	  between	  groups	  was	  performed	  using	  the	  Chi-­‐Square	  (χ2)	  test	  or	  
Chi-­‐square	  test	  for	  trend,	  as	  appropriate.	  
	  
In	  all	  cases,	  a	  p	  value	  of	  0.05	  or	  less	  was	  taken	  to	  be	  evidence	  of	  a	  statistically	  
significant	  difference	  between	  groups.	  
	  
	  
6.VII.ii.	   DEATH	  RATES	  AND	  SURVIVAL	  ANALYSIS	  
Crude	  rates	  of	  death	  were	  determined	  by	  assessing	  the	  number	  of	  patients	  alive	  at	  
30	  days	  and	  1	  year	  of	  follow	  up	  from	  the	  date	  of	  the	  first	  day	  of	  the	  index	  admission	  
in	  the	  cohort	  as	  a	  whole,	  and	  in	  each	  subgroup	  of	  age.	  Advancing	  age	  at	  the	  time	  of	  
admission	  was	  recognized	  as	  an	  obvious	  effect	  modifier	  and	  so,	  as	  well	  as	  analysis	  by	  
subgroup	  of	  age,	  standardized	  mortality	  ratios	  were	  calculated	  for	  the	  cohort,	  
stratified	  by	  five-­‐year	  age	  groups,	  using	  mortality	  data	  for	  the	  population	  of	  England	  
and	  Wales	  as	  the	  reference	  population[181].	  By	  employing	  this	  method,	  the	  hazard	  
associated	  with	  a	  first	  admission	  with	  heart	  failure	  was	  estimated	  in	  each	  five-­‐year	  
age	  band.	  	  
	  
Formal	  survival	  analyses	  were	  performed	  using	  the	  Kaplan-­‐Meier	  method	  and	  
evidence	  of	  statistically	  significant	  rates	  of	  survival	  between	  groups	  was	  determined	  
by	  application	  of	  the	  log-­‐rank	  test.	  Individuals	  in	  the	  cohort	  were	  censored	  on	  the	  
date	  of	  closure	  of	  the	  study	  database	  (01/08/2010)	  if	  the	  outcome	  of	  interest	  had	  
not	  occurred	  in	  the	  period	  of	  follow-­‐up	  before	  that	  time.	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6.VIII.	  DATA	  PROTECTION	  AND	  DATA	  STORAGE	  
	  
All	  data	  were	  anonymized	  via	  the	  generation	  of	  a	  unique	  study	  identifier	  for	  each	  
member	  of	  the	  cohort	  following	  the	  inclusion	  of	  their	  records	  in	  the	  study.	  All	  data	  
stored	  on	  electronic	  media	  were	  encrypted	  in	  accordance	  with	  the	  standards	  of	  
Imperial	  College	  London	  and	  East	  Sussex	  Hospitals’	  NHS	  Trust	  and	  data	  were	  only	  
accessed	  according	  to	  the	  principals	  of	  the	  Caldicott	  Report.	  The	  Caldicott	  Guardian	  
for	  the	  trust,	  Dr	  David	  Scott	  approved	  the	  study	  protocol	  in	  this	  respect.	  
All	  paper	  records	  pertaining	  to	  the	  study	  contained	  no	  patient	  identifiable	  data	  and	  
were	  kept	  in	  a	  securely	  locked	  filing	  cabinet	  in	  a	  securely	  locked	  room	  at	  all	  times	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7.	   RESULTS	  	  	  
	  
7.I.	   FINAL	  COMPOSITION	  OF	  THE	  COHORT	  
	  
Examination	  of	  the	  Admitted	  Patient	  Care	  (APC)	  dataset	  in	  the	  period	  01/01/2005	  –	  
31/12/2007	  identified	  1543	  admissions	  where	  heart	  failure	  was	  coded	  in	  the	  1st	  or	  
2nd	  position	  according	  to	  the	  study	  protocol.	  Of	  these	  cases,	  453	  (29.4%)	  were	  
excluded	  on	  the	  basis	  that	  the	  episode	  represented	  a	  readmission	  with	  heart	  failure	  
during	  the	  period	  of	  interest,	  or	  that	  a	  record	  of	  a	  previous	  admission	  with	  heart	  
failure	  coded	  in	  the	  1st	  or	  2nd	  position	  was	  identified	  in	  the	  5	  years	  prior	  to	  the	  first	  
recorded	  admission	  in	  the	  period	  of	  interest.	  1090	  cases	  remained	  for	  potential	  
inclusion	  in	  the	  final	  dataset,	  of	  which	  148	  (13.6%)	  were	  inadmissible	  on	  the	  basis	  of	  
the	  initial	  examination	  of	  the	  data.	  These	  148	  cases	  were	  excluded	  from	  further	  
analysis	  according	  to	  the	  following	  criteria:	  
1. 75	  cases	  (50.7%)	  were	  excluded	  on	  the	  basis	  that	  there	  was	  no	  clear	  evidence	  
of	  previous	  registration	  with	  the	  Conquest	  Hospital	  due	  to	  the	  absence	  of	  an	  
historical	  “H-­‐number”	  associated	  with	  the	  patient	  records.	  
2. 39	  cases	  (26.4%)	  were	  excluded	  on	  the	  basis	  that	  their	  postcode	  of	  residence	  
was	  outside	  that	  defined	  by	  the	  study	  protocol.	  
3. 29	  cases	  (19.6%)	  were	  excluded	  on	  the	  basis	  that	  the	  only	  recorded	  hospital	  
admission	  during	  the	  period	  of	  interest	  was	  for	  a	  day	  case	  procedure.	  
4. 5	  cases	  (3.4%)	  were	  excluded	  on	  the	  basis	  that	  it	  was	  clear	  from	  review	  of	  the	  
medical	  record	  that	  the	  majority	  of	  their	  contacts	  with	  the	  healthcare	  system	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were	  at	  a	  tertiary	  care	  heart	  failure	  centre	  (3	  cases)	  or	  in	  the	  private	  sector	  (2	  
cases).	  
	  
Following	  exclusion	  of	  these	  cases,	  942	  patients	  were	  identified	  for	  potential	  
inclusion	  in	  the	  final	  cohort.	  These	  were	  screened	  for	  diagnostic	  evidence	  of	  heart	  
failure	  during	  the	  index	  admission	  and	  on	  this	  basis	  59	  cases	  (6.3%)	  were	  excluded.	  
	  
In	  total,	  883	  cases	  were	  considered	  eligible	  for	  inclusion	  in	  the	  final	  cohort	  for	  















7.II.	   DEMOGRAPHICS	  AND	  CHARACTERISTICS	  OF	  THE	  FINAL	  COHORT	  
	  
883	  patients	  were	  included	  in	  the	  final	  cohort,	  with	  a	  median	  age	  of	  82.4	  years	  
(mean	  80.4).	  Just	  over	  half	  of	  the	  cohort	  were	  women	  (51.3%)	  and	  women	  in	  the	  
cohort	  were	  significantly	  older	  on	  average	  than	  men	  (median	  age	  84	  years	  vs.	  80	  
years;	  p<0.001).	  	  
	  
Co-­‐morbid	  cardiovascular	  conditions	  were	  common	  in	  the	  cohort	  as	  a	  whole	  with	  
rates	  of	  atrial	  fibrillation	  (AF	  –	  50%),	  systemic	  hypertension	  (46%),	  ischaemic	  heart	  
disease	  (IHD	  –	  45%)	  and	  prior	  stroke	  (15%)	  all	  being	  high.	  There	  was	  no	  significant	  
difference	  between	  male	  and	  female	  members	  of	  the	  cohort	  in	  rates	  of	  AF,	  systemic	  
hypertension	  or	  prior	  stroke.	  However,	  a	  significantly	  higher	  proportion	  of	  male	  
members	  of	  the	  cohort	  had	  a	  history	  of	  documented	  IHD	  (49%	  vs.	  41%	  of	  women;	  
p=0.026).	  	  
	  
Other	  important	  chronic	  conditions	  were	  prevalent	  in	  the	  cohort	  with	  22%	  of	  
patients	  known	  to	  have	  been	  diabetic	  and	  21%	  of	  patients	  previously	  having	  been	  
diagnosed	  with	  chronic	  lung	  disease.	  Again,	  there	  was	  no	  significant	  difference	  in	  the	  
rates	  of	  either	  diabetes	  mellitus	  or	  chronic	  lung	  disease	  when	  the	  cohort	  was	  split	  by	  
gender,	  though	  a	  trend	  towards	  higher	  rates	  of	  lung	  disease	  was	  observed	  in	  male	  
patients	  (23%	  vs.	  19%	  of	  women).	  	  	  
	  
Renal	  impairment,	  defined	  as	  eGFR	  <	  60mls/min/1.73m2	  was	  observed	  on	  admission	  
in	  60%	  of	  the	  cohort	  and	  the	  median	  eGFR	  was	  54	  mls/min/1.73m2	  	  (median	  serum	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creatinine	  105µmol/l).	  Mean	  hamoglobin	  level	  was	  12.3g/dl	  but	  rates	  of	  anaemia	  
(Hb	  <	  13g/dl	  in	  men	  and	  Hb	  <	  12g/dl	  in	  women)	  were	  high	  at	  51%	  (data	  unavailable	  
in	  4	  cases).	  There	  was	  no	  significant	  difference	  between	  the	  rates	  of	  renal	  
impairment	  or	  the	  distribution	  of	  eGFR	  between	  men	  and	  women,	  nor	  was	  there	  a	  
difference	  in	  the	  average	  haemoglobin	  concentration	  measured	  on	  admission.	  
However,	  significantly	  higher	  rates	  of	  anaemia	  were	  observed	  in	  the	  male	  portion	  of	  
the	  cohort	  (60%	  vs.	  42%	  of	  women;	  p<0.0001).	  	  
	  
Comorbid	  conditions5	  were	  common	  and	  did	  not	  occur	  in	  isolation	  in	  individuals	  in	  
the	  cohort.	  The	  modal	  number	  of	  comorbidities	  per	  individual	  was	  3	  (min	  =	  0,	  max	  =	  
7)	  and	  only	  14.3%	  of	  the	  cohort	  had	  fewer	  than	  2	  comorbid	  conditions,	  whilst	  79.6%	  
of	  individuals	  had	  2	  –	  5	  co-­‐existing	  comorbidities.	  Table	  13	  shows	  the	  number	  of	  
patients	  in	  the	  cohort	  with	  multiple	  comorbidities.	  No	  significant	  difference	  in	  
admission	  free	  survival	  was	  noted	  for	  those	  with	  3	  or	  more	  comorbidities	  when	  
compared	  with	  those	  patients	  with	  fewer	  than	  3	  (p=0.31).	  
	  
Hyponatraemia	  (Na+	  <	  130mmol/l)	  on	  admission	  was	  present	  in	  only	  9%	  of	  cases	  in	  
both	  sexes	  (data	  unavailable	  in	  6	  cases)	  and	  the	  median	  serum	  sodium	  was	  
138mmol/l,	  with	  no	  difference	  observed	  in	  the	  distribution	  of	  serum	  sodium	  values	  
between	  the	  two	  gender	  groups.	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Being: AF, HTN, IHD, Chronic lung disease, Previous stroke, Anaemia on admission, eGFR < 60 on 
admission.  
The maximum total number was 7 – no patient had all 8 comorbidities 
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Serum	  albumin	  results	  were	  available	  for	  773	  members	  of	  the	  cohort	  (87.5%).	  Nearly	  
a	  quarter	  of	  these	  patients	  (23.3%)	  were	  classified	  as	  having	  hypoalbuminaemia	  
(serum	  albumin	  <	  35g/l).	  The	  median	  serum	  albumin	  was	  38	  (interquartile	  range	  32	  –	  
44).	  No	  differences	  were	  observed	  between	  genders	  in	  terms	  of	  the	  frequency	  of	  
albumin	  results	  being	  available,	  the	  rates	  of	  hypoalbuminaemia,	  or	  the	  distribution	  
of	  albumin	  values.	  	  	  	  
	  
Serum	  Troponin-­‐T	  was	  measured	  at	  the	  time	  of	  the	  index	  admission	  in	  76%	  of	  cases	  
and	  was	  recorded	  as	  positive	  (Troponin-­‐T	  ≥	  0.10)	  in	  73%	  of	  these	  cases.	  Neither	  sex	  
was	  found	  to	  have	  a	  higher	  rate	  of	  either	  measurement	  of	  Troponin-­‐T,	  or	  an	  
increased	  frequency	  of	  positive	  Troponin-­‐T	  results,	  where	  the	  test	  had	  been	  
performed.	  
	  
Prior	  Contacts	  with	  Secondary	  Care	  Services	  	  
The	  majority	  of	  patients	  in	  the	  cohort	  (62%)	  had	  been	  admitted	  at	  least	  once	  to	  one	  
of	  the	  acute	  hospitals	  in	  ESHT	  in	  the	  two	  years	  prior	  to	  the	  index	  admission	  for	  a	  
reason	  other	  than	  the	  management	  of	  heart	  failure.	  Of	  these	  551	  patients,	  42%	  had	  
been	  admitted	  only	  once,	  27%	  twice,	  13%	  three	  times	  and	  18%	  had	  four	  or	  more	  
previous	  admissions.	  
	  
Only	  21.5%	  of	  patients	  in	  the	  cohort	  had	  outpatient	  contact	  with	  a	  cardiologist	  in	  the	  
period	  2	  years	  prior	  to	  the	  index	  admission	  and,	  of	  those	  that	  had,	  only	  27%	  had	  
more	  than	  one	  contact	  per	  year.	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31%	  of	  patients	  had	  contact	  with	  either	  a	  cardiologist	  or	  a	  specialist	  heart	  failure	  
geriatrician	  and,	  again,	  only	  27%	  of	  these	  had	  more	  than	  one	  contact	  per	  year.	  
Only	  12%	  of	  patients	  had	  contact	  with	  a	  heart	  failure	  specialist	  nurse	  and	  71%	  of	  
these	  had,	  on	  average,	  only	  one	  or	  fewer	  contacts	  per	  year.	  
	  
Prior	  rates	  of	  contact	  with	  generalist	  services	  were	  similarly	  low	  in	  the	  cohort.	  Only	  
20%	  of	  the	  cohort	  had	  any	  out-­‐patient	  appointment	  with	  a	  geriatrician	  in	  the	  two	  
years	  prior	  to	  their	  index	  admission	  and	  only	  13.5%	  had	  contact	  with	  a	  general	  
medical	  clinic.	  
	  
Rates	  of	  contact	  with	  non-­‐medical	  specialists,	  which	  might	  be	  predicted	  to	  be	  high	  in	  
an	  elderly	  cohort	  regardless	  of	  underlying	  heart	  failure,	  showed	  similar	  patterns.	  
29%	  of	  patients	  in	  this	  cohort	  had	  been	  seen	  at	  least	  once	  in	  ophthalmology	  out-­‐
patients	  in	  the	  2	  years	  prior	  to	  admission,	  19%	  of	  the	  cohort	  had	  at	  least	  one	  out-­‐
patient	  contact	  with	  an	  orthopaedic	  surgeon,	  and	  33%	  had	  been	  seen	  at	  least	  once	  
in	  a	  general	  surgery	  clinic.	  	  
	  
	  
Speciality	  of	  in-­‐patient	  care	  
For	  the	  cohort	  as	  a	  whole,	  the	  majority	  of	  patients	  received	  care	  from	  a	  geriatrician	  	  
(71%),	  with	  the	  remaining	  members	  of	  the	  cohort	  split	  equally	  between	  care	  by	  a	  





The	  median	  length	  of	  follow-­‐up	  was	  730	  days	  (minimum	  0	  days	  [died	  on	  day	  of	  
admission],	  maximum	  2037	  days	  [5.6	  years]).	  Patients	  were	  censored	  on	  the	  date	  of	  
the	  closure	  of	  the	  study	  database	  if	  there	  was	  no	  record	  of	  their	  death	  before	  this	  
time.	  The	  total	  number	  of	  deaths	  in	  the	  cohort	  over	  the	  entire	  period	  of	  follow-­‐up	  
was	  558	  (63%	  of	  patients).	  Mortality	  at	  30	  days	  from	  the	  date	  of	  the	  index	  admission	  

















7.III.	   COMPARISON	  OF	  THOSE	  SURVIVING	  TO	  DISCHARGE	  WITH	  THOSE	  NOT	  SURVIVING	  
THE	  INDEX	  ADMISSION.	  
	  
Of	  the	  total	  cohort	  of	  883	  patients,	  160	  (18%)	  died	  during	  the	  index	  admission.	  Table	  
14	  compares	  the	  characteristics	  of	  patients	  not	  surviving	  to	  discharge	  with	  the	  
remainder	  of	  the	  cohort.	  
	  
Patients	  not	  surviving	  to	  discharge	  were	  older	  (85.2	  years	  vs.	  82.0	  years;	  p<0.001)	  
and	  had	  higher	  rates	  of	  renal	  dysfunction	  (eGFR	  <	  60:	  52.5%	  vs	  32.6%;	  p<0.001),	  
hyponatraemia	  (Na+	  <	  130:	  13.9%	  vs	  7.8%;	  p=0.014),	  anaemia	  (86.9%	  vs.	  79.4%;	  
p=0.03)	  and	  myocardial	  ischaemia,	  evidenced	  by	  elevated	  troponins	  on	  admission	  












7.IV.	   CHARACTERISTICS	  OF	  THE	  COHORT	  SURVIVING	  TO	  DISCHARGE	  
	  
Analysis	  of	  the	  cohort	  of	  patients	  surviving	  to	  discharge	  from	  the	  index	  admission	  
(n=723)	  was	  performed	  to	  investigate	  for	  evidence	  of	  inequality.	  The	  median	  age	  in	  
this	  cohort	  was	  82	  years	  (range	  32.3	  –	  100.5)	  and,	  again,	  51.3%	  of	  the	  cohort	  were	  
female.	  The	  majority	  of	  patients	  were	  cared	  for	  by	  a	  geriatrician	  (69%)	  with	  an	  even	  
split	  of	  the	  remaining	  patients	  being	  cared	  for	  by	  a	  cardiologist	  or	  a	  general	  
physician.	  	  
	  
Numbers	  of	  patients	  in	  the	  least	  deprived	  quintile	  were	  low	  (7.7%	  of	  the	  cohort),	  but	  
there	  was	  a	  fairly	  even	  spread	  of	  patients	  between	  the	  other	  4	  quintiles	  (see	  table	  
14).	  	  
	  
Overall	  rates	  of	  comorbidity	  were	  high,	  with	  55%	  of	  patients	  having	  AF,	  and	  half	  of	  
patients	  having	  had	  a	  documented	  history	  of	  hypertension,	  with	  similar	  numbers	  
having	  a	  recorded	  history	  of	  ischaemic	  heart	  disease	  (49%).	  Almost	  a	  quarter	  of	  all	  
patients	  had	  a	  diagnosis	  of	  chronic	  lung	  disease	  (24%)	  or	  diabetes	  (23%).	  
	  
Hyponatraemia	  (Na+	  <	  130)	  was	  uncommon	  in	  the	  cohort	  surviving	  to	  discharge	  





7.V.	   SES	  IN	  THE	  COHORT	  SURVIVING	  TO	  DISCHARGE	  AND	  ITS	  AFFECT	  ON	  OUTCOME	  
	  
Characteristics	  of	  this	  cohort	  are	  presented	  in	  table	  16,	  according	  to	  quintile	  of	  
deprivation.	  The	  pre-­‐specified	  method	  of	  assigning	  quintile	  of	  deprivation	  was	  based	  
on	  national	  ranking	  of	  IMD2007	  scores,	  rather	  than	  internal	  ranking,	  and	  there	  were	  
thus	  different	  proportions	  of	  the	  cohort	  in	  each	  quintile	  of	  deprivation	  (Q1	  19%,	  Q2	  
28%,	  Q3	  24%,	  Q4	  21%,	  Q5	  8%).	  	  
	  
A	  significant	  trend	  was	  observed	  for	  a	  younger	  age	  at	  the	  time	  of	  the	  first	  admission	  
for	  those	  in	  more	  deprived	  quintiles.	  Mean	  age	  at	  time	  of	  first	  admission	  was	  77.9	  
years	  (S.D.	  11.6	  years)	  in	  the	  most	  deprived	  quintile	  and	  82.3	  years	  (S.D.	  8.9	  years)	  in	  
the	  least	  deprived	  quintile	  (p	  for	  trend	  across	  the	  five	  groups	  =	  0.036	  –	  see	  table	  16).	  	  
	  
Rates	  of	  recorded	  chronic	  lung	  disease	  appeared	  to	  be	  higher	  in	  those	  in	  the	  most	  
deprived	  two	  quintiles	  (30%)	  when	  compared	  with	  the	  least	  deprived	  quintile	  (16%).	  
Rates	  of	  recorded	  ischaemic	  heart	  disease	  also	  appeared	  significantly	  higher	  in	  the	  
most	  deprived	  group	  (60%	  vs.	  46%)	  but	  without	  any	  significant	  observable	  trend	  
across	  hierarchical	  levels	  of	  deprivation.	  Rates	  of	  prior	  outpatient	  contact	  with	  a	  
cardiology	  clinic,	  however,	  were	  not	  significantly	  different	  between	  quintiles	  (32%	  
overall	  and	  35%	  in	  the	  most	  deprived	  quintile	  vs.	  36%	  in	  the	  least	  deprived).	  	  	  
	  
Overall	  mortality	  rates	  did	  not	  differ	  between	  quintiles	  of	  deprivation	  –	  1	  year	  
mortality	  23%	  in	  the	  most	  deprived	  group	  vs.	  25%	  in	  the	  least	  deprived	  (28%	  overall	  
with	  no	  observable	  trend	  across	  levels	  of	  deprivation).	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A	  relationship	  was	  observed	  between	  deprivation	  and	  30-­‐day	  readmission	  rates.	  
Overall	  rates	  of	  readmission	  at	  30	  days	  were	  21%	  in	  the	  cohort	  surviving	  to	  discharge	  
as	  a	  whole	  but	  25%	  in	  the	  most	  deprived	  quintile,	  compared	  with	  13%	  in	  the	  least	  
deprived.	  When	  considering	  30-­‐day	  readmission	  rates	  across	  all	  5	  quintiles,	  
statistically	  significant	  differential	  rates	  of	  readmission	  were	  evident	  across	  the	  five	  
groups	  with	  a	  trend	  for	  lower	  rates	  as	  level	  of	  deprivation	  decreased	  (p=0.01).	  	  	  
	  
Survival	  analysis	  did	  not	  demonstrate	  any	  survival	  advantage	  associated	  with	  lower	  
levels	  of	  deprivation	  (see	  table	  20),	  nor	  any	  association	  between	  quintile	  of	  
deprivation	  and	  the	  combined	  end-­‐point	  of	  death	  or	  readmission	  with	  heart	  failure	  













7.VI.	   THE	  EFFECT	  OF	  AGE	  ON	  OUTCOMES	  IN	  THE	  COHORT	  SURVIVING	  TO	  DISCHARGE	  
	  
Overall	  survival	  differed	  significantly	  between	  the	  three	  subgroups	  of	  age.	  There	  was	  
a	  clear	  survival	  advantage	  associated	  with	  those	  under	  76	  years	  old	  at	  first	  
presentation	  compared	  with	  those	  in	  the	  older	  two	  groups,	  and	  there	  was	  an	  equally	  
significant	  survival	  advantage	  associated	  with	  those	  76-­‐85	  years	  when	  compared	  
with	  those	  85	  and	  older	  (p<0.0001	  across	  the	  three	  groups).	  However,	  no	  significant	  
difference	  in	  30-­‐day	  readmission	  rates	  between	  subgroups	  of	  age	  was	  identified	  
(21%	  in	  those	  under	  85	  and	  22%	  in	  those	  over	  85	  years).	  
	  
Clearly	  advancing	  age	  is	  always	  likely	  to	  be	  associated	  with	  higher	  mortality	  rates.	  
Therefore,	  excess	  mortality	  throughout	  the	  life-­‐course	  associated	  with	  admission	  
with	  heart	  failure	  was	  estimated	  by	  standardised	  mortality	  ratios	  calculated	  for	  5-­‐
year	  age	  groups	  within	  the	  cohort.	  The	  life	  tables	  for	  England	  published	  for	  the	  mid-­‐
point	  of	  the	  study	  period	  were	  used	  as	  the	  reference	  population	  (table	  23).	  By	  this	  
method,	  a	  significantly	  increased	  mortality	  rate	  in	  the	  study	  population	  was	  
demonstrated	  even	  in	  patients	  well	  above	  80	  years	  of	  age.	  Indeed,	  patients	  aged	  80	  
–	  84	  years	  in	  this	  cohort	  had	  an	  8	  to	  9	  times	  higher	  rate	  of	  death	  than	  the	  reference	  
population,	  and	  death	  rates	  in	  even	  patients	  aged	  90	  –	  94	  were	  3.5	  –	  4	  times	  
greater.	  	  	  	  
	  
Given	  this	  excess	  mortality,	  candidate	  variables	  associated	  with	  increased	  mortality	  
were	  examined	  using	  Cox	  Proportional	  Hazards	  modelling	  and	  the	  univariate	  analysis	  
of	  pertinent	  candidate	  variables	  is	  shown	  in	  table	  20.	  Advancing	  age	  continued	  to	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confer	  a	  significant	  increased	  risk	  of	  death,	  but	  neither	  gender	  nor	  quintile	  of	  
deprivation	  were	  associated	  with	  any	  significantly	  increased	  mortality.	  Only	  anaemia	  
and	  significant	  renal	  impairment	  were	  associated	  with	  a	  significantly	  increased	  risk	  
of	  death.	  
	  
The	  prescription	  of	  medications	  known	  to	  be	  of	  benefit	  in	  improving	  prognosis	  in	  
heart	  failure	  was	  also	  examined	  with	  respect	  to	  age.	  Treatment	  with	  an	  ACEi/ARB	  on	  
discharge	  was	  associated	  with	  a	  decreased	  risk	  of	  death	  (HR	  0.78	  [95%	  C.I.	  0.63	  –	  
0.97];	  p=0.028)	  but	  significance	  was	  lost	  when	  age	  was	  added	  to	  the	  model	  (HR	  0.82	  
[95%	  C.I.	  0.66	  –	  1.02];	  p=0.073).	  	  
	  
The	  prescription	  of	  a	  β-­‐blocker	  was	  associated	  with	  a	  more	  marked	  reduction	  in	  the	  
risk	  of	  death	  (HR	  0.58	  [95%	  C.I.	  0.44	  –	  0.77];	  p<0.0001)	  and	  the	  effect	  remained	  
significant	  when	  age	  was	  added	  to	  the	  model	  (HR	  0.72	  [95%	  C.I.	  0.54	  –	  0.96];	  
p=0.024).	  
	  
Prescription	  of	  aldosterone	  antagonists	  on	  discharge	  did	  not	  appear	  to	  be	  associated	  
with	  any	  significant	  change	  in	  the	  mortality	  rate	  (HR	  1.11	  [95%	  C.I.	  0.90	  –	  1.38];	  
p=0.33).	  Where	  age	  was	  added	  to	  a	  model	  examining	  the	  effect	  of	  prescription	  of	  
aldosterone	  antagonists	  an	  apparent	  increased	  risk	  of	  death	  was	  demonstrated	  
where	  these	  agents	  were	  prescribed	  (HR	  1.29	  [95%	  C.I.	  1.03	  –	  1.60];	  p=0.025).	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7.VII.	   CARE	  QUALITY	  
	  
7.VII.i.	   OVERALL	  QUALITY	  OF	  CARE	  AND	  THE	  EFFECT	  OF	  GENDER	  	  
	  
7.VII.i.a.	   ECHOCARDIOGRAPHY	  
For	  the	  cohort	  surviving	  to	  discharge,	  echocardiography	  was	  found	  to	  have	  been	  
performed	  in	  77%	  of	  cases.	  The	  majority	  of	  those	  who	  underwent	  echocardiography	  
did	  so	  at	  some	  time	  in	  the	  follow-­‐up	  period	  of	  the	  study	  following	  their	  discharge	  
from	  the	  index	  admission	  (34%	  of	  the	  cohort	  as	  a	  whole	  /	  44%	  of	  those	  who	  
underwent	  echocardiography).	  Where	  echocardiography	  was	  performed	  other	  than	  
during	  follow-­‐up	  from	  the	  index	  admission,	  this	  was	  mostly	  done	  during	  the	  index	  
admission	  itself	  (28%	  of	  the	  cohort	  /	  36%	  of	  those	  who	  had	  an	  echo),	  with	  a	  small	  
proportion	  of	  the	  cohort	  having	  an	  echocardiogram	  in	  the	  two	  years	  prior	  to	  the	  
index	  admission	  without	  this	  being	  repeated	  at	  any	  other	  time	  (16%	  of	  the	  cohort	  /	  
20%	  of	  those	  who	  had	  an	  echo).	  The	  pre-­‐specified	  marker	  of	  care	  quality	  –	  
echocardiography	  during	  the	  index	  admission	  or	  within	  6	  weeks	  of	  discharge	  –	  was	  
achieved	  in	  37.5%	  of	  cases.	  
	  
Left	  ventricular	  ejection	  fraction	  (LVEF)	  was	  recorded	  in	  59%	  of	  the	  cohort	  as	  a	  
whole,	  corresponding	  to	  70%	  of	  those	  who	  had	  undergone	  echocardiography.	  
However,	  subjective	  assessment	  of	  the	  left	  ventricular	  function	  was	  reported	  by	  the	  
echocardiographer	  in	  a	  much	  higher	  proportion	  of	  cases	  where	  an	  echocardiogram	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was	  performed	  (95%).	  A	  similarly	  high	  level	  of	  reporting	  of	  left	  ventricular	  end	  
diastolic	  diameter	  (LVEDD)	  was	  observed	  (93%).	  
	  
Mean	  LVEF	  was	  45.7%	  for	  those	  where	  data	  were	  available	  and	  mean	  LVEDD	  5.6cm.	  
The	  distribution	  of	  the	  subjective	  measures	  of	  left	  ventricular	  systolic	  function	  are	  
illustrated	  in	  figure	  4.	  Note	  that	  70%	  of	  cases	  were	  subjectively	  assessed	  as	  having	  
some	  degree	  of	  systolic	  impairment	  and	  51%	  were	  felt	  to	  have	  more	  than	  mild	  
impairment	  alone.	  
	  
Men	  were	  significantly	  more	  likely	  to	  have	  had	  an	  echocardiogram	  performed	  at	  any	  
time	  during	  the	  period	  of	  interest	  for	  the	  study	  (94%	  vs.	  87%;	  p=0.02),	  and	  
particularly	  during	  the	  primary	  admission	  (32%	  vs.	  26%;	  p<0.001).	  For	  the	  
prespecified	  marker	  of	  care	  quality	  –	  echo	  during	  the	  index	  admission	  or	  within	  six	  
weeks	  of	  discharge	  –	  the	  difference	  in	  rates	  of	  provision	  of	  echocardiography	  was	  
less	  pronounced,	  though	  still	  reached	  statistical	  significance	  (39%	  of	  men	  vs.	  33%	  of	  
women;	  p=0.04).	  Male	  gender	  was	  also	  significantly	  associated	  with	  the	  
documentation	  of	  LVEF	  (69%	  vs.	  56%;	  p<0.001).	  	  
	  	  	  	  	  
7.VII.i.b.	   PRESCRIPTION	  OF	  MEDICATIONS	  
	  
Diuretics	  
Orally	  administered	  loop	  diuretics,	  either	  furosemide	  or	  bumetanide	  were	  
commonly	  prescribed	  on	  discharge	  from	  the	  index	  admission,	  with	  overall	  rates	  of	  
92.5%.	  Of	  all	  those	  who	  received	  diuretics,	  the	  most	  common	  total	  daily	  dosages,	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expressed	  in	  furosemide	  equivalents,	  were	  40mg	  and	  80mg	  (each	  40%	  of	  cases).	  
Doses	  above	  100mg	  per	  day	  were	  uncommon	  (11%	  of	  cases)	  and	  table	  15	  
demonstrates	  the	  number	  of	  patients	  in	  each	  dosing	  schedule.	  
	  	  	  
Inhibitors	  of	  the	  renin-­‐angiotensin-­‐aldosterone	  system	  
ACE	  inhibitors	  were	  prescribed	  widely	  in	  the	  cohort,	  with	  64%	  of	  those	  surviving	  the	  
index	  admission	  discharged	  on	  this	  class	  of	  medication.	  Prescription	  of	  an	  ARB	  was	  
less	  common	  with	  11.5%	  of	  patients	  discharged	  on	  these.	  	  Only	  2	  patients	  were	  
discharged	  with	  instructions	  to	  take	  both	  agents,	  giving	  an	  overall	  prescription	  rate	  
of	  inhibitors	  of	  the	  renin-­‐angiotensin	  system	  in	  those	  surviving	  to	  discharge	  of	  75%.	  
Rates	  of	  aldosterone	  antagonist	  prescription	  were	  low,	  with	  27%	  of	  patients	  
surviving	  to	  discharge	  from	  the	  index	  admission	  prescribed	  either	  spironolactone	  or	  
epleronone.	  Rates	  of	  aldosterone	  antagonist	  prescription	  were	  significantly	  lower	  in	  
women	  than	  men	  (21.3%	  vs.	  33.2%;	  p<0.001),	  though	  no	  gender	  inequality	  was	  
observed	  in	  the	  prescription	  of	  ACEi/ARB	  (74%	  of	  women	  vs.	  76%	  of	  men;	  p=0.59).	  	  	  
	  
Beta-­‐blockers	  
Overall	  rates	  of	  prescription	  of	  these	  disease	  modifying	  therapies	  were	  low	  in	  this	  
cohort,	  with	  only	  19%	  of	  those	  surviving	  to	  discharge	  receiving	  a	  β-­‐blocker	  licensed	  
for	  the	  treatment	  of	  heart	  failure.	  21%	  of	  men	  received	  an	  indicated	  agent	  compared	  
with	  18%	  of	  women,	  although	  this	  differential	  in	  prescribing	  rates	  was	  not	  
statistically	  significant	  (p=0.27).	  A	  very	  small	  number	  of	  patients	  (3%)	  were	  




Prescription	  of	  this	  cardiac	  glycoside	  was	  more	  common	  in	  the	  cohort	  as	  a	  whole	  
than	  prescription	  of	  β-­‐blockade,	  with	  an	  overall	  rate	  of	  28%.	  Rates	  of	  prescription	  in	  
women	  were	  found	  to	  be	  significantly	  higher	  than	  in	  men	  (36%	  vs.	  24%p=0.03).	  
	  	  	  	  
Combination	  therapy	  
Intention	  to	  treat	  with	  a	  combination	  of	  an	  inhibitor	  of	  the	  renin-­‐angiotensin	  system,	  
a	  β-­‐blocker	  and	  an	  aldosterone	  antagonist	  was	  evident	  in	  very	  few	  members	  of	  the	  
cohort	  according	  to	  the	  drugs	  prescribed	  on	  discharge	  from	  the	  index	  admission.	  
Only	  6%	  of	  cases	  received	  all	  3	  classes	  of	  drugs	  as	  part	  of	  their	  discharge	  medication.	  
18%	  of	  cases	  received	  none	  of	  these	  disease-­‐modifying	  therapies	  on	  discharge	  and	  
49%	  received	  only	  one	  class	  of	  agent.	  16.5%	  of	  cases	  were	  prescribed	  the	  
combination	  of	  ACEi/ARB	  and	  β-­‐blocker	  (18%	  of	  men	  vs.	  15%	  of	  women;	  p=0.224).	  
Of	  those	  receiving	  no	  disease	  modifying	  therapy,	  all	  were	  taking	  diuretics	  on	  
discharge	  from	  the	  index	  admission.	  	  	  
	  
Anti-­‐platelet	  agents	  and	  anticoagulants	  
Of	  those	  who	  received	  an	  anti-­‐platelet	  agent,	  the	  majority	  were	  prescribed	  aspirin	  
alone	  (38%).	  Roughly	  equal	  numbers	  of	  patients	  received	  either	  clopidogrel	  alone	  
(9%)	  or	  the	  combination	  of	  aspirin	  and	  clopidogrel	  (10%).	  Of	  those	  who	  were	  




67%	  of	  those	  with	  a	  history	  of	  IHD	  were	  prescribed	  an	  anti-­‐platelet	  agent	  but	  43%	  of	  
those	  with	  no	  such	  history	  were	  prescribed	  either	  aspirin	  or	  clopidogrel	  (p=0.01).	  
Prescription	  of	  clopidogrel,	  especially	  in	  combination	  with	  aspirin	  was	  strongly	  
associated	  with	  a	  diagnosis	  of	  IHD	  (p=0.002).	  Examination	  of	  those	  with	  a	  history	  of	  
either	  IHD	  or	  stroke	  revealed	  a	  similar	  pattern	  to	  that	  seen	  in	  those	  with	  IHD	  alone,	  
with	  63%	  of	  those	  taking	  any	  anti-­‐platelet	  therapy	  having	  at	  least	  one	  of	  these	  
diagnoses.	  	  
	  
Over	  three	  quarters	  of	  patients	  surviving	  to	  discharge	  (78%)	  had	  a	  history	  of	  at	  least	  
one	  of	  either	  IHD	  or	  AF.	  No	  relationship	  was	  observed	  between	  the	  prescription	  of	  
anti-­‐platelet	  therapy	  and	  a	  diagnosis	  of	  AF	  with	  50%	  of	  patients	  with	  AF	  receiving	  
either	  aspirin	  or	  clopidogrel.	  A	  history	  of	  AF	  did	  appear	  to	  predict	  prescription	  of	  
warfarin	  (82%	  of	  patients	  taking	  warfarin	  having	  AF)	  but	  rates	  of	  prescription	  of	  
warfarin	  to	  those	  with	  AF	  were	  only	  40%.	  Most	  patients	  with	  AF,	  however,	  were	  
prescribed	  either	  warfarin	  or	  an	  anti-­‐platelet	  agent	  (85%),	  with	  a	  small	  number	  of	  
these	  receiving	  both	  therapies	  (4.5%).	  
	  
Others	  
Low	  rates	  of	  the	  prescription	  of	  calcium	  channel	  antagonists	  were	  observed	  in	  those	  
surviving	  to	  discharge	  from	  the	  index	  admission	  (10%)	  and	  similar	  rates	  of	  
prescription	  were	  observed	  for	  dihydropyridine	  and	  non-­‐dihydropyridine	  agents	  	  
(5.5%	  and	  4.6%	  respectively).	  There	  were	  no	  observed	  differences	  in	  prescribing	  
between	  men	  and	  women.	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Rates	  of	  NSAID	  prescription	  were	  low	  at	  2.5%.	  No	  further	  analysis	  was	  attempted	  on	  





















7.VII.ii.	   THE	  EFFECT	  OF	  SOCIOECONOMIC	  STATUS	  ON	  CARE	  QUALITY	  	  
	  
Table	  17	  shows	  differences	  in	  care	  quality	  by	  quintile	  of	  deprivation.	  No	  trend	  was	  
observed	  for	  differential	  rates	  of	  prescribing	  of	  ACEi/ARB,	  B-­‐blockers	  or	  aldosterone	  
antagonists	  according	  to	  quintile	  of	  deprivation.	  Nor	  was	  there	  any	  apparent	  
deprivation	  related	  bias	  in	  the	  performance	  of	  echocardiography	  during	  the	  index	  
admission	  or	  within	  6	  weeks	  of	  discharge,	  or	  the	  recording	  of	  LVEF	  at	  the	  time	  of	  
echocardiography.	  
	  
Rates	  of	  follow-­‐up	  with	  a	  specialist	  doctor	  showed	  no	  clear	  relationship	  with	  quintile	  
of	  deprivation,	  but	  rates	  of	  follow-­‐up	  by	  a	  specialist	  nurse	  were	  significantly	  lower	  in	  
those	  in	  the	  most	  deprived	  quintile	  (9%)	  when	  compared	  with	  the	  least	  deprived	  
(16%).	  However,	  a	  convincing	  trend	  across	  the	  levels	  of	  deprivation	  was	  not	  











7.VII.iii.	   THE	  EFFECT	  OF	  AGE	  ON	  CARE	  QUALITY	  	  
	  
Table	  18	  shows	  the	  characteristics	  of	  the	  cohort	  surviving	  to	  discharge	  according	  to	  
the	  three	  subgroups	  of	  age	  	  (“young”	  -­‐	  <76;	  “old”	  –	  76-­‐85;	  and	  “very	  old”	  -­‐	  ≥85).	  A	  
significant	  trend	  was	  observed	  for	  higher	  proportions	  of	  women	  with	  advancing	  age	  
(33%	  of	  “young”	  vs.	  49%	  of	  “old”	  vs.	  77%	  of	  “very	  old”;	  p<0.001).	  	  
	  
Median	  LVEF	  showed	  a	  significant	  trend	  for	  higher	  ejection	  fractions	  with	  increasing	  
age	  (p<0.05	  for	  difference	  across	  3	  groups),	  being	  highest	  in	  the	  most	  elderly	  
subgroup	  (51%	  [29-­‐73%]),	  lower	  in	  the	  those	  aged	  76-­‐85	  (45%	  [IQR	  21-­‐69%]),	  and	  
lowest	  in	  the	  youngest	  subgroup	  (40%	  [IQR	  21-­‐59%]).	  	  
	  
A	  significant	  trend	  was	  also	  observed	  for	  lower	  rates	  of	  documented	  ischaemic	  heart	  
disease	  with	  advancing	  age	  (58%	  vs.	  48%	  vs.	  42%;	  p	  for	  trend<0.001)	  but	  this	  trend	  
was	  reversed	  for	  rates	  of	  documented	  atrial	  fibrillation	  (47%	  vs.	  56%	  vs.	  64%;	  p	  for	  
trend<0.001).	  	  
	  
Older	  patients	  tended	  to	  have	  lower	  eGFR	  on	  average	  and	  lower	  mean	  hemoglobin	  
concentrations	  but	  no	  significant	  differences	  were	  demonstrated	  between	  these	  
variables	  in	  the	  old	  and	  very	  old.	  
	  
Rates	  of	  prescription	  of	  ACEi/ARB	  were	  not	  significantly	  different	  between	  
subgroups	  of	  age,	  although	  an	  apparent	  trend	  for	  lower	  rates	  in	  the	  more	  elderly	  
was	  seen	  (80.6%	  vs.	  74.3%	  vs.	  71.4%;	  p=0.076).	  	  
	  129	  
	  
A	  striking	  trend	  was	  observed,	  however,	  for	  reduced	  rates	  of	  prescription	  of	  both	  β-­‐
blockers	  and	  aldosterone	  antagonists	  with	  advancing	  age	  (see	  table	  19).	  Indicated	  β-­‐
blockers	  were	  prescribed	  in	  36%	  of	  young	  patients	  but	  only	  15%	  of	  those	  age	  76-­‐85	  
years	  and	  11%	  of	  very	  old	  patients	  (p	  for	  trend<0.001).	  Although	  rates	  of	  
prescription	  of	  aldosterone	  antagonists	  were	  higher	  than	  those	  for	  β-­‐blockers	  in	  the	  
elderly,	  a	  significant	  difference	  in	  rates	  of	  prescribing	  across	  the	  subgroups	  of	  age	  
was	  still	  evident.	  36%	  of	  patients	  under	  75	  years	  old	  received	  an	  aldosterone	  
antagonist	  (similar	  to	  the	  rate	  of	  prescription	  of	  β-­‐blockade),	  whilst	  26%	  of	  those	  
aged	  76-­‐85	  and	  21%	  of	  those	  over	  85	  were	  prescribed	  these	  agents	  (p	  for	  trend	  =	  
0.002).	  
	  	  	  	  	  
Provision	  of	  echocardiography	  within	  6	  weeks	  of	  the	  date	  of	  admission	  was	  also	  seen	  
to	  be	  significantly	  reduced	  when	  moving	  through	  the	  age	  strata	  (51%	  vs	  36%	  vs.	  
29%;	  p	  for	  trend<0.001)	  and,	  where	  echocardiography	  was	  performed,	  there	  was	  a	  
significant	  trend	  for	  lower	  rates	  of	  reporting	  of	  LVEF	  (73%	  vs.	  66%	  vs.	  50%;	  p	  for	  








7.VII.iv.	   CONSIDERING	  THOSE	  WITH	  LV	  IMPAIRMENT	  
	  
In	  those	  where	  LV	  systolic	  function	  was	  described	  as	  anything	  other	  than	  normal	  or	  
mildly	  impaired	  (71%	  of	  those	  who	  underwent	  echocardiography),	  prescribing	  rates	  
were	  higher,	  but	  remained	  low	  for	  both	  β-­‐blocker	  and	  aldosterone	  antagonist	  
prescription	  (81%	  prescribed	  ACEi/ARB;	  23.6%	  prescribed	  β-­‐blocker;	  33.1%	  
prescribed	  aldosterone	  antagonist).	  Again	  no	  observable	  pattern	  was	  identified	  for	  
differential	  prescribing	  rates	  between	  quintiles	  of	  deprivation.	  The	  significant	  trend	  
for	  reduced	  prescribing	  of	  aldosterone	  antagonists	  in	  those	  in	  the	  more	  elderly	  
subgroups	  was	  not	  evident	  when	  only	  those	  with	  LV	  impairment,	  described	  in	  this	  
way,	  were	  included	  in	  the	  analysis	  but	  differential	  rates	  of	  β-­‐blocker	  prescription	  
between	  groups	  remained	  significant.	  Such	  results	  need	  to	  be	  interpreted	  with	  
caution	  given	  the	  lower	  rates	  of	  echocardiography	  and	  documentation	  of	  LV	  function	  










7.VII.v.	   OVERALL	  DETERMINANTS	  OF	  CARE	  QUALITY	  
	  
The	  interaction	  between	  between	  patient	  characteristics,	  specialist	  follow-­‐up,	  and	  
the	  prescription	  of	  beneficial	  medications	  was	  explored	  in	  the	  univariate	  analysis	  
presented	  in	  table	  21.	  	  
	  
This	  analysis	  confirmed	  the	  effect	  of	  age	  on	  the	  likelihood	  of	  prescription	  of	  
medication	  with	  a	  crude	  odds	  ratio	  of	  0.98	  (95%	  C.I.	  0.96-­‐0.99)	  for	  the	  prescription	  
of	  ACEi/ARB	  per	  year	  of	  advancing	  age.	  The	  most	  powerful	  age	  effect	  seemed	  to	  be	  
in	  determining	  the	  likelihood	  of	  β-­‐blockade	  prescription	  (OR	  0.95	  per	  year	  [0.94-­‐
0.97]),	  with	  age	  also	  influencing	  the	  chances	  of	  receiving	  an	  aldosterone	  antagonist	  
(OR	  0.97	  per	  year	  [0.95-­‐0.98]).	  	  
	  
Gender	  did	  not	  appear	  to	  influence	  the	  prescription	  of	  either	  ACEi/ARB	  (p=0.59)	  or	  
β-­‐blockers	  (p=0.27).	  Aldosterone	  antagonists,	  however,	  were	  84%	  more	  likely	  to	  be	  
prescribed	  in	  men	  than	  in	  women	  (OR	  for	  male	  sex	  1.84	  [95%	  C.I.	  1.32-­‐2.57];	  
p<0.001).	  	  
	  
Deprivation	  demonstrated	  no	  clear	  effect	  on	  the	  prescription	  of	  any	  class	  of	  
medication	  but	  specialist	  follow-­‐up	  was	  associated	  with	  a	  markedly	  increased	  
likelihood	  of	  prescription	  of	  all	  3	  classes	  of	  prognostically	  beneficial	  medications.	  
This	  effect	  was	  most	  marked	  for	  the	  prescription	  of	  β-­‐blockers	  (OR	  2.66	  [95%	  C.I.	  
1.82-­‐3.88])	  but	  was	  evident	  for	  both	  ACEi/ARB	  (OR	  2.40	  [1.66-­‐3.49])	  and	  aldosterone	  
antagonists	  (OR	  1.88	  [1.35-­‐2.62]).	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Comorbid	  renal	  dysfunction	  and	  documented	  history	  of	  chronic	  lung	  disease	  
respectively	  affected	  prescription	  of	  ACEi/ARB	  and	  β-­‐blockers.	  Those	  with	  stage	  IV	  or	  
V	  chronic	  kidney	  disease	  (eGFR	  <	  30)	  were	  significantly	  less	  likely	  to	  receive	  an	  
ACEi/ARB	  compared	  to	  those	  with	  normal	  renal	  function	  (OR	  for	  CKD	  stage	  IV	  0.57	  
[0.32-­‐0.99]).	  No	  significant	  differences	  in	  prescription	  rates	  according	  to	  renal	  
function	  were	  observed	  for	  β-­‐blockers	  or	  aldosterone	  antagonists.	  β-­‐blocker	  
prescription	  was,	  however,	  52%	  less	  likely	  where	  there	  was	  a	  documented	  history	  of	  
chronic	  lung	  disease	  (OR	  0.48	  [95%	  C.I.	  0.29-­‐0.81]).	  	  	  	  	  	  	  	  	  	  
	  
Of	  the	  723	  patients	  surviving	  to	  discharge,	  398	  (55%)	  had	  a	  documented	  history	  of	  
AF	  (table	  22).	  There	  was	  a	  highly	  significant	  trend	  (p<0.0001)	  for	  lower	  rates	  of	  
prescription	  of	  warfarin	  in	  more	  elderly	  patients	  (22%	  in	  those	  85	  and	  over	  vs.	  60%	  
in	  those	  under	  76)	  and	  for	  more	  common	  prescription	  of	  aspirin	  (59%	  vs.	  37%).	  Older	  
patients	  were	  more	  likely	  to	  be	  female	  and	  have	  suffered	  a	  previous	  stroke	  but	  had	  
generally	  lower	  rates	  of	  other	  comorbidities.	  CHA2DS2-­‐VASc	  scores	  were	  ≥2	  in	  all	  
patients	  and,	  therefore,	  warfarin	  prescription	  would	  have	  been	  indicated	  in	  all	  cases	  







8.	   DISCUSSION	  
	  
8.I.	   OVERALL	  SUMMARY	  OF	  FINDINGS	  
	  
This	  study	  has	  demonstrated	  that	  heart	  failure	  patients	  admitted	  to	  a	  single	  acute	  
hospital	  serving	  an	  elderly	  local	  population	  have	  an	  average	  age	  of	  over	  80	  years,	  
and	  female	  patients	  are	  significantly	  older	  than	  male	  patients	  at	  the	  time	  of	  their	  
first	  admission	  with	  heart	  failure.	  
	  	  
The	  majority	  of	  patients	  were	  not	  cared	  for	  by	  a	  cardiologist	  and	  rates	  of	  specialist	  
follow-­‐up	  were	  low,	  though	  neither	  of	  these	  factors	  were	  influenced	  by	  
socioeconomic	  status.	  Nor	  was	  prior	  contact	  with	  any	  specialist	  or	  hospital	  services	  
seen	  to	  be	  associated	  with	  level	  of	  deprivation.	  	  	  
	  
Heart	  failure	  did	  not	  commonly	  occur	  in	  isolation	  in	  this	  cohort	  and	  the	  majority	  of	  
patients	  admitted	  had	  3	  or	  more	  comorbid	  conditions	  complicating	  their	  heart	  
failure.	  Important	  comorbidities	  influencing	  outcome	  in	  terms	  of	  mortality	  were	  
significant	  renal	  dysfunction	  and	  anaemia,	  and	  these	  were	  more	  common	  with	  
advancing	  age.	  Chronic	  lung	  disease	  was	  also	  prevalent,	  particularly	  in	  more	  
deprived	  patients,	  and	  was	  seen	  to	  be	  associated	  with	  reduced	  rates	  of	  prescription	  
of	  prognostically	  beneficial	  β-­‐blockade.	  Only	  the	  most	  severe	  renal	  dysfunction	  was	  
associated	  with	  significantly	  reduced	  rates	  of	  ACEi/ARB	  prescription.	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These	  data	  confirm	  findings	  from	  the	  National	  Heart	  Failure	  Audit	  that	  increased	  
levels	  of	  deprivation	  are	  associated	  with	  a	  younger	  age	  at	  first	  admission	  with	  heart	  
failure.	  In	  contrast	  to	  previous	  reports,	  SUSSEX-­‐HF	  has	  not	  found	  any	  increased	  
mortality	  associated	  with	  increased	  deprivation	  in	  heart	  failure.	  The	  study	  has,	  
however,	  demonstrated	  increased	  rates	  of	  readmission	  at	  30	  days	  in	  patients	  with	  
increasing	  levels	  of	  deprivation.	  
	  
Other	  than	  an	  observation	  that	  rates	  of	  specialist	  nurse	  follow	  up	  were	  low	  in	  the	  
most	  deprived	  admitted	  quintile	  of	  patients,	  SUSSEX-­‐HF	  has	  found	  no	  evidence	  to	  
support	  significant	  variation	  in	  quality	  of	  care	  according	  to	  socioeconomic	  status	  in	  
the	  cohort	  examined.	  
	  
What	  has	  been	  demonstrated	  is	  that	  this	  cohort	  had	  significantly	  increased	  mortality	  
compared	  to	  the	  contemporaneous	  population	  of	  England	  and	  Wales	  when	  matched	  
for	  age	  and	  gender,	  and	  I	  propose	  that	  this	  excess	  mortality	  could	  have	  been	  
reduced	  to	  an	  extent	  if	  the	  quality	  of	  heart	  failure	  management	  had	  been	  more	  
optimal	  in	  the	  cohort.	  Overall	  rates	  of	  ACEi/ARB	  use	  in	  this	  cohort	  were	  comparable	  
to	  previous	  reports,	  but	  still	  far	  from	  universal,	  and	  β-­‐blocker	  prescription	  rates	  were	  
very	  low,	  despite	  robust	  evidence	  and	  national	  guidelines	  to	  support	  their	  use	  
available	  at	  the	  time	  of	  the	  study.	  Use	  of	  aldosterone	  antagonists	  was	  limited	  and	  
gender	  bias	  appeared	  to	  be	  operating	  in	  this	  cohort	  to	  lead	  to	  lower	  rates	  of	  
prescription	  in	  women.	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The	  striking	  finding	  in	  this	  cohort	  is	  the	  extent	  to	  which	  age	  appears	  to	  influence	  
variations	  in	  care	  quality.	  Older	  patients	  were	  less	  likely	  to	  undergo	  
echocardiography,	  less	  likely	  to	  have	  formal	  documentation	  of	  their	  ejection	  
fraction,	  and	  less	  likely	  to	  receive	  all	  classes	  of	  prognostically	  beneficial	  medication	  
(though	  differences	  in	  rates	  of	  ACEi/ARB	  prescription	  by	  age	  were	  not	  statistically	  
significant).	  Such	  factors	  might	  well	  have	  determined	  to	  some	  extent	  the	  poorer	  
outlook	  for	  older	  patients	  in	  the	  cohort.	  	  	  	  	  	  	  	  	  	  	  
	  















8.II.	   DEMOGRAPHY	  
	  
This	  study	  has	  described	  a	  cohort	  of	  patients	  admitted	  for	  the	  first	  time	  with	  a	  
diagnosis	  of	  heart	  failure,	  drawn	  from	  an	  elderly	  local	  population.	  The	  cohort	  is	  
notable	  for	  its	  advanced	  age	  when	  compared	  with	  other	  published	  data.	  The	  most	  
easily	  referenced	  comparative	  data	  come	  from	  the	  UK	  National	  Heart	  Failure	  Audit,	  
from	  which	  results	  are	  available	  for	  each	  twelve	  month	  period	  since	  2007.	  April	  2008	  
–	  March	  2009[182]	  and	  April	  2009	  –	  March	  2010[183]	  are	  considered	  here	  as	  the	  
most	  meaningful	  comparative	  and	  conteporaneous	  data.	  The	  median	  age	  of	  patients	  
in	  these	  two	  audits	  was	  78	  years	  and	  79	  years	  for	  the	  two,	  consecutive	  twelve	  month	  
periods.	  The	  study	  cohort	  considered	  here	  has	  a	  much	  higher	  median	  age	  –	  82.4	  
years.	  Data	  are	  available	  from	  a	  two-­‐centre	  study	  in	  2003/4	  enrolling	  patients	  from	  
the	  same	  centre	  as	  the	  current	  study	  and	  Hillingdon,	  West	  London.	  This	  prospective	  
study,	  with	  a	  more	  rigorous	  case	  definition	  of	  heart	  failure,	  showed	  a	  median	  age	  at	  
heart	  failure	  diagnosis	  of	  75	  in	  a	  cohort	  of	  396	  patients[49].	  Data	  from	  Leicestershire	  
for	  the	  period	  1993	  –	  2001	  confirmed	  an	  increase	  in	  the	  median	  age	  at	  first	  
presentation	  with	  heart	  failure	  between	  1993/4	  and	  2000/01	  from	  74	  years	  to	  77	  
years	  for	  men	  but	  showed	  a	  static	  median	  age	  at	  first	  presentation	  of	  80	  years	  in	  
women	  in	  the	  same	  period[154].	  Medicare	  data	  from	  the	  USA,	  presented	  by	  Bueno	  
et	  al	  in	  2010	  show	  an	  essentially	  unchanged	  mean	  age	  at	  first	  admission	  of	  around	  
80	  years	  (79.5	  in	  1993/4	  to	  80.0	  in	  2005/6)[184].	  The	  EuroHeart	  Failure	  survey	  
reported	  data	  in	  2003	  pertaining	  to	  late	  2000	  and	  early	  2001,	  showing	  an	  overall	  age	  
at	  admission	  of	  71	  years	  in	  Europe	  and	  75	  years	  in	  the	  UK[185].	  Data	  from	  a	  single	  
UK	  centre	  in	  Hillingdon,	  West	  London,	  from	  1995/6	  quote	  a	  median	  age	  of	  first	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presentation	  for	  incident	  heart	  failure	  of	  76	  (73	  years	  in	  men	  and	  78	  in	  
women)[186].	  Other	  registries	  of	  heart	  failure	  admissions	  are	  available,	  from	  Europe	  
and	  North	  America,	  published	  in	  the	  first	  half	  of	  the	  last	  decade.	  The	  reported	  mean	  
age	  for	  patients	  hospitalized	  with	  heart	  failure	  in	  these	  series	  range	  from	  70	  –	  77[70,	  
137].	  These	  registry	  data	  contrast	  with	  results	  from	  the	  Framingham	  cohort	  showing	  
a	  mean	  age	  at	  diagnosis	  of	  heart	  failure	  of	  80	  years	  in	  the	  period	  1990	  –	  1999	  –	  
markedly	  older	  than	  the	  mean	  age	  of	  62.7	  years	  recorded	  between	  1950	  and	  
1969[187].	  
	  
Why	  should	  it	  be	  that	  this	  cohort	  appears	  so	  much	  older	  than	  those	  previously	  
described?	  Several	  possibilities	  present	  themselves:	  
	  
1. There	  is	  evidence	  for	  a	  secular	  trend	  for	  increasing	  age	  at	  first	  presentation	  of	  
heart	  failure	  from	  the	  available	  literature	  and	  projections	  based	  on	  the	  changing	  
population	  structure	  of	  Scotland	  have	  theorized	  that	  admissions	  of	  elderly	  
patients	  will	  increase	  as	  the	  population	  ages[51].	  The	  available	  population	  data	  
for	  the	  catchment	  area	  of	  the	  study	  site	  confirm	  that	  the	  proportion	  of	  those	  in	  
the	  recognized	  “at	  risk”	  age	  for	  heart	  failure	  (>55	  years	  old)	  is	  markedly	  higher	  
than	  the	  UK	  average,	  and	  the	  relative	  excess	  of	  those	  above	  the	  age	  of	  70	  years	  
is	  higher	  than	  the	  excess	  observed	  in	  those	  around	  retirement	  age	  (figure	  8).	  
Therefore,	  these	  data	  may	  reflect	  the	  fact	  that	  a	  generally	  more	  elderly	  




2. There	  is	  good	  evidence	  from	  previously	  published	  work	  that	  women	  present	  at	  
an	  older	  age	  than	  men.	  This	  has	  been	  confirmed	  in	  the	  current	  study.	  Perhaps	  it	  
is	  the	  case	  that	  there	  is	  an	  over-­‐representation	  of	  women	  in	  this	  cohort	  when	  
compared	  to	  other	  published	  series.	  Whilst	  it	  is	  certainly	  true	  that	  clinical	  trials	  
have	  tended	  to	  enroll	  patients	  with	  low	  ejection	  fractions	  –	  and,	  therefore,	  
recruit	  a	  younger,	  predominantly	  male	  study	  cohort	  –	  it	  would	  also	  appear	  to	  be	  
the	  case	  that	  there	  is	  an	  apparent	  gender	  bias	  in	  the	  reporting	  of	  results	  from	  
observational	  studies.	  Taking	  the	  2010	  UK	  National	  Heart	  Failure	  Audit	  (UK	  
NHFA)	  as	  an	  example,	  it	  can	  be	  seen	  that	  the	  percentage	  of	  women	  in	  the	  sample	  
overall	  is	  43%	  -­‐	  similar	  to	  EuroHeart	  Failure	  II	  (39%)[188].	  Our	  data	  agree	  with	  
the	  finding	  that	  around	  67%	  of	  heart	  failure	  patients	  75	  and	  under	  are	  male.	  The	  
authors	  make	  the	  point	  that	  in	  those	  over	  75	  years	  old	  the	  proportion	  of	  men	  
and	  women	  is	  roughly	  equal,	  a	  stark	  contrast	  to	  the	  data	  presented	  here	  where	  
this	  is	  the	  case	  in	  the	  age	  group	  76	  –	  85	  years	  but	  there	  is	  a	  marked	  reversal	  of	  
male:female	  ratio	  of	  admissions	  in	  those	  of	  85	  years	  and	  older.	  The	  resulting	  
figure	  for	  comparison	  with	  the	  national	  data	  is	  that	  68%	  of	  those	  over	  75	  years	  
old	  are	  women.	  It	  may	  well	  be	  the	  case,	  therefore,	  that	  the	  excess	  of	  women	  is	  
responsible	  for	  the	  overall	  higher	  age	  of	  the	  cohort.	  
	  
3. This	  begs	  the	  question,	  “Why	  should	  there	  be	  an	  excess	  of	  women	  in	  this	  
cohort?”	  The	  UK	  NHFA	  reports	  36.1%	  of	  patients	  studied	  being	  75	  years	  or	  
younger.	  Data	  from	  SUSSEX-­‐HF	  give	  a	  figure	  of	  26.4%	  of	  the	  cohort	  in	  this	  age	  
range.	  These	  data	  seem	  more	  consistent	  with	  statements	  that	  24.6%	  of	  patients	  
admitted	  with	  heart	  failure	  are	  ≤	  75	  years	  old.	  It	  may,	  therefore,	  be	  the	  case	  that	  
	  139	  
there	  is	  selective	  under-­‐reporting	  of	  elderly	  cases	  of	  heart	  failure	  in	  such	  national	  
audit	  programs.	  The	  UK	  NHFA	  2010	  reports	  that	  cases	  submitted	  to	  the	  Audit	  
represent	  42%	  of	  patients	  admitted	  nationally	  with	  a	  primary	  diagnosis	  of	  heart	  
failure.	  The	  participation	  of	  trusts	  in	  the	  Audit	  is	  one	  of	  several	  “Indicators	  for	  
Quality	  Improvement”	  identified	  by	  the	  Department	  of	  Health	  (DoH).	  The	  
intention	  was	  to	  record	  data	  initially	  for	  the	  first	  ten	  patients	  in	  each	  month	  
discharged	  with	  a	  primary	  diagnosis	  of	  heart	  failure;	  rolling	  out	  to	  record	  data	  for	  
all	  such	  admissions	  in	  due	  course.	  Despite	  this	  aim,	  clearly	  there	  are	  significant	  
missing	  data	  and	  there	  is	  no	  readily	  identifiable	  method	  for	  ensuring	  that	  cases	  
submitted	  to	  the	  Audit	  are	  consecutive	  and	  unselected.	  It	  is	  also	  worth	  noting	  
that	  our	  cohort	  includes	  admissions	  were	  heart	  failure	  is	  coded	  in	  the	  first	  or	  
second	  diagnostic	  position,	  in	  contrast	  to	  the	  UK	  NHFA.	  As	  such,	  it	  is	  difficult	  to	  












8.III.	   COMORBIDITY	  
	  
Rates	  of	  comorbid	  conditions	  in	  this	  cohort	  seem	  to	  largely	  be	  in	  line	  with	  those	  
observed	  in	  most	  large	  scale	  registries	  of	  heart	  failure	  patients	  conducted	  in	  
developed	  countries	  (table	  24).	  This	  lends	  weight	  to	  the	  premise	  that	  the	  methods	  
use	  to	  capture	  comorbidity	  data	  in	  this	  study	  were	  reliable.	  However,	  rates	  of	  
hypertension	  and	  ischaemic	  heart	  disease	  (IHD)	  appear	  to	  be	  lower	  than	  in	  other	  
published	  series,	  and	  this	  may	  well	  be	  due	  to	  the	  fact	  that	  SUSSEX-­‐HF	  relied	  on	  
coded	  diagnoses	  rather	  than	  recorded	  physiological	  measurements	  or	  self	  reported	  
history	  of	  hypertension	  /	  IHD,	  potentially	  reducing	  the	  apparent	  prevalence	  in	  the	  
cohort.	  Rates	  of	  comorbidity	  appear	  lower	  in	  the	  group	  who	  died	  prior	  to	  discharge	  
in	  our	  cohort,	  other	  than	  for	  prior	  stroke.	  Given	  that	  only	  data	  from	  secondary	  care	  
were	  available	  in	  this	  analysis,	  it	  may	  be	  that	  those	  individuals	  not	  surviving	  the	  
index	  admission	  were	  “hospital	  naïve”	  and	  so	  had	  no	  coded	  diagnoses	  made	  
previously	  and	  recording	  of	  co-­‐morbidity	  on	  death	  certificates	  and	  subsequent	  
coding	  of	  this	  information	  was	  not	  robust.	  It	  is	  pertinent	  to	  note	  that	  one	  US	  author	  
has	  published	  evidence	  that	  of	  a	  cohort	  of	  122630	  Medicare	  benificiaries	  with	  
known	  chronic	  heart	  failure	  only	  4%	  had	  heart	  failure	  alone	  and	  the	  risk	  of	  
hospitalization	  in	  their	  cohort	  was	  strongly	  correlated	  with	  the	  number	  of	  non-­‐
cardiac	  comorbidities	  present[189].	  Such	  comorbidity	  would	  be	  recorded	  on	  
discharge	  from	  the	  index	  admission	  but	  not	  necessarily	  in	  those	  who	  did	  not	  survive.	  
Prior	  stroke	  is	  the	  one	  comorbidity	  recorded	  which	  is	  most	  likely	  to	  have	  
necessitated	  hospital	  admission	  and	  rates	  were	  similar	  amongst	  those	  who	  survived	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to	  discharge	  and	  those	  who	  did	  not.	  	  No	  significant	  differences	  were	  seen	  in	  the	  
number	  of	  prior	  outpatient	  contacts	  of	  individuals	  who	  failed	  to	  survive	  the	  index	  
admission,	  lending	  weight	  to	  the	  proposal	  that	  rates	  of	  comorbidity	  in	  those	  
individuals	  was	  no	  higher	  than	  in	  those	  who	  survived.	  
	  	  
Rates	  of	  AF	  are	  higher	  than	  those	  seen	  in	  most	  published	  series,	  yet	  similar	  to	  those	  
seen	  in	  the	  octogenarian	  sub-­‐cohort	  of	  EuroHeart	  II,	  supporting	  the	  premise	  that	  AF	  
prevalence	  increases	  with	  age.	  Indeed,	  in	  terms	  of	  overall	  comorbidity,	  the	  study	  
cohort	  seems	  to	  most	  closely	  resemble	  this	  elderly,	  European	  group,	  with	  high	  rates	  
of	  non-­‐cardiac	  chronic	  conditions.	  Such	  levels	  of	  comorbidity	  have	  previously	  been	  
cited	  as	  important	  contributors	  to	  adverse	  clinical	  outcomes	  in	  heart	  failure	  in	  the	  
elderly,	  particularly	  in	  relation	  to	  high	  rates	  of	  readmission[190].	  	  
	  
Despite	  high	  levels	  of	  comorbidity,	  these	  data	  reveal	  low	  rates	  of	  prior	  hospital	  out-­‐
patient	  contact,	  both	  with	  specialist	  and	  generalist	  /	  geriatric	  services,	  within	  the	  
cohort.	  This	  is	  likely	  to	  represent	  an	  increased	  focus	  towards	  managing	  chronic	  
conditions	  in	  the	  community	  rather	  than	  in	  the	  hospital	  setting[191],	  certainly	  in	  the	  
UK,	  and	  this	  study	  is	  limited	  by	  not	  having	  access	  to	  data	  regarding	  exposure	  to	  
primary	  care.	  It	  is	  not	  possible	  to	  comment	  from	  these	  data	  on	  whether	  or	  not	  
improved	  rates	  of	  prior	  contact	  might	  be	  a	  factor	  in	  preventing	  hospitalizations	  as	  





8.IV.	   MORTALITY	  
	  
Crude	  mortality	  rates	  in	  SUSSEX-­‐HF	  appear	  to	  be	  reasonably	  consistent	  with	  
previously	  published	  data	  for	  admitted	  heart	  failure	  patients.	  The	  Rotterdam	  Study	  
reported	  a	  1-­‐year	  mortality	  for	  incident	  heart	  failure	  of	  37%,	  with	  a	  30-­‐day	  mortality	  
of	  14%[64].	  Most	  published	  data	  on	  incident	  heart	  failure	  give	  similar	  figures	  of	  
between	  10	  –	  20%	  for	  30-­‐day	  mortality.	  1	  year	  mortality	  in	  the	  Hillingdon	  study	  –	  a	  
not	  exclusively	  hospitalized	  group	  –	  was	  38%[179],	  although	  recent	  evidence	  has	  
suggested	  that	  the	  secular	  trend	  is	  for	  improved	  survival	  –	  26%	  at	  6	  months	  in	  the	  
original	  Hillingdon	  cohort	  (1995-­‐1996)	  vs.	  14%	  at	  6	  months	  in	  the	  2004-­‐2005	  
cohort[49].	  	  	  	  	  	  	  	  
	  
1-­‐year	  mortality	  in	  the	  2010	  UK	  NHFA	  was	  32%,	  though	  rates	  of	  death	  during	  the	  
index	  admission	  were	  considerably	  lower	  in	  the	  National	  Audit	  than	  those	  observed	  
in	  our	  study	  (10%	  vs.	  18%).	  The	  explanation	  for	  such	  disparity	  may	  well	  lie	  in	  the	  fact	  
that	  this	  was	  a	  generally	  older	  cohort,	  with	  high	  rates	  of	  admission	  to	  non-­‐cardiology	  








8.V.	   READMISSION	  
	  
Best	  estimates	  are	  that	  around	  a	  third	  of	  patients	  are	  readmitted	  for	  the	  
management	  of	  heart	  failure	  within	  a	  year	  of	  discharge[48].	  Data	  presented	  here	  
would	  suggest	  that	  this	  is	  still	  the	  case	  despite	  marked	  developments	  in	  the	  
understanding	  and	  management	  of	  heart	  failure	  since	  this	  result	  was	  first	  reported.	  
It	  is	  difficult	  to	  compare	  readmission	  rates	  internationally	  but	  figures	  from	  SUSSEX-­‐
HF	  for	  readmission	  at	  one	  year	  are	  similar	  to	  those	  reported	  in	  Japan[161].	  Rates	  for	  
readmission	  within	  a	  year	  are	  not	  generally	  reported	  in	  the	  USA,	  but	  readmission	  
rates	  at	  6	  months	  have	  been	  reported	  as	  approaching	  50%[116].	  
	  
The	  finding	  that	  30-­‐day	  readmission	  rates	  were	  6.6%	  for	  heart	  failure	  and	  21.3%	  for	  
any	  cause	  is	  of	  high	  clinical	  relevance	  as	  well	  as	  carrying	  significant	  health	  economic	  
consequences.	  It	  is	  also	  interesting	  to	  note	  that	  the	  all	  cause	  30-­‐day	  readmission	  rate	  
was	  similar	  across	  all	  three	  age	  groups	  studied,	  suggesting	  that	  age	  alone	  is	  not	  the	  
primary	  determinant	  of	  readmission	  in	  this	  heart	  failure	  cohort.	  
	  
All	  cause	  30-­‐day	  readmission	  rates	  did	  appear	  to	  be	  higher	  in	  the	  most	  deprived	  
groups	  compared	  with	  the	  least	  deprived	  group.	  This	  finding	  is	  not	  easily	  explained	  
by	  any	  factor	  considered	  in	  this	  analysis.	  Although	  rates	  of	  contact	  with	  specialist	  
nurses	  were	  lower	  in	  the	  same	  groups,	  it	  seems	  unlikely	  that	  there	  is	  a	  causal	  link	  
between	  these	  two	  facts	  as	  rates	  of	  follow-­‐up	  by	  specialist	  nurses	  over	  the	  course	  of	  
two	  years	  were	  generally	  too	  low	  to	  have	  a	  clinically	  significant	  impact	  on	  reducing	  
30	  day	  readmission	  rates.	  	  One	  might	  theorize	  that	  lower	  levels	  of	  social	  support	  or,	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as	  previously	  reported,	  reduced	  rates	  of	  contact	  with	  GP	  services	  in	  more	  deprived	  





















8.VI.	   THE	  EFFECT	  OF	  DEPRIVATION	  
	  
Whilst	  overall	  the	  SUSSEX-­‐HF	  cohort	  is	  elderly,	  there	  is	  some	  evidence	  to	  support	  
presentation	  at	  an	  earlier	  age	  in	  more	  deprived	  individuals.	  This	  finding	  is	  not	  readily	  
explained	  by	  any	  differences	  between	  individuals	  in	  each	  quintile	  of	  deprivation	  
identified	  in	  this	  study,	  though	  similarly	  younger	  ages	  in	  more	  deprived	  groups	  have	  
been	  seen	  in	  the	  UK	  National	  Audit	  at	  the	  time	  of	  an	  unscheduled	  admission	  for	  
heart	  failure.	  It	  is	  also	  the	  case	  that	  previous	  studies	  reporting	  increased	  incidence	  of	  
heart	  failure	  associated	  with	  lower	  SES	  generally	  recruited	  patients	  of	  a	  young	  age	  
and	  so	  some	  of	  the	  increased	  incidence	  seen	  in	  those	  of	  lower	  SES	  might	  well	  be	  
related	  to	  a	  tendency	  for	  earlier	  onset	  of	  heart	  failure	  in	  these	  individuals.	  Rates	  of	  
co-­‐morbidity	  were	  generally	  high	  in	  all	  quintiles	  of	  deprivation,	  although	  rates	  of	  
documented	  ischaemic	  heart	  disease	  and	  chronic	  lung	  disease	  were	  noted	  to	  be	  
higher	  in	  the	  most	  deprived	  group.	  We	  have	  found	  no	  evidence	  to	  suggest	  that	  more	  
deprived	  members	  of	  the	  cohort	  were	  more	  or	  less	  unwell	  at	  the	  time	  of	  
presentation	  or	  subsequently	  in	  terms	  of	  rates	  of	  inpatient	  death	  in	  each	  quintile	  of	  
deprivation	  and	  subsequent	  mortality	  rates	  in	  those	  surviving	  to	  discharge,	  in	  
contrast	  to	  previous	  reports.	  	  
	  
Our	  data	  do	  show	  that,	  following	  an	  admission	  with	  heart	  failure,	  subsequent	  
management	  and	  outcome	  are	  not	  dependent	  on	  level	  of	  deprivation.	  No	  
differences	  in	  survival	  are	  demonstrated	  between	  members	  of	  the	  cohort	  surviving	  
to	  discharge	  according	  to	  quintile	  of	  deprivation,	  and	  no	  significant	  differences	  are	  
observed	  between	  quintiles	  in	  access	  to	  echocardiography,	  recording	  of	  LVEF,	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prescription	  of	  beneficial	  medications	  or	  provision	  of	  specialist	  follow-­‐up.	  There	  is,	  
however,	  a	  suggestion	  from	  these	  data	  that	  contact	  with	  specialist	  nursing	  services	  
was	  lower	  in	  the	  more	  deprived	  2	  quintiles	  and	  that	  30	  day	  readmission	  rates	  are	  
also	  higher	  in	  this	  group.	  
	  
Rates	  of	  death	  were	  not	  found	  to	  be	  robustly	  associated	  with	  IMD	  2007	  Quintile	  in	  
this	  cohort	  and	  no	  differences	  were	  observed	  in	  survival	  time,	  or	  time	  to	  death	  or	  
first	  admission	  with	  heart	  failure.	  This	  contrasts	  with	  several	  previous	  reports	  which	  
have	  proposed	  a	  link	  between	  increased	  deprivation,	  or	  lower	  socioeconomic	  status,	  
and	  decreased	  survival	  times	  in	  heart	  failure	  patients.	  
	  
We	  have	  employed	  a	  method	  for	  identifying	  individual	  levels	  of	  deprivation	  by	  using	  
a	  proxy	  measure	  based	  on	  postcode	  of	  residence,	  allowing	  comparison	  of	  individuals	  
according	  to	  nationally	  available	  comparative	  data.	  It	  may	  be	  argued	  that	  such	  a	  tool	  
provides	  an	  inappropriate	  measure	  of	  deprivation	  for	  elderly	  individuals,	  as	  it	  is	  a	  
cross-­‐sectional	  measure,	  purely	  based	  on	  residence	  at	  the	  time	  of	  sampling	  for	  the	  
study.	  However,	  it	  seems	  reasonable	  to	  propose	  that	  an	  individual’s	  postcode	  of	  
residence	  in	  retirement	  is	  a	  meaningful	  proxy	  for	  status	  over	  the	  life-­‐course	  of	  that	  
individual,	  as	  their	  eventual	  position	  in	  a	  hierarchical	  measure	  of	  deprivation	  is	  likely	  
to	  have	  been	  predicted	  by	  their	  overall	  lifetime	  experience.	  
	  
Not	  withstanding	  such	  argument,	  it	  is	  the	  case	  that	  previously	  reported	  data	  have	  
employed	  similar	  methods	  for	  defining	  socioeconomic	  status	  in	  heart	  failure	  cohorts	  
and	  have	  demonstrated	  an	  apparent	  association	  between	  deprivation	  and	  mortality	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or	  readmission	  rates.	  I	  cannot	  identify	  such	  an	  association	  in	  this	  cohort	  and	  propose	  
several	  possible	  explanations	  for	  these	  findings:	  
	  
1. Available	  comparative	  data	  are	  based	  mainly	  on	  studies	  of	  cohorts	  assembled	  
in	  1998-­‐2000.	  This	  period	  was	  a	  time	  of	  rapid	  advancement	  in	  heart	  failure	  
therapies	  and	  management	  strategies.	  The	  application	  of	  such	  developments	  
in	  clinical	  practice	  is	  known	  to	  lag	  behind	  the	  publication	  of	  important	  clinical	  
trial	  data,	  not	  only	  because	  guidelines	  for	  clinical	  practice	  take	  time	  to	  be	  
released,	  but	  also	  because	  these	  guidelines	  need	  time	  to	  become	  
disseminated	  and	  acted	  upon	  at	  “the	  coal	  face”.	  Where	  interventions	  are	  
novel,	  and	  have	  potential	  cost	  implications	  –	  especially	  in	  health	  economies	  
not	  operating	  universal	  coverage	  –	  then	  there	  is	  the	  potential	  for	  inequity	  to	  
operate.	  The	  reasons	  which	  underlie	  this	  phenomenon	  are	  legion,	  but	  are	  
likely	  to	  include	  higher	  awareness	  and	  demand	  for	  timely	  investigation	  and	  
novel	  therapies	  amongst	  those	  of	  higher	  socioeconomic	  status.	  These	  data	  
may	  suggest	  that	  in	  a	  more	  contemporary	  cohort,	  such	  factors	  may	  be	  
playing	  a	  less	  important	  role	  in	  determining	  access	  to	  beneficial	  therapies	  as	  
these	  are	  now	  considered	  as	  “routine”	  elements	  of	  heart	  failure	  
management.	  In	  support	  of	  this	  argument	  is	  the	  fact	  that	  deprivation	  
appeared	  to	  have	  no	  predictable	  association	  with	  access	  to	  
echocardiography,	  follow-­‐up,	  or	  the	  prescription	  of	  any	  class	  of	  disease	  
modifying	  therapy	  in	  this	  cohort.	  However,	  the	  argument	  that	  “routine”	  
heart	  failure	  management	  is	  being	  universally	  applied	  is	  not	  well	  supported	  
by	  these	  data,	  given	  the	  low	  overall	  rates	  of	  medication	  prescription	  –	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particularly	  in	  the	  cases	  of	  β-­‐blockers	  and	  aldosterone	  antagonists.	  Other	  
factors	  than	  deprivation	  appear	  to	  be	  responsible	  for	  mediating	  these	  effects.	  
	  
2. Health	  inequality	  has	  been	  a	  focus	  of	  political	  interest	  in	  the	  UK	  over	  the	  
course	  of	  the	  last	  decade.	  It	  may	  be	  the	  case	  that	  awareness	  of	  this	  issue,	  in	  
part	  as	  a	  consequence	  of	  the	  previously	  published	  data	  in	  this	  area,	  and	  as	  a	  
result	  of	  national	  programmes	  to	  highlight	  inequality	  and	  encourage	  health	  
inequality	  audit,	  has	  borne	  fruit	  in	  tackling	  inequity	  in	  heart	  failure	  
management	  –	  effectively	  abolishing	  health	  inequality	  according	  to	  
socioeconomic	  status	  in	  this	  cohort.	  	  
	  
3. These	  data	  demonstrates	  indirect	  support	  for	  previous	  findings	  that	  incident	  
heart	  failure	  occurs	  at	  an	  earlier	  age	  in	  more	  deprived	  individuals	  and	  
confirm	  the	  findings	  of	  the	  NHFA	  that	  more	  deprived	  patients	  present	  on	  
average	  at	  a	  younger	  age.	  Median	  age	  at	  first	  admission	  with	  heart	  failure	  in	  
this	  cohort	  was	  significantly	  lower	  in	  the	  most	  deprived	  group	  than	  the	  least	  
deprived,	  with	  an	  observable	  trend	  across	  the	  quintiles	  of	  deprivation.	  This	  
finding	  raises	  the	  possibility	  that	  the	  lack	  of	  observable	  differences	  in	  survival	  
in	  those	  in	  higher	  quintiles	  of	  deprivation	  is	  a	  consequence	  of	  “survivor	  
selection”	  amongst	  those	  admitted.	  The	  multivariate	  analysis	  does	  not	  
support	  an	  interaction	  between	  age	  and	  quintile	  of	  deprivation	  in	  
determining	  survival,	  with	  age	  remaining	  the	  strongest	  predictor	  of	  outcome,	  
regardless	  of	  quintile	  of	  IMD-­‐2007.	  Once	  admitted	  with	  heart	  failure,	  
therefore,	  these	  data	  suggest	  that	  deprivation	  does	  not	  affect	  outcome,	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despite	  the	  fact	  that	  admission	  is	  likely	  to	  occur	  earlier	  in	  life.	  Therefore,	  
factors	  which	  determine	  the	  development	  of	  heart	  failure	  are	  likely	  to	  be	  
more	  influenced	  by	  the	  operation	  of	  health	  inequality	  than	  is	  subsequent	  
management	  of	  the	  syndrome	  itself.	  
	  
All	  cause	  readmission	  at	  30	  days	  did	  appear	  to	  be	  more	  frequent	  in	  members	  of	  the	  
cohort	  from	  the	  more	  deprived	  quintiles.	  This	  fact	  is	  not	  easily	  explicable	  by	  any	  of	  
the	  data	  that	  have	  been	  collected	  as	  part	  of	  this	  study.	  No	  assessment	  of	  the	  severity	  
of	  heart	  failure	  on	  admission	  was	  made	  but	  it	  seems	  unlikely	  that	  the	  severity	  on	  
discharge	  was	  markedly	  different	  between	  quintile	  of	  deprivation	  as	  no	  differences	  
in	  average	  diuretic	  dose	  was	  observed	  between	  groups.	  Groups	  also	  showed	  no	  
significant	  differences	  in	  any	  of	  the	  markers	  of	  care	  quality,	  which	  might	  have	  been	  
predicted	  to	  avoid	  readmission,	  other	  than	  the	  observation	  that	  low	  rates	  of	  
specialist	  nurse	  follow	  up	  was	  seen	  in	  the	  most	  deprived	  quintile.	  Comorbidity	  might	  
be	  a	  potential	  explanation	  for	  these	  findings,	  particularly	  the	  higher	  rates	  of	  chronic	  
lung	  disease	  and	  ischaemic	  heart	  disease	  recorded	  in	  the	  more	  deprived	  quintiles.	  A	  
lack	  of	  data	  on	  community	  support	  and	  GP	  services,	  however,	  limits	  the	  ability	  to	  
draw	  firm	  conclusions	  on	  this.	  
	  
The	  finding	  that	  readmission	  rates	  were	  higher	  in	  those	  from	  more	  deprived	  groups	  
is	  pertinent	  given	  evidence	  from	  the	  USA	  that	  survival	  in	  the	  very	  elderly	  is	  
improving	  but	  admission	  rates	  remain	  high[192]	  and	  also	  given	  that	  assessments	  of	  
quality	  include	  measures	  of	  readmission	  rates	  in	  the	  UK.	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8.VII.	   AGE	  RELATED	  INEQUITY	  
	  
SUSSEX-­‐HF	  provides	  novel	  data	  for	  the	  operation	  of	  age	  related	  inequity	  in	  the	  
management	  of	  heart	  failure	  in	  the	  elderly.	  These	  data	  demonstrate	  that	  admission	  
for	  a	  first	  presentation	  with	  heart	  failure	  in	  this	  cohort	  carries	  an	  increased	  hazard	  
ratio	  for	  death	  compared	  to	  the	  general	  population	  regardless	  of	  the	  age	  at	  which	  
this	  admission	  occurs.	  Given	  this	  finding,	  it	  should	  be	  considered	  iniquitous	  to	  
observe	  differential	  care	  quality	  on	  the	  basis	  of	  age	  alone.	  However,	  we	  have	  
observed	  considerable	  evidence	  for	  the	  operation	  of	  such	  inequity	  in	  this	  cohort.	  
	  
The	  prescription	  rates	  of	  ACE	  inhibitors,	  or	  ARBs,	  in	  the	  cohort	  do	  not	  appear	  to	  be	  
influenced	  by	  age	  when	  other	  important	  factors	  are	  taken	  into	  consideration.	  Initial	  
analysis	  of	  the	  data	  does	  appear	  to	  show	  a	  trend	  for	  lower	  rates	  of	  prescription	  
according	  to	  advancing	  age,	  and	  univariate	  analysis	  of	  prescription	  related	  to	  age	  
reveals	  this	  non-­‐significant	  trend	  observed	  across	  the	  three	  age	  groups	  to	  be	  a	  result	  
of	  an	  apparent	  decreasing	  likelihood	  of	  prescription	  with	  increasing	  age.	  However,	  
encouragingly,	  this	  association	  is	  not	  significant	  in	  a	  multivariate	  model	  which	  takes	  
into	  account	  LVEF	  and	  renal	  function.	  The	  apparently	  strong	  association	  between	  
specialist	  follow-­‐up	  and	  ACEi/ARB	  prescription	  is	  also	  lost	  in	  the	  final	  model.	  This	  is	  
most	  likely	  to	  be	  explained	  by	  the	  fact	  that	  age	  was	  the	  most	  powerful	  predictor	  of	  
specialist	  follow-­‐up.	  	  
	  
Such	  findings	  are	  encouraging	  in	  that	  they	  suggest	  that	  the	  decision	  to	  prescribe	  
ACEi/ARB	  is	  based	  mainly	  on	  appropriate	  clinical	  consderations,	  regardless	  of	  the	  age	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of	  the	  patient.	  It	  also	  implies	  that	  “non-­‐specialist”	  physicians	  are	  comfortable	  with	  
the	  use	  of	  these	  agents	  for	  the	  management	  of	  heart	  failure	  in	  the	  elderly.	  
Given	  that	  ACE	  inhibition	  is	  the	  modern	  prognostically	  beneficial	  therapy	  for	  which	  
there	  is	  the	  longest	  standing	  historical	  evidence,	  these	  results	  support	  the	  theory	  
that	  inequity	  is	  less	  likely	  to	  operate	  where	  there	  is	  long-­‐standing	  experience	  and	  
general	  guidance	  regarding	  the	  use	  of	  a	  treatment.	  
	  
Contrasting	  these	  findings	  with	  the	  results	  regarding	  the	  relationship	  between	  age	  
and	  β-­‐blocker	  or	  aldosterone	  antagonist	  prescription,	  there	  is	  evidence	  from	  this	  
cohort	  that	  age	  related	  inequitous	  prescribing	  behaviour	  is	  operating.	  	  
	  
Our	  results	  lend	  weight	  to	  the	  supposition	  that	  several	  factors	  conspire	  to	  determine	  
the	  reluctance	  of	  physicians	  to	  prescribe	  β-­‐blockers	  to	  patients	  admitted	  with	  heart	  
failure.	  
	  
Firstly,	  overall	  rates	  of	  β-­‐blocker	  prescription	  were	  low	  and	  this	  may	  be	  explained	  by	  
a	  reluctance	  to	  institute	  β-­‐blockade	  in	  the	  setting	  of	  a	  recent	  acute	  decompensation	  
or	  recent	  myocardial	  infarction	  (given	  the	  high	  numbers	  of	  patients	  in	  the	  cohort	  
with	  recorded	  positive	  Troponin-­‐I).	  The	  methods	  used	  in	  this	  study	  did	  not	  allow	  for	  
any	  recommendation	  to	  start	  β-­‐blockers	  post-­‐hospital	  discharge	  to	  be	  recorded.	  
However,	  there	  is	  evidence	  from	  the	  post-­‐MI	  setting	  that	  unless	  therapies	  are	  
instituted	  at	  discharge,	  or	  in	  the	  immediate	  post-­‐discharge	  period,	  then	  chances	  of	  
long-­‐term	  therapy	  are	  low[193].	  Therefore,	  the	  generally	  low	  rates	  of	  β-­‐blockade	  
observed	  on	  discharge	  in	  this	  cohort	  are	  disappointing,	  especially	  when	  compared	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with	  data	  on	  prescription	  rates	  provided	  by	  the	  contaporaneous	  UK	  NHFA	  and	  other,	  
recent	  European	  and	  North	  American	  registries.	  Some	  explanation	  for	  these	  lower	  
comparative	  rates	  may	  lie	  in	  the	  decision	  to	  include	  in	  the	  study	  patients	  with	  heart	  
failure	  diagnosed	  in	  the	  secondary	  position,	  where	  the	  primary	  diagnosis,	  felt	  to	  be	  
the	  ultimate	  reason	  for	  admission,	  might	  increase	  reluctance	  to	  institute	  β-­‐blockade.	  
However,	  patients	  with	  heart	  failure	  recorded	  in	  the	  second	  diagnostic	  position	  have	  
as	  much	  requirement	  for	  prognostically	  beneficial	  β-­‐blockade	  as	  those	  admitted	  with	  
a	  primary	  diagnosis.	  	  	  
	  
Despite	  evidence	  supporting	  the	  use	  of	  cardioselective	  β-­‐blockers	  in	  heart	  failure	  
with	  co-­‐existing	  lung	  disease[93]	  clinicians	  are	  generally	  more	  reluctant	  to	  prescribe	  
these	  agents	  in	  this	  setting[165].	  These	  data	  appear	  to	  lend	  weight	  to	  this	  
supposition,	  demonstrating	  a	  strong	  association	  between	  history	  of	  chronic	  lung	  
disease	  and	  reduced	  chances	  of	  β-­‐blocker	  prescription	  on	  univariate	  analysis.	  
However,	  adding	  other	  variables	  to	  investigate	  the	  relationship	  further	  
demonstrates	  that	  this	  association	  is	  abolished	  when	  other	  factors	  are	  taken	  into	  
account.	  	  Advancing	  age	  powerfully	  predicts	  likelihood	  of	  β-­‐blocker	  prescription	  in	  
this	  cohort	  along	  with	  LVEF.	  It	  is	  clear	  from	  the	  data	  that	  specialist	  follow-­‐up	  is	  
strongly	  associated	  with	  age	  and	  powerfully	  predicts	  β-­‐blocker	  prescription.	  	  
	  
Taken	  together,	  these	  results	  seem	  to	  show	  that	  those	  patients	  who	  receive	  
specialist	  follow-­‐up	  are	  more	  likely	  to	  be	  young	  and	  more	  likely	  to	  be	  started	  on	  a	  β-­‐
blocker	  on	  discharge.	  The	  fact	  that	  the	  effects	  of	  chronic	  lung	  disease	  are	  muted	  by	  
these	  factors	  would	  imply	  that	  those	  patients	  who	  receive	  specialist	  input	  are	  less	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likely	  to	  have	  a	  β-­‐blocker	  withheld	  for	  reasons	  of	  perceived	  risk.	  Our	  data,	  therefore,	  
suggest	  that	  ageism	  operates	  both	  directly	  and	  indirectly	  in	  this	  cohort	  to	  reduce	  β-­‐
blocker	  prescription	  rates	  in	  the	  elderly.	  Those	  patients	  who	  are	  treated	  by	  
generalists	  (in	  this	  case	  geriatricians)	  are	  potentially	  less	  likely	  to	  receive	  β-­‐blockers	  
due	  to:	  
	  
1. Less	  physician	  experience	  of	  β-­‐blocker	  use	  in	  heart	  failure	  due	  to	  the	  fact	  that	  
this	  therapy	  is	  more	  novel	  than	  ACE	  inhibition.	  
2. Increased	  perception	  of	  the	  risks	  of	  β-­‐blockade,	  especially	  in	  the	  elderly.	  
	  
The	  picture	  is	  similar	  for	  those	  patients	  receiving	  aldosterone	  antagonists	  on	  
discharge.	  	  The	  SUSSEX-­‐HF	  data	  have	  demonstrated	  a	  strong	  age	  effect	  on	  the	  
prescription	  of	  these	  agents,	  with	  patients	  in	  each	  age	  group	  analysed	  being	  
progressively	  less	  likely	  to	  receive	  treatment	  as	  age	  advances.	  Female	  gender	  also	  
seemed	  to	  be	  predictive	  of	  lower	  rates	  of	  aldosterone	  antagonist	  prescription	  on	  
univariate	  analysis	  but	  further	  exploration	  suggests	  that	  this	  is	  mainly	  mediated	  by	  
the	  higher	  proprtion	  of	  women	  present	  in	  the	  cohort	  as	  age	  advances.	  Interestingly,	  
renal	  dysfunction	  appeared	  not	  to	  influence	  the	  prescription	  of	  aldosterone	  
antagonists,	  despite	  data	  in	  this	  cohort	  demonstrating	  that	  increased	  mortality	  is	  
associated	  with	  the	  prescription	  of	  these	  agents	  in	  the	  setting	  of	  renal	  dysfunction,	  
especially	  with	  increasing	  age.	  
	  
Evidence	  for	  the	  use	  of	  aldosterone	  antagonism	  in	  heart	  failure	  at	  the	  time	  of	  this	  
study	  was	  based	  on	  data	  from	  the	  RALES	  trial	  (1999)[78]	  –	  performed	  in	  a	  generally	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much	  younger	  cohort	  and	  in	  patients	  exclusively	  with	  severe	  left	  ventricular	  
dysfunction	  –	  and	  to	  some	  extent	  on	  data	  from	  EPHESUS	  (2003)[194],	  using	  
eplerenone	  in	  the	  post-­‐MI	  setting.	  These	  data	  have	  been	  considered	  and	  formed	  the	  
basis	  of	  recommendations	  made	  in	  North	  American,	  European	  and	  UK	  NICE	  guidance	  
for	  the	  treatment	  of	  heart	  failure	  to	  use	  aldosterone	  antagonists	  as	  a	  third	  line	  
agent.	  In	  the	  UK,	  at	  the	  time	  of	  this	  study,	  the	  published	  NICE	  guidance	  
recommended	  addition	  of	  aldosterone	  antagonists	  to	  treatment	  with	  ACE	  inhibitor	  
and	  β-­‐blocker	  under	  the	  direction	  of	  a	  specialist.	  
	  
Given	  these	  contemporary	  recommendations,	  our	  data	  regarding	  the	  prescription	  of	  
aldosterone	  antagonists	  are	  interesting	  for	  several	  reasons:	  
	  
1. Overall	  rates	  of	  prescription	  are	  higher	  than	  those	  for	  β-­‐blockers,	  
suggesting	  that	  physicians	  are	  in	  general	  happier	  to	  prescribe	  these	  agents	  
in	  heart	  failure.	  This	  may	  be	  explained,	  in	  part,	  by	  perceptions	  regarding	  
the	  diuretic	  effect	  of	  spironolactone	  and	  familiaritry	  with	  its	  use	  in	  the	  
treatment	  of	  chronic	  liver	  disease.	  Such	  perceptions	  may	  well	  lead	  
physicians	  to	  be	  more	  comfortable	  with	  using	  aldosterone	  antagonists	  in	  
the	  acute	  setting,	  with	  the	  primary	  aim	  of	  reducing	  congestion.	  
2. Higher	  subsequent	  rates	  of	  follow	  up	  with	  specialist	  services	  were	  
asssociated	  with	  prescription	  of	  aldosterone	  antagonists	  at	  discharge	  on	  
univariate	  analysis	  but,	  whereas	  this	  effect	  seems	  to	  be	  clearly	  age	  
mediated	  in	  its	  association	  with	  β-­‐blockade,	  the	  relationships	  are	  more	  
difficult	  to	  identify	  regarding	  aldosterone	  antagonism.	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3. Univariate	  analysis	  of	  the	  effect	  of	  gender	  on	  the	  prescription	  of	  
aldosterone	  antagonists	  reveals	  a	  strong	  relationship,	  which	  persists	  with	  
the	  addition	  of	  age	  to	  the	  model,	  suggesting	  that	  there	  is	  an	  inherent	  
gender	  bias	  in	  prescribing	  in	  this	  area.	  
	  
What	  seems	  to	  be	  suggested	  by	  these	  data	  is	  that	  patterns	  of	  aldosterone	  
prescribing	  are	  less	  predictable	  than	  those	  observed	  for	  either	  ACEI/ARB	  or	  for	  β-­‐
blockade.	  This	  is	  most	  likely	  to	  be	  explained	  by	  the	  fact	  that	  the	  use	  of	  these	  agents	  
in	  heart	  failure	  is	  less	  well	  understood	  by	  non-­‐specialists	  and	  their	  use	  has	  not	  been	  
as	  clearly	  mandated	  by	  robust	  evidence	  and	  national	  guidance.	  Where	  there	  is	  such	  
potential	  for	  variation	  in	  practice	  then	  inequity	  is	  more	  likely	  to	  occur,	  and	  this	  
appears	  to	  be	  demonstrated	  here.	  
	  
Further	  support	  for	  this	  proposition	  comes	  from	  the	  finding	  that	  warfarin	  
prescription	  rates	  are	  significantly	  lower	  in	  the	  more	  elderly	  AF	  patients	  in	  this	  
cohort.	  Awareness	  of	  the	  importance	  of	  formal	  anticoagulation	  in	  high-­‐risk	  patients,	  
as	  determined	  by	  a	  validated	  risk	  assessment	  tool	  –	  the	  CHA2DS2-­‐VASc	  score,	  has	  
increased	  with	  the	  publication	  of	  European	  guidelines	  on	  AF[99],	  since	  the	  initial	  
work	  in	  developing	  the	  score	  was	  undertaken.	  In	  the	  period	  over	  which	  data	  for	  
SUSSEX-­‐HF	  were	  collected,	  such	  guidelines	  were	  not	  available	  and	  so	  the	  judgement	  
of	  individual	  clinicians	  exclusively	  informed	  decisions	  regarding	  the	  prescription	  of	  
formal	  anticoagulation.	  Clearly	  clinicians	  still	  exercise	  such	  judgement	  regarding	  
these	  decisions,	  but	  robust	  risk	  assessment	  tools	  give	  more	  confidence	  in	  the	  
decision	  to	  prescribe	  medications	  when	  personal	  experience	  may	  have	  previously	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caused	  physicians	  to	  adopt	  a	  more	  cautious	  approach	  to	  anticoagulation	  due	  to	  
perceived	  risks	  of	  bleeding	  in	  the	  elderly.	  Having	  said	  this,	  clearly	  data	  are	  not	  
available	  from	  SUSSEX-­‐HF	  regarding	  the	  potential	  bleeding	  and	  falls	  risk	  of	  the	  
patients	  in	  the	  study,	  and	  this	  needs	  to	  be	  borne	  in	  mind	  when	  considering	  these	  
data.	  	  	  	  	  	  	  	  
	  
A	  significant	  trend	  has	  been	  observed	  for	  reduced	  provision	  of	  echocardiography	  in	  
elderly	  patients	  in	  this	  cohort.	  This	  is	  associated	  with	  an	  overall	  effect	  of	  there	  being	  
significantly	  fewer	  timely	  echocardiograms	  performed	  in	  women	  in	  this	  cohort	  than	  
in	  men.	  At	  the	  very	  least,	  indirect	  gender	  based	  inequality	  in	  provision	  of	  
echocardiography	  exists	  in	  this	  cohort,	  and	  there	  is	  evidence	  for	  age	  based	  iniquitous	  
access	  to	  echocardiography.	  It	  is	  also	  worth	  noting	  that	  similar	  iniquitous	  patterns	  
were	  observed	  in	  the	  recording	  of	  LVEF	  where	  echocardiography	  was	  performed.	  
	  
The	  benefits	  of	  echocardiography	  and	  assessment	  of	  LVEF	  are	  likely	  to	  stem	  from	  the	  
administration	  of	  beneficial	  therapies	  on	  the	  basis	  of	  the	  information	  gained.	  Indeed,	  
when	  analysis	  was	  confined	  to	  the	  administration	  of	  drug	  therapy	  in	  those	  with	  
documented	  LV	  impairment,	  prescription	  rates	  were	  improved	  and	  iniquitous	  
prescribing	  on	  the	  basis	  of	  age	  was	  diminished.	  This	  cohort	  is	  constructed	  primarily	  
on	  the	  basis	  of	  coded	  diagnosis	  of	  heart	  failure	  with	  corroboration	  of	  this	  coding	  on	  
the	  basis	  of	  clinical	  findings.	  Where	  echocardiography	  has	  been	  performed	  in	  the	  
cohort	  it	  is	  clear	  that	  higher	  LVEF	  have	  been	  recorded	  in	  elderly	  patients,	  and	  yet	  
fewer	  measurements	  of	  LVEF	  have	  been	  taken	  in	  this	  group.	  It	  may	  well	  be	  the	  case	  
that	  those	  with	  reduced	  LVEF	  are	  not	  being	  identified	  and	  appropriately	  managed	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due	  to	  iniquitous	  provision	  of	  echocardiography.	  To	  a	  certain	  extent	  this	  may	  be	  a	  
result	  of	  the	  widely	  reported	  predominance	  of	  heart	  failure	  with	  normal	  ejection	  
fraction	  in	  elderly	  women	  reported	  in	  the	  literature.	  Physicians	  may	  well	  be	  aware	  of	  
these	  facts,	  either	  from	  such	  epidemiological	  reports,	  or	  from	  their	  own	  experience,	  
and	  this	  may	  drive	  the	  reduced	  provision	  of	  echocardiography	  in	  elderly,	  female	  
patients	  –	  especially	  where	  a	  limited	  resource	  may	  already	  be	  under	  pressure	  in	  
terms	  of	  numbers	  of	  echocardiograms	  which	  can	  be	  performed.	  This	  finding	  is	  of	  
particular	  relevance,	  given	  the	  fact	  that	  recently	  updated	  NICE	  guidance	  
recommends	  that	  echocardiography	  be	  performed	  within	  two	  weeks	  in	  cases	  of	  new	  
or	  suspected	  heart	  failure[40].	  
	  
It	  is	  worth	  noting	  that	  these	  data	  do	  not	  consider	  the	  aetiology	  of	  heart	  failure	  in	  this	  
cohort.	  Clearly	  echocardiography	  is	  a	  key	  investigation	  for	  defining	  this	  in	  the	  acute	  
setting.	  Identification	  of	  valve	  disease	  or	  acute	  left	  ventricular	  regional	  wall	  motion	  










9.	   LIMITATIONS	  OF	  THE	  CURRENT	  STUDY	  
	  
Clearly	  the	  study	  has	  several	  important	  limitations	  and	  the	  results	  and	  conclusions	  
must	  be	  considered	  in	  the	  light	  of	  these.	  
	  
Firstly,	  this	  is	  a	  single	  centre	  study.	  Examination	  has	  been	  made	  of	  the	  outcomes	  and	  
management	  of	  an	  historical	  cohort	  presenting	  to	  a	  single	  hospital	  and	  therefore	  
managed	  by	  a	  limited	  number	  of	  physicians.	  No	  attempt	  has	  been	  made	  in	  the	  
analysis	  to	  examine	  individual	  physician	  behaviour,	  but	  it	  is	  possible	  that	  the	  results	  
may	  be	  affected	  by	  the	  “rogue”	  behaviour	  of	  a	  single	  individual.	  Such	  a	  conclusion	  is	  
unlikely,	  especially	  given	  the	  similarity	  of	  our	  data	  to	  contemporary	  national	  audits	  
in	  terms	  of	  event	  rates	  and	  ACEi/ARB	  and	  aldosterone	  antagonist	  prescription	  rates.	  
It	  is	  difficult	  to	  believe	  that	  the	  actions	  of	  a	  single	  individual,	  or	  indeed	  the	  influence	  
of	  a	  prevailing	  practice	  within	  the	  centre,	  are	  responsible	  for	  the	  markedly	  low	  β-­‐
blocker	  prescription	  rate.	  
	  
The	  lack	  of	  availability	  of	  GP	  data	  in	  this	  study	  significantly	  limits	  the	  generalizability	  
of	  the	  conclusions.	  Both	  selection	  bias	  and	  spectrum	  bias	  are	  introduced	  due	  to	  the	  
lack	  of	  availability	  of	  such	  data.	  Much	  of	  the	  treatment	  of	  long-­‐term	  conditions,	  
including	  heart	  failure,	  is	  carried	  out	  in	  the	  community	  and	  this	  study	  has	  been	  
unable	  to	  provide	  a	  picture	  of	  the	  ongoing	  treatment	  of	  patients	  over	  time	  following	  
their	  discharge	  from	  hospital,	  or	  indeed	  any	  information	  on	  those	  patients	  with	  
heart	  failure	  who	  are	  exclusively	  managed	  in	  the	  community.	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Patients	  may	  have	  been	  admitted	  to	  hospital	  with	  varying	  degrees	  of	  severity	  of	  
heart	  failure	  depending	  both	  on	  their	  contact	  with	  primary	  care	  services	  and	  the	  
ability	  of	  those	  services	  to	  manage	  heart	  failure.	  Such	  data	  may	  well	  be	  pertinent	  in	  
determining	  overall	  quality	  of	  care	  in	  the	  population	  as	  differences	  in	  the	  quality	  of	  
heart	  failure	  management	  provided	  by	  primary	  care	  services	  might	  well	  have	  an	  
impact	  on	  the	  rates	  of	  acute	  admissions	  to	  hospital,	  both	  in	  terms	  of	  index	  
admissions	  and	  readmissions.	  	  	  
	  	  	  
The	  sample	  size	  calculation	  to	  investigate	  for	  a	  mortality	  effect	  of	  deprivation	  was	  
based	  on	  limited	  information	  from	  previously	  published	  studies.	  Death	  rates	  in	  the	  
cohort	  were	  higher	  than	  those	  initially	  predicted	  and	  it	  is	  unlikely	  that	  these	  analyses	  
would	  not	  detect	  a	  clinically	  relevant	  effect	  if	  it	  were	  present.	  However,	  numbers	  of	  
patients	  in	  the	  least	  deprived	  quintile	  were	  lower	  than	  predicted	  as	  the	  spread	  of	  
patients	  was	  not	  even	  between	  quintiles	  (based	  on	  national	  ranking).	  This	  may	  have	  
had	  consequences	  in	  detecting	  smaller	  numbers	  of	  event	  rates	  in	  the	  least	  deprived	  
quintile.	  However,	  the	  lack	  of	  any	  discernable	  trend	  across	  quintiles	  of	  deprivation	  
makes	  it	  unlikely	  that	  any	  important	  effect	  was	  missed	  in	  the	  analysis.	  	  
	  
The	  retrospective	  nature	  of	  the	  study	  and	  the	  reliance	  of	  collection	  of	  data	  from	  
health	  records	  limit	  the	  confidence	  with	  which	  any	  associations	  observed	  may	  be	  
ascribed	  to	  causal	  relationships.	  The	  study	  design	  attempted	  to	  allow	  for	  as	  many	  
potential	  confounding	  factors	  as	  possible	  in	  the	  analyses,	  but	  some	  data	  were	  not	  
reliably	  available.	  Significantly,	  blood	  pressure,	  smoking	  status	  and	  NYHA	  status	  are	  
not	  included	  in	  our	  analyses.	  Certainly	  there	  was	  no	  robust	  assessment	  of	  the	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severity	  of	  heart	  failure	  on	  admission	  and	  this,	  leaves	  the	  study	  open	  to	  spectrum	  
bias	  as	  the	  heart	  failure	  cohort	  considered	  might	  well	  be	  a	  very	  heterogeneous	  one	  
in	  terms	  of	  severity.	  	  
	  
The	  study	  is	  also	  limited	  by	  the	  fact	  that	  the	  case	  definition	  of	  heart	  failure	  used	  
relies	  heavily	  on	  retrospective	  coding	  of	  hospital	  admissions.	  Attempts	  have	  been	  
made	  to	  introduce	  some	  internal	  validity	  into	  this	  system	  by	  using	  available	  clinical	  
data.	  It	  is	  possible	  that	  an	  element	  of	  selection	  bias	  has	  operated	  in	  so	  far	  as	  heart	  
failure	  cases	  have	  been	  excluded	  or	  included	  inappropriately	  on	  this	  basis.	  By	  
assembling	  a	  large	  cohort	  over	  the	  course	  of	  consecutive	  years	  an	  attempt	  has	  been	  













10.	   CLINICAL	  RELEVANCE	  
	  
Inequalities	  in	  health	  according	  to	  socioeconomic	  status	  are	  well	  recognised	  within	  
the	  UK,	  and	  life	  expectancies	  in	  those	  in	  the	  most	  deprived	  groups	  are	  up	  to	  ten	  
years	  lower	  than	  those	  in	  the	  least	  deprived	  stratum[195].	  Of	  even	  greater	  concern	  
is	  the	  observation	  that	  disease	  free	  life	  expectancy	  shows	  an	  even	  more	  marked	  
social	  gradient.	  	  
	  
This	  study	  confirms	  that	  this	  health	  inequalities	  gap	  is	  evident	  in	  heart	  failure,	  with	  
admission	  to	  hospital	  for	  the	  management	  of	  a	  first	  episode	  of	  heart	  failure	  
occurring	  on	  average	  4	  years	  earlier	  in	  those	  in	  the	  most	  deprived	  quintile	  vs.	  those	  
in	  the	  least	  deprived	  quintile.	  However,	  policies	  targeting	  health	  inequality	  based	  
upon	  deprivation	  would	  do	  well	  to	  address	  factors	  occurring	  earlier	  in	  the	  life-­‐course	  
in	  order	  to	  derive	  maximal	  benefit.	  	  
	  
This	  study	  has	  demonstrated	  no	  adverse	  social	  gradient	  in	  outcome	  following	  
admission	  with	  heart	  failure	  in	  this	  cohort,	  other	  a	  tendency	  to	  higher	  rates	  of	  early	  
readmission	  in	  the	  most	  deprived.	  Neither	  has	  any	  evidence	  been	  found	  that	  
iniquitous	  provision	  of	  services	  operates	  once	  admission	  has	  occurred.	  It	  is	  likely	  that	  
earlier	  onset	  of	  ischaemic	  heart	  disease,	  less	  well	  managed	  hypertension,	  poorer	  
nutrition	  and	  “status	  syndrome”	  itself	  all	  contribute	  to	  earlier	  onset	  of	  heart	  failure.	  
However,	  it	  is	  encouraging	  that	  clinicians,	  on	  the	  basis	  of	  these	  findings,	  seem	  blind	  
to	  deprivation	  factors	  when	  managing	  admitted	  heart	  failure.	  In	  a	  time	  of	  austerity,	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and	  attention	  to	  maximizing	  the	  impact	  of	  health	  interventions,	  these	  data	  do	  not	  
support	  investment	  in	  specific	  policies	  aimed	  to	  direct	  heart	  failure	  services	  into	  
more	  deprived	  areas.	  
	  
Despite	  such	  encouraging	  findings,	  these	  data	  have	  demonstrated	  evidence	  for	  
disappointingly	  low	  rates	  of	  β-­‐blocker	  use	  in	  this	  cohort,	  in	  stark	  contrast	  to	  
nationally	  reported	  data.	  A	  broader	  definition	  of	  heart	  failure	  admissions	  and	  the	  
generally	  older	  nature	  of	  this	  cohort	  may	  explain	  this	  observation.	  However,	  this	  
cohort	  does	  appear	  to	  be	  representative,	  and	  the	  population	  from	  which	  it	  is	  drawn	  
is	  similar	  to	  that	  predicted	  for	  the	  UK	  over	  the	  next	  decade.	  As	  such,	  these	  data	  
serve	  as	  a	  clarion	  call	  against	  complacency	  in	  improving	  treatment	  of	  heart	  failure.	  	  
	  
There	  is	  evidence	  of	  marked	  age	  related	  inequity	  in	  the	  management	  of	  heart	  failure	  
in	  this	  cohort	  and	  if	  this	  were	  to	  be	  translated	  to	  a	  national	  scale	  then	  the	  
consequences	  in	  terms	  of	  early	  heart	  failure	  deaths	  and	  potentially	  avoidable	  
readmissions	  would	  be	  vast.	  Access	  to	  echocardiography	  and	  disease	  modifying	  
therapy	  in	  the	  elderly	  heart	  failure	  population	  should	  be	  a	  key	  priority	  in	  the	  UK	  in	  
the	  future.	  
	  
These	  data	  support	  the	  proposition	  that	  more	  novel	  therapies	  are	  those	  which	  are	  
most	  likely	  to	  be	  under-­‐utilized	  according	  to	  iniquitous	  patterns.	  Data	  regarding	  the	  
lower	  rates	  of	  use	  of	  aldosterone	  antagonists	  in	  women	  and	  the	  elderly	  are	  of	  
particular	  concern	  given	  the	  strongly	  positive	  results	  of	  the	  recent	  EMPHASIS	  
trial[95].	  The	  indication	  for	  use	  of	  these	  agents	  now	  seems	  stronger	  than	  ever,	  but	  it	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will	  take	  time	  for	  this	  message	  to	  reach	  general	  physicians,	  who,	  on	  the	  basis	  of	  
these	  results,	  are	  commonly	  treating	  heart	  failure,	  especially	  in	  the	  elderly.	  	  
	  
In	  order	  to	  minimize	  age	  related	  inequality	  in	  the	  treatment	  of	  heart	  failure	  this	  
study	  has	  provided	  some	  evidence	  that	  specialist	  follow-­‐up	  is	  important,	  and	  these	  
findings	  are	  supported	  by	  other	  available	  data.	  A	  multi-­‐disciplinary	  model	  of	  heart	  
failure	  management	  in	  the	  elderly,	  involving	  cardiologists	  and	  specialist	  geriatricians	  
is	  likely	  to	  be	  required	  to	  ensure	  optimal	  management	  of	  these	  patients	  over	  the	  
course	  of	  the	  next	  ten	  years.	  Studies	  to	  explore	  the	  practicalities	  and	  impact	  of	  such	  














11.	   GENERAL	  CONCLUSIONS	  AND	  PRACTICAL	  RECOMMENDATIONS	  
	  
These	  data	  from	  the	  SUSSEX-­‐HF	  study	  provide	  evidence	  for	  an	  increasingly	  elderly	  
heart	  failure	  population	  in	  the	  UK.	  Management	  of	  heart	  failure	  in	  this	  cohort	  is	  not	  
affected	  by	  socioeconomic	  factors	  but	  does	  appear	  to	  be	  strongly	  influenced	  by	  
advancing	  age.	  The	  significantly	  higher	  proportion	  of	  women	  amongst	  the	  very	  
elderly	  results	  in	  the	  indirect	  operation	  of	  gender	  inequality	  in	  the	  management	  of	  
the	  syndrome.	  	  
	  
Ongoing	  audit	  on	  a	  national	  scale	  continues	  to	  highlight	  these	  inequalities	  on	  a	  
yearly	  basis	  and	  yet	  they	  persist.	  What,	  therefore,	  can	  be	  done	  to	  reduce	  iniquitous	  
provision	  of	  services	  along	  lines	  of	  age	  and	  gender?	  
	  
The	  UK	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  has	  published	  quality	  
standards	  for	  chronic	  heart	  failure	  explicitly	  setting	  out	  the	  aspects	  of	  care	  which	  
should	  be	  provided	  for	  all	  patients	  presenting	  with	  the	  syndrome[196].	  Of	  particular	  
relevance	  when	  considering	  the	  data	  presented	  in	  this	  thesis	  are	  the	  standards	  for	  
admitted	  patients	  with	  heart	  failure:	  
	  
“Quality	  statement	  10:	  Management	  plans	  for	  people	  admitted	  to	  hospital.	  People	  
admitted	  to	  hospital	  for	  heart	  failure	  have	  a	  personalised	  management	  plan	  that	  is	  
shared	  with	  them,	  their	  carer(s)	  and	  their	  GP.”	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“Quality	  statement	  11:	  Contribution	  of	  multidisciplinary	  heart	  failure	  team	  to	  
management	  plans.	  People	  admitted	  to	  hospital	  because	  of	  heart	  failure	  receive	  
input	  to	  their	  management	  plan	  from	  a	  multidisciplinary	  heart	  failure	  team.”	  	  
	  
“Quality	  statement	  12:	  Hospital	  discharge	  and	  follow-­‐up	  care.	  People	  admitted	  to	  
hospital	  for	  heart	  failure	  are	  discharged	  only	  when	  stable	  and	  receive	  a	  clinical	  
assessment	  by	  a	  member	  of	  the	  multidisciplinary	  heart	  failure	  team	  within	  2	  weeks	  
of	  discharge.”	  	  
	  
These	  standards	  provide	  a	  framework	  against	  which	  high	  quality	  care	  may	  be	  
assessed	  and	  provide	  a	  tool	  whereby	  local	  audit	  may	  be	  designed	  to	  assess	  the	  
adherence	  to	  these	  standards.	  In	  order	  to	  facilitate	  continuous	  local	  audit,	  acute	  
hospitals	  should	  develop	  pathways	  for	  the	  care	  of	  the	  admitted	  heart	  failure	  patient	  
to	  ensure	  adherence	  with	  each	  of	  the	  standards	  by	  mandating	  echocardiography	  and	  
necessitating	  review	  by	  the	  heart	  failure	  multi-­‐disciplinary	  team	  within	  a	  specified	  
period	  of	  admission.	  Checklists	  for	  recommended	  investigations	  could	  easily	  be	  
included	  in	  such	  pathways	  and	  they	  should	  also	  include	  prompts	  for	  consideration	  of	  
the	  introduction	  of	  ACEi/ARB,	  β-­‐blockers	  and	  aldosterone	  antagonists	  with	  a	  section	  
to	  record	  any	  variance	  from	  recommended	  management	  and	  the	  justification	  for	  
this.	  	  
	  
Providing	  a	  personalized	  management	  plan	  could	  easily	  be	  assessed	  by	  designing	  
standardized	  electronic	  discharge	  summaries	  with	  relevant	  fields	  recording	  clinical	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status,	  location	  of	  in-­‐patient	  care,	  investigations	  performed,	  medications	  prescribed,	  
and	  plans	  for	  follow-­‐up.	  
	  
A	  key	  point,	  demonstrated	  in	  both	  SUSSEX-­‐HF	  and	  the	  UK	  NHFA,	  is	  that	  patients	  
often	  present	  for	  admission	  with	  heart	  failure	  in	  the	  absence	  of	  a	  preceding	  
diagnosis.	  My	  data	  also	  demonstrate	  that	  these	  patients	  are	  commonly	  admitted	  
with	  heart	  failure	  in	  the	  second	  diagnostic	  position	  and	  with	  multiple	  comorbidities.	  
Such	  patients	  are	  predominantly	  elderly	  and	  local	  systems	  exist	  to	  divert	  their	  care	  
away	  from	  cardiologists	  due	  to	  admissions	  policies	  and	  ward	  based	  systems	  of	  care	  –	  
common	  in	  acute	  hospitals	  in	  the	  NHS.	  The	  quality	  standards	  regarding	  diagnosis	  and	  
initial	  management	  are	  designed	  to	  facilitate	  pathways	  for	  the	  management	  of	  heart	  
failure	  patients	  in	  the	  community,	  but	  I	  would	  recommend	  a	  more	  robust	  guideline	  
laying	  out	  the	  standards	  of	  management	  for	  patients	  presenting	  to	  hospital	  with	  
acutely	  decompensated	  heart	  failure,	  and	  this	  is	  something	  that	  has	  been	  
commissioned	  by	  NICE.	  Such	  a	  guideline	  would	  do	  well	  to	  include	  specific	  standards	  
for	  the	  timing	  of	  echocardiography	  for	  de-­‐novo	  admissions,	  the	  documentation	  of	  LV	  
systolic	  function,	  and	  for	  the	  care	  of	  patients	  on	  cardiology	  units.	  Of	  paramount	  
importance	  when	  drawing	  up	  such	  a	  guideline	  will	  be	  that	  it	  specifically	  recommends	  
standards	  for	  patients	  of	  all	  ages.	  	  
	  
With	  such	  standards	  in	  place,	  commissioning	  of	  acute	  heart	  failure	  services	  could	  be	  
better	  informed	  and	  high	  quality	  care	  could	  be	  further	  incentivized	  by	  linking	  the	  
achievement	  of	  these	  standards	  to	  the	  tariff	  paid	  for	  a	  heart	  failure	  admission.	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Penalizing	  early	  readmission	  would	  not	  appear	  to	  be	  a	  reasonable	  strategy	  to	  
improve	  care	  quality	  on	  the	  basis	  of	  the	  data	  presented	  in	  this	  thesis	  as	  higher	  rates	  
observed	  in	  more	  deprived	  individuals	  seem	  independent	  of	  quality	  of	  care	  and	  no	  
increased	  rates	  were	  observed	  in	  more	  elderly	  individuals	  despite	  the	  fact	  that	  
markers	  of	  care	  quality	  were	  worse.	  
	  
The	  SUSSEX-­‐HF	  demographic	  data	  have	  important	  consequences	  for	  benchmarking	  
when	  commissioning	  services.	  Attention	  should	  be	  paid	  to	  the	  high	  numbers	  of	  
elderly	  female	  patients	  in	  the	  cohort	  presenting	  with	  heart	  failure.	  Epidemiological	  
data	  used	  as	  the	  assumption	  for	  benchmark	  activity	  in	  localities	  may	  well	  be	  
inaccurate	  where	  there	  are	  high	  numbers	  of	  the	  very	  elderly	  and	  women	  may	  be	  
over-­‐represented.	  Commissioners	  in	  such	  areas	  will	  need	  to	  be	  attuned	  to	  this	  fact	  
to	  ensure	  adequate	  resources	  are	  made	  available	  to	  ensure	  high	  quality	  services	  in	  
these	  populations.	  
	  
Ongoing	  work	  in	  this	  area	  will	  need	  to	  concentrate	  on	  the	  reasons	  behind	  the	  
presentation	  of	  patients	  from	  more	  deprived	  backgrounds	  at	  an	  early	  age,	  but	  this	  is	  
likely	  to	  require	  an	  ambitious	  longitudinal	  population	  based	  study.	  	  
	  
Examination	  of	  the	  interplay	  between	  primary	  and	  secondary	  care	  in	  the	  treatment	  
of	  heart	  failure,	  alongside	  the	  development	  of	  integrated	  systems	  of	  care	  designed	  
to	  improve	  outcomes	  for	  patients	  throughout	  their	  transit	  through	  the	  healthcare	  
system,	  will	  require	  continuous	  and	  rigorous	  audit	  at	  both	  a	  local	  and	  national	  level.	  
Highlighting	  good	  practice	  should	  be	  a	  key	  feature	  of	  the	  national	  audit	  programme	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and	  this	  should	  be	  combined	  with	  high	  quality	  education	  as	  part	  of	  the	  continuing	  
professional	  development	  of	  those	  involved	  in	  the	  care	  of	  heart	  failure	  patients.	  
Evidence	  of	  involvement	  in	  such	  practice	  should	  be	  provided	  as	  a	  key	  part	  of	  the	  



































12.	   FIGURES	  AND	  TABLES	  
	  
	  















Description	   Category	  
I	  
No	  limitation:	  ordinary	  physical	  activity	  does	  not	  cause	  fatigue,	  
breathlessness	  or	  palpitations	  
Asymptomatic	  
I	  
Slight	  limitation	  in	  physical	  activity:	  comfortable	  at	  rest	  but	  
ordinary	  activity	  results	  in	  fatigue,	  breathlessness	  or	  palpitations	  
Mild	  
III	  
Marked	  limitation	  of	  physical	  activity:	  comfortable	  at	  rest	  but	  




Unable	  to	  carry	  out	  any	  physical	  activity	  without	  discomfort:	  
symptoms	  of	  cardiac	  failure	  at	  rest	  with	  increased	  discomfort	  
with	  any	  physical	  activity	  
Severe	  
Table	  1.	   New	  York	  Heart	  Association	  (NYHA)	  classification	  of	  heart	  failure	  


















Drug	   Initial	  dose	  (mg)	   Maximum	  recommended	  

























Table	  2.	   Diuretics	  used	  in	  the	  treatment	  of	  heart	  failure	  (based	  on	  















ACE	  inhibitor	   Starting	  dose	   Target	  dose	  
Captopril	   6.25mg	  three	  times	  daily	  	   50mg	  three	  times	  daily	  
Enalapril	   2.5mg	  twice	  daily	   10-­‐20mg	  twice	  daily	  
Lisinopril	   2.5-­‐5mg	  once	  daily	   20mg	  once	  daily	  
Ramipril	   2.5mg	  once	  daily	   5mg	  twice	  daily	  or	  10mg	  once	  daily	  
Trandolapril	   0.5mg	  once	  daily	   4mg	  once	  daily	  
Table	  3.	   ACE	  inhibitors	  used	  in	  the	  treatment	  of	  heart	  failure	  (based	  on	  



















BB	   Starting	  dose	   Target	  dose	  
Bisoprolol	   1.25mg	  once	  daily	   10mg	  once	  daily	  
Carvedilol	   3.125mg	  twice	  daily	   25-­‐50mg	  twice	  daily	  
Nebivolol	   1.25mg	  once	  daily	   10mg	  once	  daily	  
Table	  4.	   Beta-­‐blockers	  used	  in	  the	  treatment	  of	  heart	  failure	  (based	  on	  


















CHA2DS2-­‐VASc	  Risk	  Factor	   Score	  
CHF	  /	  LVEF	  <	  40%	   1	  
Hypertension	   1	  
Age	  >	  75	   2	  
Diabetes	   1	  
Stroke/TIA/	  Thromboembolism	   2	  
Vascular	  Disease	   1	  
Age	  65	  -­‐	  74	   1	  
Female	   1	  














CHF	  Grade	   Definition	  
0	   No	  dyspnoea,	  cardiac	  disease	  score	  =	  0	  &	  no	  treatment	  for	  CHF	  
1	   Cardiac	  disease	  score	  >	  0,	  no	  dyspnoea	  &	  no	  treatment	  for	  CHF	  
2	   Cardiac	  disease	  score	  >	  0	  &	  either	  dyspnoea	  or	  treatment	  for	  CHF	  
3	   Triad	  of	  cardiac	  disease	  score	  >	  0,	  dyspnoea	  and	  treatment	  for	  CHF	  
4	   Died	  with	  CHF	  during	  follow-­‐up	  
Table	  6:	   Congestive	  Heart	  Failure	  (CHF)	  Grade	  according	  to	  the	  criteria	  
specified	  in	  the	  original	  1987	  European	  Heart	  Journal	  article	  by	  
Eriksson	  et	  al.	  to	  validate	  a	  scoring	  test	  for	  cardiac	  and	  pulmonary	  





















Hastings	  &	  Rother	  PCT	   East	  Sussex	  Downs	  &	  Weald	  PCT	  
Bexhill	  Hospital	  
• Outpatient	  services	  
• GP	  managed	  respite	  and	  rehabilitation	  
in-­‐patient	  beds	  
• Day-­‐surgery	  
• Radiology	  (plain	  X-­‐ray)	  
Lewes	  Victoria	  Hospital	  
• Outpatient	  services	  
• GP	  managed	  respite	  and	  rehabilitation	  
in-­‐patient	  beds	  
• Day-­‐surgery	  
• Radiology	  (plain	  X-­‐ray)	  
• Minor	  Injuries	  Unit	  
Rye	  Memorial	  Hospital	  
• Outpatient	  services	  
Uckfield	  Community	  Hospital	  
• Outpatient	  services	  
• Day-­‐surgery	  
• Minor	  Injuries	  Unit	  	  
Table	  7:	   Services	  provided	  by	  East	  Sussex	  Hospitals’	  NHS	  Trust	  at	  each	  location	  


























Figure	  2:	   Map	  showing	  the	  road	  network	  and	  geographic	  setting	  of	  Conquest	  
Hospital	  (A)	  within	  the	  region	  served	  by	  East	  Sussex	  Hospitals’	  NHS	  



















ICD-­‐10	  Code	   Definition	  
I50.0	   Congestive	  Heart	  Failure	  
I50.1	   Left	  Ventricular	  Failure	  
I50.9	   Heart	  Failure,	  unspecified	  
I42.0	   Dilated	  Cardiomyopathy	  
I42.9	   Cardiomyopathy,	  unspecified	  
I25.5	   Ischaemic	  Cardiomyopathy	  
I11.0	   Hypertensive	  Heart	  Disease	  with	  (Congestive)	  Heart	  Failure	  


































Domain	   Weight	  given	  to	  domain	  in	  determining	  overall	  
IMD	  2007	  (%)	  
Income	  Deprivation	  	   22.5	  
Employment	  Deprivation	   22.5	  
Health	  Deprivation	  and	  Disability	   13.5	  
Education,	  Skills	  &	  Training	  Deprivation	   13.5	  
Barriers	  to	  Housing	  &	  Services	   9.3	  
Crime	   9.3	  
Living	  Environment	  Deprivation	   9.3	  
Table	  10:	   Domains	  used	  in	  the	  calculation	  of	  the	  IMD	  2007	  score,	  including	  the	  
























IMD	  2007	  Rank	  for	  England	   Quintile	  of	  Deprivation	  
1	  –	  6,	  496	   1	  (Most	  Deprived)	  
6,	  497	  –	  12,	  993	   2	  
12,	  994	  –	  19,	  489	   3	  
19,	  499	  –	  25,	  986	   4	  
25,	  987	  –	  32,	  482	   5	  (Least	  Deprived)	  


























CKD	  Stage	   eGFR	  (mls/min/1.73m2)	  
Estimation	  of	  renal	  impairment	  
used	  in	  SUSSEX-­‐HF	  
1	   ≥90	  
2	   60	  –	  89	  
No	  significant	  renal	  impairment	  
3a	   45	  –	  49	  
3b	   30	  –	  44	  
4	   15	  –	  29	  
5	   <15	  
Significant	  renal	  impairment	  
Table	  12:	   The	  association	  between	  Chronic	  Kidney	  Disease	  (CKD)	  Stage,	  

























Figure	  3:	   Flowchart	  describing	  the	  exclusion	  of	  potential	  members	  of	  the	  


















Admissions	  with	  heart	  failure	  coded	  in	  the	  1st	  or	  2nd	  position	  
1061	  
First	  presentation	  heart	  failure	  admissions	  	  
453	  
Repeat	  admissions	  during	  
the	  period	  of	  interest	  or	  
admitted	  for	  heart	  failure	  
in	  the	  previous	  5	  years.	  
986	  
Patients	  known	  to	  have	  been	  registered	  at	  Conquest	  Hospital	  prior	  to	  
2004	  	  	  
75	  
Cases	  without	  historical	  “H-­‐
number”	  
942	  
First	  presentation	  heart	  failure	  patients	  known	  to	  have	  been	  
registered	  at	  Conquest	  Hospital	  prior	  to	  2004	  and	  known	  to	  be	  
resident	  in	  catchment	  area	  of	  Conquest	  Hospital	  	  	  
39	  
Cases	  with	  postcode	  
outside	  study	  area	  
29	  
Day	  case	  procedure	  
admissions	  only	  
5	  
Cases	  managed	  mainly	  in	  
the	  private	  sector	  
883	  
First	  presentation	  heart	  failure	  patients	  screened	  for	  evidence	  of	  clinical	  heart	  failure,	  known	  
to	  have	  been	  registered	  at	  Conquest	  Hospital	  prior	  to	  2004,	  and	  known	  to	  be	  resident	  in	  
catchment	  area	  of	  Conquest	  Hospital	  	  	  
59	  
Cases	  not	  fulfilling	  criteria	  
for	  heart	  failure	  diagnosis	  
on	  review	  of	  records	  
	  184	  
Number	  of	  Comorbidities	   Females	  (%)	   Males	  (%)	  
0	  -­‐	  1	   16	   12	  
2	   24	   22	  
3	   24	   24	  
4	   17	   21	  
≥5	   18	   21	  
















Died	  prior	  to	  discharge	  
n	  =	  160	  (18.1%)	  
Survived	  to	  discharge	  
n	  =	  723	  (81.9%)	  
	  
Age	  [median	  (IQR)]	   85.2	  (10.2)	   82.0	  (12.0)	   P<0.001	  
Male	  [n	  (%)]	   78	  (48.8)	   352	  (48.7)	   P=0.98	  
Comorbidity	  [n	  (%)]	  
	   Atrial	  Fibrillation	  
	   Hypertension	  
	   IHD	  	  
	   Diabetes	  
	   Lung	  disease	  

















	   1	  (18.9%)	  
	   2	  (28%)	  
	   3	  (24.1%)	  
	   4	  (21.4%)	  















	   ≥60	  










Sodium	  [mean	  (S.D.)]	  
137.1	  (4.84)	   135.6	  (6.73)	   P=0.002	  
Sodium	  <	  130	  [n(%)]	   22	  (13.9)	   56	  (7.8)	   P=0.014	  
Anaemia	   139	  (86.9)	   571	  (79.4)	   P=0.03	  
Troponin	  +ve	  [n(%)]	   55	  (46.7)	   125	  (22.6)	   P<0.001	  
LVEF	  
	   Recorded	  [n(%)]	  









	   Recorded	  [n(%)]	  
















Speciality	  of	  care	  [n(%)]	  
	   Cardiology	  
	   Gen.	  Medicine	  


















Table	  14:	   Characteristics	  of	  those	  patients	  surviving	  to	  discharge	  from	  the	  index	  































Daily	  diuretic	  dose	  (furosemide	  equivalents	  in	  mg)	   Frequency	  (%)	  
0	   54	  (7.5)	  
1	  –	  39	  	   15	  (2)	  
40	  –	  79	  	   288	  (39.8)	  
80	  –	  119	   286	  (39.6)	  
≥120	   80	  (11.1)	  
Total	   723	  (100)	  
Table	  15:	   Frequency	  of	  different	  diuretic	  dosing	  schedules	  in	  the	  cohort	  








































	   1	  































	   AF	  
	   HTN	  
	   IHD	  
	   DM	  
	   Stroke	  
























































































































































Table	  16:	   Characteristics	  of	  the	  cohort	  surviving	  to	  discharge	  according	  to	  
















Figure	  7:	   Kaplan	  Meir	  analysis	  of	  time	  to	  death	  or	  first	  readmission	  with	  heart	  

















































































































































Age	  Group	   Under	  76	  	  
N=191	  
76	  –	  85	  	  
n=280	  
85	  and	  over	  
n=252	  	  
	  









LVEF	  	  	  	  	  	  	  
mean	  




Daily	  furosemide	  dose	  
mean	  
63	   66	   62	   NS	  
Hb	  
mean	  (SD)	  








138	   137	   137	   NS	  
eGFR	  
mean	  (SD)	  
































Age	  Group	   Under	  76	   76	  –	  85	   85	  and	  over	   	  














































































Variable	   Crude	  Hazard	  Ratio	  (95%	  C.I.)	  
Age	  (per	  year	  of	  advancing	  age))	   1.04	  (1.03	  –	  1.05)	  
Male	  gender	   1.04	  (0.88	  –	  1.23)	  
IMD	  2007	  
	   	   	   Q1	  
	   	   	   Q2	  
	   	   	   Q3	  
	   	   	   Q4	  
	   	   	   Q5	  
	  
1.0	  
1.17	  (0.90	  –	  1.53)	  
1.31	  (0.87	  –	  1.48)	  
0.98	  (0.75	  –	  1.29)	  
1.17	  (0.89	  –	  1.52)	  
Chronic	  Kidney	  Disease	  
	   	   	   Stage	  I	  
	   	   	   Stage	  II	  
	   	   	   Stage	  III	  
	   	   	   Stage	  IV-­‐V	  
	  
1.0	  
1.08	  (0.86	  –	  1.35)	  
1.66	  (1.32	  –	  2.07)	  
2.10	  (1.64	  –	  2.67)	  
LVEF	  <	  50%	   1.14	  (0.91	  –	  1.42)	  
Anaemia	   1.28	  (1.02	  –	  1.59)	  
























	   Crude	  OR	  for	  
prescription	  of	  
ACEi/ARB	  
Crude	  OR	  for	  
prescription	  of	  B-­‐
blocker	  




Age	  (per	  year)	   0.98	  (0.96-­‐0.99)	   0.95	  (0.94-­‐0.97)	   0.97	  (0.95-­‐0.98)	  
Male	  Gender	   1.10	  (0.78-­‐1.54)	   1.23	  (0.85-­‐1.79)	   1.84	  (1.32-­‐2.57)	  
IMD	  2007	  
	   	   Q1	  
	   	   Q2	  
	   	   Q3	  
	   	   Q4	  




















	   	   Stage	  I	  
	   	   Stage	  II	  
	   	   Stage	  III	  
	   	   Stage	  IV	  



















Specialist	  follow-­‐up	   2.40	  (1.66-­‐3.49)	   2.66	  (1.82-­‐3.88)	   1.88	  (1.35-­‐2.62)	  
Documented	  chronic	  lung	  
disease	  
-­‐	   0.48	  (0.29-­‐0.81)	   -­‐	  
LVEF	  (per	  1%,	  n=450)	   0.97	  (0.96-­‐0.99)	   0.98	  (0.96-­‐0.99)	   0.96	  (0.95-­‐0.98)	  
Table	  21:	   Univariate	  analysis	  of	  candidate	  variables	  affecting	  the	  likelihood	  of	  



















Age	  Group	  (years)	   <76	  (n=82)	   76	  –	  85	  (n=	  156)	   ≥85	  (n=	  160)	  
Female	  (%)	   28	   49	   68	  
Hypertension	  (%)	   51	   58	   45	  
Diabetes	  (%)	   35	   28	   16	  
Ischaemic	  heart	  
disease	  (%)	  
51	   52	   39	  
Prior	  stroke	  (%)	   11	   15	   24	  
Median	  CHA2DS2VASc	  
(range)	  
4	  (2	  –	  7)	   5	  (3	  –	  8)	   5	  (3	  –	  8)	  	  
Aspirin	  alone	  (%)	   37	   48	   59	  
VKA	  (%)	   60	   45	   22	  


























Deaths	   SMR	  
Standard	  Error	  
of	  SMR	  
30-­‐34	   M	   0.00198	   0	   0	   0	  
35-­‐39	   M	   0	   0	   	   	  
40-­‐44	   M	   0.0036	   1	   277.7778	   277.7778	  
45-­‐49	   M	   0.01375	   1	   72.72727	   72.72727	  
50-­‐54	   M	   0.03087	   3	   97.18173	   56.1079	  
55-­‐59	   M	   0.07513	   2	   26.62052	   18.82355	  
60-­‐64	   M	   0.23604	   10	   42.3657	   13.39721	  
65-­‐69	   M	   0.64908	   14	   21.56899	   5.764555	  
70-­‐74	   M	   1.41984	   24	   16.90331	   3.450374	  
75-­‐79	   M	   4.13019	   50	   12.10598	   1.712044	  
80-­‐84	   M	   8.63674	   69	   7.989126	   0.9617777	  
85-­‐89	   M	   11.26777	   66	   5.857415	   0.7209979	  
90-­‐94	   M	   7.16224	   27	   3.76977	   0.7254927	  
95-­‐99	   M	   2.89128	   8	   2.766941	   0.9782612	  
100+	   M	   0.91448	   1	   1.093518	   1.093518	  
Overall	  (Male)	   	   37.43299	   276	   7.373175	   0.443813	  
30-­‐34	   F	   0	   0	   	   	  
35-­‐39	   F	   0.0007	   1	   1428.572	   1428.572	  
40-­‐44	   F	   0	   0	   	   	  
45-­‐49	   F	   0.00362	   1	   276.2431	   276.2431	  
50-­‐54	   F	   0.0058	   0	   0	   0	  
55-­‐59	   F	   0.03942	   3	   76.1035	   43.93837	  
60-­‐64	   F	   0.07656	   2	   26.1233	   18.47196	  
65-­‐69	   F	   0.12364	   3	   24.26399	   14.00882	  
70-­‐74	   F	   0.60224	   19	   31.54888	   7.23781	  
75-­‐79	   F	   2.08193	   33	   15.85068	   2.759249	  
80-­‐84	   F	   6.6798	   59	   8.8326	   1.149907	  
85-­‐89	   F	   11.95294	   86	   7.194882	   0.7758442	  
90-­‐94	   F	   15.484	   55	   3.552054	   0.4789588	  
95-­‐99	   F	   8.22146	   18	   2.189392	   0.5160447	  
100+	   F	   0.793	   2	   2.522068	   1.783371	  
Overall	  (Female)	   	   46.06511	   282	   6.12177	   0.3645461	  
Population	  Total	   	   83.4981	   558	   6.682787	   0.2829049	  
Table	  23:	   Standardized	  Mortality	  Ratio	  (SMR)	  by	  5	  year	  age	  band	  for	  men	  and	  















Figure	  8:	   	  Population	  pyramids	  for	  the	  districts	  of	  Hastings	  (A)	  and	  Rother	  (B)	  
compared	  with	  UK	  average.	  Crown	  Copyright	  2008.	  Source	  National	  





















































CAD	   62	   45	   51	   54	   57	   49.5	  
HTN	   55	   46	   67	   61	   73	   70.9	  
DM	   28	   22	   29	   34	   44	   41.5	  
AF	   35	   50	   48	   36	   31	   30.8	  
COPD	  /	  CLD	   26	   21	   22	   19	   30	   27.6	  
Stroke	   15	   15	   20	   12	   	   15.5	  
Anaemia	   	   51	   47	   37	   	   17.6	  
Table	  24:	   Data	  comparing	  comorbidity	  in	  the	  SUSSEX-­‐HF	  cohort	  with	  rates	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